Document:

<PAGE>

                                                                    Exhibit 10.7

                           REVOLVING CREDIT AGREEMENT

                          DATED AS OF NOVEMBER 24, 2003

                                      among

                         NORTHERN BORDER PARTNERS, L.P.,
                                   as Borrower

                                 SUNTRUST BANK,
                            as Administrative Agent,

                            THE LENDERS NAMED HEREIN,
                                   as Lenders,

          HARRIS NESBITT CORP. AND WACHOVIA BANK, NATIONAL ASSOCIATION,
                            as Co-Syndication Agents,

                                CITIGROUP, N.A.,
                             as Documentation Agent,

                                       and

                         SUNTRUST CAPITAL MARKETS, INC.,
                                as Lead Arranger

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                                       PAGE
<S>                                                                                                                    <C>
ARTICLE I           DEFINITIONS AND TERMS........................................................................        1
         SECTION 1.1          Definitions........................................................................        1
         SECTION 1.2          Number and Gender of Words; Other References.......................................       16
         SECTION 1.3          Accounting Principles..............................................................       16

ARTICLE II          BORROWING PROVISIONS.........................................................................       16
         SECTION 2.1          Facility...........................................................................       16
         SECTION 2.2          LC Subfacility.....................................................................       16
         SECTION 2.3          Terminations, Reductions or Increases of Commitments...............................       20
         SECTION 2.4          Borrowing Procedure................................................................       21

ARTICLE III         TERMS OF PAYMENT.............................................................................       23
         SECTION 3.1          Loan Accounts, Notes, and Payments.................................................       23
         SECTION 3.2          Interest and Principal Payments....................................................       24
         SECTION 3.3          Prepayments........................................................................       24
         SECTION 3.4          Interest Options...................................................................       25
         SECTION 3.5          Quotation of Rates.................................................................       25
         SECTION 3.6          Default Rate.......................................................................       25
         SECTION 3.7          Interest Recapture.................................................................       25
         SECTION 3.8          Interest Calculations..............................................................       26
         SECTION 3.9          Maximum Rate.......................................................................       26
         SECTION 3.10         Interest Periods...................................................................       26
         SECTION 3.11         Conversions........................................................................       27
         SECTION 3.12         Order of Application...............................................................       27
         SECTION 3.13         Sharing of Payments, Etc...........................................................       28
         SECTION 3.14         Offset.............................................................................       28
         SECTION 3.15         Booking Borrowings.................................................................       29

ARTICLE IV          CHANGE IN CIRCUMSTANCES......................................................................       29
         SECTION 4.1          Increased Cost and Reduced Return..................................................       29
         SECTION 4.2          Limitation on Types of Loans.......................................................       30
         SECTION 4.3          Illegality.........................................................................       31
         SECTION 4.4          Treatment of Affected Loans........................................................       31
         SECTION 4.5          Compensation.......................................................................       32
         SECTION 4.6          Taxes..............................................................................       32

ARTICLE V           FEES.........................................................................................       34
         SECTION 5.1          Treatment of Fees..................................................................       34
         SECTION 5.2          Fees of Administrative Agent and Arranger..........................................       34
         SECTION 5.3          Facility Fees......................................................................       34
         SECTION 5.4          LC Fees............................................................................       35
</TABLE>

                                       -i-
<PAGE>

<TABLE>
<S>                                                                                                                     <C>
ARTICLE VI          GUARANTY.....................................................................................       35
         SECTION 6.1          Guaranty...........................................................................       35

ARTICLE VII         CONDITIONS PRECEDENT.........................................................................       35
         SECTION 7.1          Conditions Precedent to Closing....................................................       35
         SECTION 7.2          Conditions Precedent to Each Borrowing.............................................       35

ARTICLE VIII        REPRESENTATIONS AND WARRANTIES...............................................................       36
         SECTION 8.1          Purpose of Credit Facility.........................................................       36
         SECTION 8.2          Existence, Good Standing, Authority, and Authorizations............................       36
         SECTION 8.3          Subsidiaries.......................................................................       37
         SECTION 8.4          Authorization and No Contravention.................................................       37
         SECTION 8.5          Binding Effect.....................................................................       37
         SECTION 8.6          Financial Statements...............................................................       37
         SECTION 8.7          Litigation, Claims, Investigations.................................................       38
         SECTION 8.8          Taxes..............................................................................       38
         SECTION 8.9          Environmental Matters..............................................................       38
         SECTION 8.10         Employee Benefit Plans.............................................................       38
         SECTION 8.11         Properties; Liens..................................................................       39
         SECTION 8.12         Government Regulations.............................................................       39
         SECTION 8.13         Transactions with Affiliates.......................................................       39
         SECTION 8.14         Material Agreements................................................................       39
         SECTION 8.15         Insurance..........................................................................       40
         SECTION 8.16         Compliance with Laws...............................................................       40
         SECTION 8.17         Regulation U.......................................................................       40
         SECTION 8.18         Full Disclosure....................................................................       40
         SECTION 8.19         No Default.........................................................................       40

ARTICLE IX          AFFIRMATIVE COVENANTS........................................................................       41
         SECTION 9.1          Use of Proceeds....................................................................       41
         SECTION 9.2          Books and Records..................................................................       41
         SECTION 9.3          Items to be Furnished..............................................................       41
         SECTION 9.4          Inspections........................................................................       42
         SECTION 9.5          Taxes..............................................................................       42
         SECTION 9.6          Payment of Obligations.............................................................       43
         SECTION 9.7          Maintenance of Existence, Assets, and Business.....................................       43
         SECTION 9.8          Compliance with Laws, etc..........................................................       43
         SECTION 9.9          Insurance..........................................................................       43
         SECTION 9.10         Preservation and Protection of Rights..............................................       43
         SECTION 9.11         Pari Passu Status..................................................................       44
         SECTION 9.12         Maintenance of Tax Status..........................................................       44

ARTICLE X           NEGATIVE COVENANTS...........................................................................       44
         SECTION 10.1         Debt and Guaranties................................................................       44
         SECTION 10.2         Liens..............................................................................       45
         SECTION 10.3         Transactions with Affiliates.......................................................       46
         SECTION 10.4         Assignment.........................................................................       46
</TABLE>

                                      -ii-
<PAGE>

<TABLE>
<S>                                                                                                                     <C>
         SECTION 10.5         Government Regulations.............................................................       46
         SECTION 10.6         Mergers; Sale of Assets............................................................       46
         SECTION 10.7         Loan and Investments...............................................................       47
         SECTION 10.8         Distributions......................................................................       47
         SECTION 10.9         Limitation on Business Activities..................................................       47
         SECTION 10.10        Certain Amendments to Cash Distribution Policies and Partnership Agreements........       48
         SECTION 10.11        Restrictive Agreements, etc........................................................       48
         SECTION 10.12        Employee Benefit Plans.............................................................       48
         SECTION 10.13        Interest Coverage Ratio............................................................       48
         SECTION 10.14        Consolidated Leverage Ratio........................................................       48

ARTICLE XI          DEFAULT......................................................................................       49
         SECTION 11.1         Payment of Obligation..............................................................       49
         SECTION 11.2         Covenants..........................................................................       49
         SECTION 11.3         Debtor Relief......................................................................       49
         SECTION 11.4         Judgments and Attachments..........................................................       50
         SECTION 11.5         Misrepresentation..................................................................       50
         SECTION 11.6         Change of Control..................................................................       50
         SECTION 11.7         Default Under Other Debt and Agreements............................................       50
         SECTION 11.8         Employee Benefit Plans.............................................................       50
         SECTION 11.9         Validity and Enforceability of Loan Documents......................................       51
         SECTION 11.10        Environmental Liability............................................................       51
         SECTION 11.11        Dissolution........................................................................       51

ARTICLE XII         RIGHTS AND REMEDIES..........................................................................       51
         SECTION 12.1         Remedies Upon Default..............................................................       51
         SECTION 12.2         Loan Party Waivers.................................................................       52
         SECTION 12.3         Performance by Administrative Agent................................................       52
         SECTION 12.4         Delegation of Duties and Rights....................................................       52
         SECTION 12.5         Not in Control.....................................................................       52
         SECTION 12.6         Course of Dealing..................................................................       53
         SECTION 12.7         Cumulative Rights..................................................................       53
         SECTION 12.8         Application of Proceeds............................................................       53
         SECTION 12.9         Certain Proceedings................................................................       54
         SECTION 12.10        Expenditures by Lenders............................................................       54
         SECTION 12.11        INDEMNIFICATION....................................................................       54

ARTICLE XIII        AGREEMENT AMONG LENDERS......................................................................       56
         SECTION 13.1         Administrative Agent...............................................................       56
         SECTION 13.2         Expenses...........................................................................       57
         SECTION 13.3         Proportionate Absorption of Losses.................................................       58
         SECTION 13.4         Delegation of Duties; Reliance.....................................................       58
         SECTION 13.5         Limitation of Liability............................................................       58
         SECTION 13.6         Default............................................................................       59
         SECTION 13.7         Limitation of Liability............................................................       60
         SECTION 13.8         Relationship of Lenders............................................................       60
</TABLE>

                                      -iii-
<PAGE>

<TABLE>
<S>                                                                                                                     <C>
         SECTION 13.9         Benefits of Agreement..............................................................       60
         SECTION 13.10        Agents.............................................................................       60
         SECTION 13.11        Obligations Several................................................................       60

ARTICLE XIV         MISCELLANEOUS................................................................................       61
         SECTION 14.1         Headings...........................................................................       61
         SECTION 14.2         Nonbusiness Days...................................................................       61
         SECTION 14.3         Communications.....................................................................       61
         SECTION 14.4         Form and Number of Documents.......................................................       61
         SECTION 14.5         Exceptions to Covenants............................................................       61
         SECTION 14.6         Survival...........................................................................       62
         SECTION 14.7         GOVERNING LAW......................................................................       62
         SECTION 14.8         Invalid Provisions.................................................................       62
         SECTION 14.9         Entirety...........................................................................       62
         SECTION 14.10        Jurisdiction; Venue; Service of Process............................................       62
         SECTION 14.11        Amendments, Consents, Conflicts, and Waivers.......................................       63
         SECTION 14.12        Multiple Counterparts..............................................................       64
         SECTION 14.13        Successors and Assigns; Assignments and Participations.............................       64
         SECTION 14.14        Confidentiality....................................................................       67
         SECTION 14.15        Discharge Only Upon Payment in Full; Reinstatement in Certain Circumstances........       67
         SECTION 14.16        No General Partners' Liability.....................................................       68
</TABLE>

                                      -iv-
<PAGE>

EXHIBITS AND SCHEDULES

Exhibit A       -    Form of Note

Exhibit B-1     -    Form of Borrowing Notice

Exhibit B-2     -    Form of Conversion Notice

Exhibit B-3     -    Form of LC Request

Exhibit C       -    Form of Guaranty

Exhibit D       -    Form of Compliance Certificate

Exhibit E       -    Form of Assignment and Acceptance Agreement

Exhibit F-1     -    Form of Opinion of Counsel of Borrower

Exhibit F-2     -    Form of Opinion of General Counsel of Northern Plains
                     Natural Gas Company

Exhibit F-3     -    Form of Opinion of Counsel of Pan Border

Exhibit F-4     -    Form of Opinion of Counsel of Northwest Border

Schedule 2.1    -    Lenders and Commitments

Schedule 7.1    -    Conditions Precedent to Closing

Schedule 8.3    -    Subsidiaries and Partnership Interests

Schedule 10.1   -    Existing Debt

Schedule 14.3   -    Address for Notices

                                       -v-
<PAGE>

                           REVOLVING CREDIT AGREEMENT

         THIS CREDIT AGREEMENT is entered into as of November 24, 2003, among
NORTHERN BORDER PARTNERS, L.P., a Delaware limited partnership ("BORROWER"),
Lenders (hereinafter defined) and SUNTRUST BANK, as Administrative Agent
(hereinafter defined) for itself and the other Lenders.

                                    RECITALS

         A.       Borrower has requested that Lenders extend credit to Borrower,
providing for a revolving loan and standby letter of credit facility in the
aggregate principal amount of $275,000,000, to refinance existing bank debt and
to finance investments permitted hereunder, working capital, capital
expenditures, acquisitions and other general business purposes.

         B.       Upon and subject to the terms and conditions of this
Agreement, Lenders are willing to extend such credit to Borrower. Accordingly,
in consideration of the mutual covenants contained herein, the parties agree as
follows:

                                    ARTICLE I
                              DEFINITIONS AND TERMS

         SECTION 1.1 DEFINITIONS.

         As used herein:

         "2010 SENIOR NOTES" means the unsecured 8-7/8% notes dated as of June
2, 2000 issued by Borrower in an aggregate principal amount of $250,000,000 with
a maturity date of June 15, 2010.

         "2010 SENIOR NOTE INDENTURE" means the indenture authorizing the
issuance of the 2010 Senior Notes, as the same may from time to time be amended,
supplemented or otherwise modified.

         "2011 SENIOR NOTES" means the unsecured notes dated as of March 21,
2001 issued by Borrower in an aggregate principal amount of $225,000,000 with a
maturity date of March 15, 2011.

         "2011 SENIOR NOTE INDENTURE" means the indenture authorizing the
issuance of the 2011 Senior Notes, as the same may from time to time be amended,
supplemented or otherwise modified.

         "ACQUISITION" means any transaction or series of related transactions
for the purpose of, or resulting in, directly or indirectly, (a) the acquisition
by a Person of all or substantially all of the assets of another Person or of
any business or division of another Person, (b) the acquisition by a Person of
more than 50% of any class of Voting Stock (or similar ownership interests) of
any other Person (provided that, formation or organization of any entity shall
not constitute an "Acquisition" to the extent that the amount of the loan,
advance, investment, or capital contribution in such entity constitutes a
permitted investment under Section 10.7); or (c) a

<PAGE>

merger, consolidation, amalgamation, or other combination by any Person with
another Person if a Loan Party is the surviving entity; provided that, in any
merger involving Borrower, Borrower must be the surviving entity.

         "ADDITIONAL LENDER" shall have the meaning given to such term in
Section 2.6.

         "ADJUSTED CONSOLIDATED EBITDA" means, for any fiscal period of
Borrower, the sum of Consolidated EBITDA of Borrower for such period plus, to
the extent not already reflected in Consolidated EBITDA for such period,
Consolidated EBITDA for such period of (i) any other Person or (ii) all or
substantially all of the business or assets of any other Person or (iii)
operating division or business unit of any other Person, acquired during such
period.

         "ADMINISTRATIVE AGENT" means SunTrust Bank, and its permitted
successors or assigns as "Administrative Agent" for Lenders under the Loan
Documents.

         "AFFILIATE" of any Person means any other individual or entity who
directly or indirectly controls, or is controlled by, or is under common control
with, such Person, and, for purposes of this definition only, "control,"
"controlled by," and "under common control with" mean possession, directly or
indirectly, of the power to direct or cause the direction of management or
policies (whether through ownership of voting securities, by contract, or
otherwise).

         "AGREEMENT" means this Revolving Credit Agreement (as the same may
hereafter be amended, modified, supplemented, or restated from time to time).

         "ANNIVERSARY DATE" means each of November 24, 2004, November 24, 2005,
November 24, 2006 and November 24, 2007.

         "APPLICABLE LENDING OFFICE" means, for each Lender and for each Type of
Borrowing, the "Lending Office" of such Lender (or an affiliate of such Lender)
designated on Schedule 14.3 attached hereto or such other office that such
Lender (or an affiliate of such Lender) may from time to time specify to
Administrative Agent and Borrower by written notice in accordance with the terms
hereof.

         "APPLICABLE AMOUNT AND APPLICABLE MARGIN" means, on any date of
determination, with respect to Borrowings under the Facility and facility fees
and letter of credit fees under the Facility the following annualized rates
(stated in terms of basis points ("BPS")) that correspond to the ratings
established by both S&P and Moody's applicable to Borrower's long-term senior
unsecured non-credit enhanced indebtedness for borrowed money ("INDEX DEBT") at
such date of determination:

<TABLE>
<CAPTION>
                                      APPLICABLE MARGIN                        APPLICABLE AMOUNT
                          ------------------------------------------           -----------------
                          BASE RATE             EURODOLLAR RATE
SENIOR UNSECURED          BORROWINGS       BORROWINGS AND LETTERS OF             FACILITY FEE
   DEBT RATING              (BPS)                 CREDIT (BPS)                       (BPS)
----------------          ----------       -------------------------           -----------------
<S>                       <C>              <C>                                 <C>
Category 1
Greater than or              0.0                      65.0                           10.0
equal to A-/A3

Category 2
BBB+/Baa1                    0.0                      75.0                           12.5
</TABLE>

                                       -2-
<PAGE>

<TABLE>
<S>                          <C>                     <C>                             <C>
Category 3
BBB/Baa2                     0.0                      85.0                           15.0

Category 4
BBB-/Baa3                    0.0                     100.0                           25.0

Category 5
Less than BBB-               0.0                     112.5                           37.5
/Baa3
</TABLE>

For purposes of determining the Applicable Amount and the Applicable Margin,
with respect to the debt ratings criteria: (i) if neither Moody's nor S&P shall
have in effect a rating for Index Debt (other than by reason of the
circumstances referred to in the penultimate sentence of this definition), then
both such rating agencies will be deemed to have established ratings for Index
Debt in Category 5; (ii) if either of Moody's or S&P shall fail to have in
effect a rating for Index Debt (other than by reason of the circumstances
referred to in the penultimate sentence of this definition), then such rating
agency shall be deemed to have established a rating in Category 5; (iii) if the
ratings established by Moody's and S&P (including the deemed ratings pursuant to
clause (ii)) shall differ, the Applicable Amount and the Applicable Margin shall
be based on (1) if the ratings differential is one category, the higher of the
two ratings, (2) if the rating differential is two categories, the rating which
falls between them or (3) if the rating differential is three categories or
more, the rating immediately above the lower of the two ratings; and (iv) if any
rating established by Moody's or S&P shall be changed (other than as a result of
a change in the rating system of either Moody's or S&P), such change shall be
effective as of the date on which such change is first announced by the rating
agency making such change. Subject to clauses (i) and (ii) of the preceding
sentence, if the rating system of either Moody's or S&P shall change, or if
either Moody's or S&P shall cease to be in the business of rating corporate debt
obligations, Borrower and Lenders shall negotiate in good faith to amend this
definition to reflect such changed rating system or the unavailability of
ratings from such rating agency and pending the effectiveness of such amendment,
the Applicable Amount and the Applicable Margin shall be determined by reference
to the rating most recently in effect prior to such change or cessation. From
the Closing Date until any change in the rating of Borrower's Index Debt as
described above, the Applicable Amount and Applicable Margin shall be based on
Category 2.

         "ARRANGER" means SunTrust Capital Markets, Inc., and its successors and
assigns, in its capacity as lead arranger under the Loan Documents.

         "AUTHORIZATIONS" means all filings, recordings, and registrations with,
and all validations or exemptions, approvals, orders, authorizations, consents,
franchises, licenses, certificates, and permits from, any Governmental
Authority.

         "BASE RATE" means, for any day, the rate per annum equal to the higher
of (a) the Federal Funds Rate for such day plus one-half of one percent (0.5%)
and (b) the Prime Rate for such day. Any change in the Base Rate due to a change
in the Prime Rate or the Federal Funds Rate shall be effective on the effective
date of such change in the Prime Rate or the Federal Funds Rate.

         "BASE RATE BORROWING" means a Borrowing bearing interest at the sum of
the Base Rate plus the Applicable Margin for Base Rate Borrowings.

         "BORROWER" is defined in the preamble to this Agreement.

                                      -3-
<PAGE>

         "BORROWING" means any amount disbursed (a) by one or more Lenders under
the Loan Documents (under the Facility or the LC Subfacility), whether such
amount constitutes an original disbursement of funds, the continuation or
conversion of an amount outstanding, or payment of a draft under an LC, or (b)
by any Lender in accordance with, and to satisfy the obligations of any Loan
Party under, any Loan Document.

         "BORROWING DATE" is defined in Section 2.4(a).

         "BORROWING NOTICE" means a request for Borrowing made pursuant to
Section 2.4(a), substantially in the form of Exhibit B-1.

         "BUSINESS DAY" means (a) for all purposes, any day other than Saturday,
Sunday and any other day on which commercial banking institutions are required
or authorized by Law to be closed in Atlanta, Georgia or New York, New York, and
(b) in addition to the foregoing, in respect of any Eurodollar Rate Borrowing, a
day on which dealings in United States dollars are conducted in the London
interbank market and commercial banks are open for international business in
London.

         "CAPITAL LEASE" means any capital lease or sublease which should be
capitalized on a balance sheet in accordance with GAAP.

         "CHANGE OF CONTROL" means (i) the failure of Borrower directly, or
indirectly through Intermediate Partnership, to own as a general partner, free
and clear of all Liens, at least 60% of the partnership interests in NBPC or
(ii) the failure of Subsidiaries of Enron Corp., CrossCountry Energy Corp.,
CrossCountry Energy, L.L.C. and/or TransCanada PipeLines Limited directly, or
indirectly through one or more wholly-owned Subsidiaries, to own, free and clear
of all Liens, general partner interests in Borrower and the Intermediate
Partnership such that the aggregate voting rights of such Persons is greater
than 50% of the outstanding voting rights of all general partners of Borrower
and the Intermediate Partnership.

         "CLOSING DATE" means the date upon which this Agreement has been
executed by Borrower, Lenders, and Administrative Agent and all conditions
precedent specified in Section 7.1 have been satisfied or waived.

         "CODE" means the Internal Revenue Code of 1986, as amended, together
with the rules and regulations promulgated thereunder.

         "COMMITMENT" means, on any date of determination, the sum of all
Committed Sums then in effect for all Lenders in respect of the Facility.

         "COMMITMENT PERCENTAGE" means, at any date of determination, for any
Lender, the proportion (stated as a percentage) that its Committed Sum bears to
the aggregate Committed Sums of all Lenders.

         "COMMITMENT USAGE" means, at the time of any determination thereof, the
sum of (a) the aggregate Principal Debt plus, without duplication, (b) the LC
Exposure.

                                      -4-
<PAGE>

         "COMMITTED SUM" means for any Lender, with respect to the Facility, at
any date of determination occurring prior to the Termination Date for the
Facility, the amount stated beside such Lender's name on the most-recently
amended Schedule 2.1 to this Agreement (which amount is subject to reduction or
cancellation in accordance with the Loan Documents).

         "COMMON UNIT" means units representing limited partnership interests in
Borrower offered for sale to the public.

         "COMPLIANCE CERTIFICATE" means a certificate signed by a Responsible
Officer, substantially in the form of Exhibit D.

         "CONSEQUENTIAL LOSS" means any loss or expense which any Lender may
reasonably incur in respect of a Eurodollar Rate Borrowing as a consequence of
any event described in Section 4.5.

         "CONSOLIDATED EBITDA" means, for any person and its consolidated
subsidiaries and for any period, an amount equal to the sum of (i) Net Income
for such period plus (ii) to the extent deducted in determining Net Income for
such period, (A) Consolidated Interest Expense, (B) income tax expense, (C)
depreciation and amortization and (D) all other non-cash charges, determined on
a consolidated basis in accordance with GAAP in each case for such period.

         "CONSOLIDATED INTEREST EXPENSE" means, for any Person and its
consolidated Subsidiaries and for any period, the amount of interest expense,
both expensed and capitalized, of such Person for such period, determined on a
consolidated basis in accordance with GAAP.

         "CONSOLIDATED TOTAL DEBT" means, as of any date of determination, all
Debt of Borrower and its Subsidiaries measured on a consolidated basis as of
such date.

         "CONSTITUENT DOCUMENTS" means, for any Person, the documents for its
formation and organization, which, for example, (i) for a corporation are its
corporate charter and bylaws, (ii) for a partnership is its partnership
agreement, (iii) for a limited liability company are its certificate of
organization and regulations, and (iv) for a trust is the trust agreement or
indenture under which it is created.

         "CONVERSION NOTICE" means a request pursuant to Section 3.11,
substantially in the form of Exhibit B-2.

         "CURRENT FINANCIALS" means, at the time of any determination thereof,
the more recently delivered to Lenders of either (a) the Financial Statements of
the type described in Section 9.3(b) for the fiscal year ended December 31,
2002, or (b) the most recent Financial Statements required to be delivered under
Sections 9.3(a) and (b).

         "DEBT" means (without duplication), for any Person, the sum of the
following: (a) all liabilities, obligations, and indebtedness of such Person
which in accordance with GAAP should be classified upon such Person's balance
sheet as liabilities in respect of (i) money borrowed, including, without
limitation, the Principal Debt, (ii) obligations of such Person under Capital
Leases, and (iii) obligations of such Person issued or assumed as the deferred
purchase price of property, all conditional sale obligations, and obligations
under any title retention agreement (but

                                      -5-
<PAGE>

excluding trade accounts payable arising in the ordinary course of business);
(b) the face amount of all letters of credit and banker's acceptances issued for
the account of such Person, and without duplication, all drafts drawn and unpaid
thereunder; (c) any liability with respect to obligations to deliver goods or
services in consideration of advance payments therefor, including any liability
with respect to payments received in consideration of oil, gas, or other
minerals yet to be acquired or produced at the time of payment (such as
obligations under contracts to deliver oil or gas in return for payments already
received and production payments created by such Person or for the creation of
which such Person directly or indirectly received payment); (d) all obligations
of the type referred to in clauses (a) through (c) preceding of other Persons
for the payment of which such Person is responsible or liable as obligor,
guarantor, or otherwise; and (e) all obligations of the type referred to in
clauses (a) through (d) preceding of other Persons secured by any Lien on any
property or asset of such Person whether or not such obligation is assumed by
such Person (except obligations of others secured by Liens, neither assumed nor
guaranteed by such Person nor on which it customarily pays interest, existing
upon real estate or rights in or relating to real estate acquired by such Person
for substation, metering station, gathering line, transmission line,
transportation line, distribution line or right of way purposes, and any Liens
reserved in leases for rent and for compliance with the terms of the leases in
the case of leasehold estates, to the extent that any such Lien referred to in
this clause (e) does not materially impair the use of the property), and, the
amount of such obligation being deemed to be the lesser of the value of such
property or assets or the amount of the obligation so secured, provided,
however, that the obligations referenced in this clause (e) shall not include
indebtedness (which is not assumed or guaranteed by Borrower or any Subsidiary
of Borrower) under the Fort Union Project Finance Documents which is secured by
Liens on the limited liability company interests of Crestone Powder River,
L.L.C. in Fort Union, L.L.C., nor indebtedness (which is not assumed or
guaranteed by Borrower or any Subsidiary of Borrower) which is secured by Liens
on the limited liability company interests of Crestone Wind River, L.L.C. in
Lost Creek, L.L.C. The Debt of any Person shall include the Debt of any other
Person (including any partnership in which such Person is a general partner) to
the extent such Person is liable therefor as a result of such Person's ownership
interest in or other relationship with such entity, except to the extent the
terms of such Debt provide that such Person is not liable therefor.

         "DEBTOR RELIEF LAWS" means the Bankruptcy Code of the United States of
America and all other applicable liquidation, conservatorship, bankruptcy,
moratorium, rearrangement, receivership, insolvency, reorganization, fraudulent
transfer or conveyance, suspension of payments, or similar Laws from time to
time in effect affecting the Rights of creditors generally.

         "DEFAULT" is defined in Article 11.

         "DEFAULT RATE" means an interest rate equal to the lesser of (a) Base
Rate plus the Applicable Margin, if any, applicable to Base Rate Borrowings plus
2% per annum and (b) the Maximum Rate; provided, however, that with respect to a
Eurodollar Rate Borrowing, until the end of the applicable Interest Period, the
Default Rate shall be an interest rate equal to the lesser of (x) the interest
rate (including any Applicable Margin) otherwise applicable to such Borrowing
plus 2% per annum, and (y) the Maximum Rate.

         "DERIVATIVE TRANSACTION" means (a) any rate, basis, commodity,
currency, debt or equity swap, (b) any cap, collar or floor agreement, (c) any
rate, basis, commodity, currency, debt or

                                      -6-
<PAGE>

equity exchange or forward agreement, (d) any rate, basis, commodity, currency,
debt or equity option, (e) any other similar agreement, (f) any option to enter
into any of the foregoing, (g) any master agreement or other agreement providing
for any of the foregoing and (h) any combination of any of the foregoing.

         "DISTRIBUTION" for any Person means, with respect to any shares of any
capital stock or other equity securities issued by such Person, (a) the
retirement, redemption, purchase, or other acquisition for value of any such
securities, (b) the declaration or payment of any dividend on or with respect to
any such securities, and (c) any other payment by such Person with respect to
such securities.

         "DOLLARS" and the symbol "$" means lawful money of the United States of
America.

         "ELIGIBLE ASSIGNEE" means a Lender or its Affiliates or any other
Person approved by Administrative Agent (which approval will not be unreasonably
withheld or delayed by Administrative Agent); provided, however, that neither
Borrower nor any Affiliate of Borrower shall qualify as an Eligible Assignee.
Unless a Default or Potential Default has occurred and is continuing at the time
any assignment is effected in accordance with Section 14.13, Borrower shall also
have the right to approve any Eligible Assignee, such approval not to be
unreasonably withheld or delayed by Borrower and such approval to be deemed
given by Borrower if no objection is received by the assigning Lender and
Administrative Agent from Borrower within five Business Days after notice of
such proposed assignment has been provided by the assigning Lender to Borrower.

         "EMPLOYEE PLAN" means an employee pension benefit plan covered by Title
IV of ERISA or subject to the minimum funding standards under Section 412 of the
Code and is or has been within the past five years established or maintained by
any Loan Party, Subsidiary thereof, or ERISA Affiliate or to which any Loan
Party, Subsidiary thereof or ERISA Affiliate is making, has made, is accruing or
has accrued an obligation to make contributions or has, within the past five
years made or accrued an obligation to make contributions, but not including any
Multiemployer Plan.

         "ENVIRONMENTAL LAW" means any applicable Law that relates to (a) the
condition or protection of air, groundwater, surface water, soil, or other
environmental media, (b) the environment, including natural resources or any
activity which affects the environment, (c) the regulation of any pollutants,
contaminants, wastes, substances, and Hazardous Substances, or (d) the Release
or threatened Release of Hazardous Substances.

         "ENVIRONMENTAL LIABILITY" means any obligation, liability (including,
without limitation, any strict liability), loss, fine, penalty, charge, Lien,
damage, cost, or expense of any kind to the extent that it results (a) from any
violation of or any obligation or liability under any Environmental Law, (b)
from the presence, Release, or threatened Release of any Hazardous Substance, or
(c) from actual or threatened damages to natural resources.

         "ERISA" means the Employee Retirement Income Security Act of 1974, as
amended from time to time, and any rule or regulation issued thereunder.

                                      -7-
<PAGE>

         "ERISA AFFILIATE" means each "person" (as defined in Section 3(a) of
ERISA) (whether or not incorporated) which, for purposes of Title IV of ERISA,
is, or has been within the past five years, a member of any Loan Party's
controlled group.

         "ERISA EVENT" means any of the following: (a) the occurrence of a
Reportable Event; (b) the application for a minimum funding waiver with respect
to an Employee Plan, or becoming obligated to file with the PBGC a notice of
failure to make a required payment with respect to any Employee Plan; (c) the
provision by the administrator of any Employee Plan of a notice of intent to
terminate such Employee Plan; (d) the withdrawal by any Loan Party, Subsidiary
thereof, or ERISA Affiliate, in whole or in part, from a Multiemployer Plan
under circumstances that give rise to withdrawal liability under Title IV of
ERISA; (e) the occurrence of any condition (under ERISA, the Code, or otherwise)
for the imposition of a Lien in favor of the PBGC on the assets of any Loan
Party, Subsidiary thereof, or ERISA Affiliate; (f) the adoption of an amendment
to an Employee Plan requiring the provision of security to such Employee Plan;
(g) institution by the PBGC of proceedings to terminate or impose liability in
respect of (other than premiums under Section 4007 of ERISA), any Employee Plan,
or the occurrence of any event or condition that constitutes grounds for
termination of, or the appointment of a trustee to administer, any Employee
Plan; (h) institution by the sponsor of a Multiemployer Plan of proceedings to
terminate or reorganize such Multiemployer Plan, or to impose withdrawal
liability on any Loan Party, Subsidiary thereof, or ERISA Affiliate with respect
to such Multiemployer Plan; (i) the cessation of operations at a facility of any
Loan Party, Subsidiary thereof, or ERISA Affiliate in the circumstances
described in Section 4062(e) of ERISA; or (j) any Loan Party, Subsidiary
thereof, or ERISA Affiliate has engaged in any "prohibited transaction" (as
defined in Section 406 of ERISA or Section 4975 of the Code).

         "EURODOLLAR RATE" means, for any Eurodollar Rate Borrowing for any
Interest Period therefor, the rate per annum (rounded upwards, if necessary, to
the nearest 1/100 of 1%) appearing on Dow Jones Markets Page 3750 (or any
successor page) as the London interbank offered rate for deposits in Dollars at
approximately 11:00 a.m. (London time) two Business Days prior to the first day
of such Interest Period for a term comparable to such Interest Period. If for
any reason such rate is not available, the term "EURODOLLAR RATE" shall mean,
for any Eurodollar Rate Borrowing for any Interest Period therefor, the rate per
annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) appearing on
Reuters Screen LIBO Page as the London interbank offered rate for deposits in
Dollars at approximately 11:00 a.m. (London time) two Business Days prior to the
first day of such Interest Period for a term comparable to such Interest Period;
provided, however, if more than one rate is specified on Reuters Screen LIBO
Page, the applicable rate shall be the arithmetic mean of all such rates
(rounded upwards, if necessary, to the nearest 1/100 of 1%).

         "EURODOLLAR RATE BORROWING" means a Borrowing bearing interest at the
sum of the Eurodollar Rate plus the Applicable Margin for Eurodollar Rate
Borrowings.

         "EXISTING CREDIT AGREEMENT" means the Revolving Credit Agreement, dated
as of March 21, 2001, as amended, among Borrower, SunTrust Bank, as
administrative agent, and the other agents and lenders named therein.

         "EXHIBIT" means an exhibit to this Agreement unless otherwise
specified.

                                      -8-
<PAGE>

         "FACILITY" means the credit facility as described in and subject to the
limitations set forth in Section 2.1 hereof, including the LC Subfacility.

         "FEDERAL FUNDS RATE" means, for any day, the rate per annum (rounded
upwards, if necessary, to the nearest 1/100 of 1%) determined (which
determination shall be conclusive and binding, absent manifest error) by
Administrative Agent to be equal to the weighted average of the rates on
overnight Federal funds transactions with member banks of the Federal Reserve
System arranged by Federal funds brokers on such day, as published by the
Federal Reserve Bank of New York on the Business Day next succeeding such day;
provided that (a) if such day is not a Business Day, the Federal Funds Rate for
such day shall be such rate on such transactions on the next preceding Business
Day as so published on the next succeeding Business Day, and (b) if no such rate
is so published on such next succeeding Business Day, the Federal Funds Rate for
such day shall be the average rate charged to Administrative Agent (in its
individual capacity) on such day on such transactions as determined by
Administrative Agent (which determination shall be conclusive and binding,
absent manifest error).

         "FINANCIAL STATEMENTS" is defined in Section 9.3(a).

         "FORT UNION, L.L.C." means Fort Union Gas Gathering, L.L.C., a Delaware
limited liability company.

         "FORT UNION PROJECT FINANCE DOCUMENTS" means the Construction and Term
Credit Agreement dated as of April 16, 1999 among Fort Union, L.L.C. as
Borrower, Fleet National Bank, as administrative agent and the other lenders and
agents parties thereto, and the other agreements executed as security therefor
or pursuant thereto, as the same may from time to time be amended.

         "GAAP" means generally accepted accounting principles of the Accounting
Principles Board of the American Institute of Certified Public Accountants and
the Financial Accounting Standards Board which are applicable from time to time.

         "GENERAL PARTNER" means any of Northern Plains, Pan Border, Northwest
Border, any other general partner of Borrower and each of their successors and
assigns in such capacity.

         "GOVERNMENTAL AUTHORITY" means any (a) local, state, municipal, or
federal judicial, executive, or legislative instrumentality, (b) private
arbitration board or panel, or (c) central bank.

         "GUARANTOR" means Intermediate Partnership and any other Person that
becomes a "Guarantor" under the Guaranty.

         "GUARANTY" means (a) a Guaranty in substantially the form and upon the
terms of Exhibit C, executed and delivered by any Person pursuant to the
requirements of the Loan Documents; and (b) any amendments, modifications,
supplements, restatements, ratifications, or reaffirmations of any Guaranty made
in accordance with the Loan Documents.

         "GUARDIAN" means Guardian Pipeline, L.L.C., a Delaware limited
liability company.

                                      -9-
<PAGE>

         "HAZARDOUS SUBSTANCE" means (a) any substance that is designated,
defined, or classified as a hazardous waste, hazardous material, pollutant,
contaminant, or toxic or hazardous substance, or that is otherwise regulated,
under any Environmental Law, including without limitation, any hazardous
substance within the meaning of Section 101(14) of the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 ("CERCLA"), (b)
petroleum, oil, gasoline, natural gas, fuel oil, motor oil, waste oil, diesel
fuel, jet fuel, and other petroleum hydrocarbons, (c) asbestos and
asbestos-containing materials in any form, (d) polychlorinated biphenyls, or (e)
urea formaldehyde foam.

         "INTEREST PERIOD" is determined in accordance with Section 3.10.

         "INTERMEDIATE PARTNERSHIP" means Northern Border Intermediate Limited
Partnership, a Delaware limited partnership.

         "INTERMEDIATE PARTNERSHIP AGREEMENT" means that certain Amended and
Restated Agreement of Limited Partnership of Northern Border Intermediate
Limited Partnership dated as of October 1, 1993 as the same may have been or may
hereafter be amended, supplemented, restated or otherwise modified from time to
time.

         "LAWS" means all applicable statutes, laws, treaties, ordinances,
tariff requirements, rules, regulations, orders, writs, injunctions, decrees,
judgments, opinions, awards or interpretations of any Governmental Authority.

         "LC" means the letter(s) of credit issued hereunder in the form agreed
upon among Borrower, Administrative Agent, and the beneficiary thereof at the
time of issuance thereof and participated in by Lenders pursuant to the terms
and conditions of Section 2.2 hereof.

         "LC AGREEMENT" means a letter of credit application and agreement (in
form and substance satisfactory to Administrative Agent) submitted by Borrower
to Administrative Agent for an LC for its own account (and for its benefit or
the benefit of any of Borrower's Subsidiaries); provided that this Agreement
shall control any conflict between this Agreement and any such LC Agreement.

         "LC EXPOSURE" means, at any time and without duplication, the sum of
(a) the aggregate undrawn portion of all uncancelled and unexpired LCs plus (b)
the aggregate unpaid reimbursement obligations of Borrower in respect of
drawings of drafts under any LC.

         "LC REQUEST" means a request pursuant to Section 2.2(a), substantially
in the form of Exhibit B-3.

         "LC SUBFACILITY" means a subfacility of the Facility for the issuance
of LCs as described in and subject to the limitations of Section 2.2, under
which the LC Exposure may never (a) collectively exceed $50,000,000 and (b)
together with the Principal Debt may never exceed the Commitment.

         "LENDERS" means, on any date, the financial institutions named on
Schedule 2.1 (as the same may be amended from time to time by Administrative
Agent to reflect the assignments made in accordance with Section 14.13(b) of
this Agreement), and subject to the terms and

                                      -10-
<PAGE>

conditions of this Agreement, and their respective successors and assigns (but
not any Participant who is not otherwise a party to this Agreement).

         "LETTER OF CREDIT CASH COLLATERAL ACCOUNT" means a blocked deposit
account held by Administrative Agent with respect to which Borrower hereby
pledges and grants a security interest in and lien on such account to
Administrative Agent for and on behalf of Lenders as security for LC Exposure
and with respect to which Borrower agrees to execute and deliver from time to
time such documentation as Administrative Agent may reasonably request to
further assure and confirm such security interest.

         "LIEN" means any lien, mortgage, security interest, pledge, assignment,
charge, title retention agreement, encumbrance of any kind, Right or arrangement
with or for the benefit of any creditor (other than under or relating to
subordination or other intercreditor arrangements) to have its claim satisfied
out of any property or assets, or the proceeds therefrom, prior to the general
creditors of the owner thereof.

         "LIMITED PARTNERSHIP UNITS" means Common Units and any other units
representing a limited partner's interest in Borrower.

         "LITIGATION" means any action by or before any Governmental Authority.

         "LOAN DOCUMENTS" means (a) this Agreement and all schedules and
exhibits attached hereto, the Notes, each Guaranty, LCs, and LC Agreements, (b)
all agreements, documents, or instruments in favor of the Administrative Agent
or Lenders now or hereafter delivered pursuant to this Agreement or otherwise
delivered in connection herewith, and (c) any and all future renewals,
extensions, restatements, reaffirmations, or amendments of, or supplements to,
all or any part of the foregoing.

         "LOAN PARTIES" means, on any date of determination, Borrower and all
Guarantors; and "LOAN PARTY" means any one of them.

         "LOST CREEK L.L.C." means Lost Creek Gathering Company, L.L.C., a
Delaware limited liability company.

         "LOST CREEK PROJECT FINANCE DOCUMENTS" means the Construction and Term
Credit Agreement dated as of September 24, 1999 among Lost Creek, L.L.C. as
Borrower, Barclays Bank PLC, as Administrative Agent and the other Lenders party
thereto and the other agreements executed as security therefor or pursuant
thereto, as the same may from time to time be amended.

         "MATERIAL ADVERSE EVENT" means any set of one or more circumstances or
events which, individually or collectively, result in any (a) material
impairment of the ability of any Loan Party to perform any of its payment or
other material obligations under the Loan Documents or the ability of
Administrative Agent or any Lender to enforce any such obligations or any of
their respective Rights under the Loan Documents, (b) material and adverse
effect on the business, properties, condition (financial or otherwise), or
results of operations of any Loan Party, NBPC, or any Loan Party and its
Subsidiaries taken as a whole, or (c) a Default or Potential Default.

                                      -11-
<PAGE>

         "MATERIAL SUBSIDIARY" means any Subsidiary the assets of which
comprised more than 5% of consolidated assets of Borrower and its Subsidiaries
at the end of the fiscal year of Borrower immediately prior to the date of
determination, or the gross revenue of which for any of the three fiscal years
of Borrower immediately prior to the date of determination comprised more than
5% of consolidated gross revenue, all as determined by reference to the
applicable financial statements of such Subsidiary and Borrower.

         "MAXIMUM AMOUNT" and "MAXIMUM RATE" respectively mean, for each Lender,
the maximum non-usurious amount and the maximum non-usurious rate of interest
which, under applicable Law, such Lender is permitted to contract for, charge,
take, reserve, or receive on the Obligation.

         "MOODY'S" means Moody's Investor Service, Inc. or any successor
thereto.

         "MULTIEMPLOYER PLAN" means a multiemployer plan as defined in Section
4001(a)(3) of ERISA or Section 414(f) of the Code to which Borrower or any of
its Subsidiaries, or any ERISA Affiliate of Borrower or any of its Subsidiaries
is making, has made, is accruing, or has accrued, an obligation to make
contributions or has, within any of the preceding five plan years, made or
accrued an obligation to make contributions.

         "NBPC" means Northern Border Pipeline Company, a Texas general
partnership.

         "NBPC LEVERAGE RATIO" means the ratio calculated in accordance with
Section 6.3.1 of that certain Credit Agreement, dated May 16, 2002, among NBPC,
Bank One, NA, as agent, and the lenders defined therein, as in effect on the
date of this Agreement, without regard to whether said credit agreement is
amended or ceases to be in effect after the date hereof.

         "NET INCOME" means, for any Person and its consolidated Subsidiaries
and for any period, the profit or loss of such Person and its consolidated
Subsidiaries for such period after deducting all operating expenses, provision
for income taxes and reserves, and all other deductions calculated, in each
case, in accordance with GAAP, but excluding (a) extraordinary items, and (b)
the profit or loss of any Subsidiary accrued before the date that (i) it becomes
a Subsidiary of such Person, (ii) it is merged with such Person or any of its
Subsidiaries, or (iii) its assets are acquired by such Person of any of its
Subsidiaries.

         "NORTHERN BORDER PARTNERSHIP AGREEMENT" means that certain General
Partnership Agreement relating to the formation of NBPC effective as of March 9,
1978 as heretofore amended, modified and supplemented and as such agreement may
hereafter from time to time be further amended, modified or supplemented.

         "NORTHERN PLAINS" means Northern Plains Natural Gas Company, a Delaware
corporation.

         "NORTHWEST BORDER" means Northwest Border Pipeline Company, a Delaware
corporation.

                                      -12-
<PAGE>

         "NOTE" means a promissory note of the Borrower payable to the order of
a requesting Lender in the principal amount of such Lender's Committed Sum,
substantially in the form of Exhibit A, and all renewals, extensions or
replacements of all or any part thereof.

         "OBLIGATION" means all present and future indebtedness, liabilities,
and obligations, and all renewals and extensions thereof, or any part thereof,
now or hereafter owed to Administrative Agent, any Lender, or any Affiliate of
any Lender by any Loan Party or any Subsidiary thereof arising from, by virtue
of, or pursuant to any Loan Document, together with all interest accruing
thereon, fees, costs, and expenses (including, without limitation, all
attorneys' fees and expenses incurred in the enforcement or collection thereof)
payable under the Loan Documents.

         "PAN BORDER" means Pan Border Gas Company, a Delaware corporation.

         "PARTICIPANT" is defined in Section 14.13(e).

         "PARTNERSHIP AGREEMENT" means the Amended and Restated Agreement of
Limited Partnership of Northern Border Partners, L.P., dated as of October 1,
1993 as the same may have been or may hereafter be amended, supplemented,
restated or otherwise modified from time to time.

         "PBGC" means the Pension Benefit Guaranty Corporation, or any successor
thereof, established pursuant to ERISA.

         "PERMITTED LIENS" means Liens permitted under Section 10.2 as described
in such Section.

         "PERSON" means any individual, partnership, firm, corporation,
association, joint venture, limited liability company, trust or other entity, or
any Governmental Authority.

         "POTENTIAL DEFAULT" means the occurrence of any event or existence of
any circumstance which, with the giving of notice or lapse of time or both,
would become a Default.

         "PRIME RATE" means the per annum rate of interest established from time
to time by SunTrust Bank, as its prime rate, which rate may or may not be the
lowest rate of interest charged by SunTrust Bank to its customers.

         "PRINCIPAL DEBT" means, on any date of determination, the aggregate
unpaid principal balance of all Borrowings under the Facility, together with the
aggregate unpaid reimbursement obligations of Borrower in respect of drawings
under any LC.

         "PRO RATA" or "PRO RATA PART," for each Lender, means on any date of
determination (a) for purposes of sharing any amount or fee payable to any
Lender in respect of the Facility or the LC Subfacility (as the case may be) the
proportion which the portion of the Principal Debt for the Facility or LC
Subfacility owed to such Lender (whether held directly or through a
participation in respect of the LC Subfacility and determined after giving
effect thereto) bears to the Principal Debt under the Facility or LC Subfacility
(as the case may be) owed to all Lenders at the time in question, and (b) for
all other purposes, the proportion which the portion of the Principal Debt owed
to such Lender bears to the Principal Debt owed to all Lenders at the time in

                                      -13-
<PAGE>

question, or if no Principal Debt is outstanding, then the proportion that the
aggregate of such Lender's Committed Sum then in effect under the Facility and
LC Subfacility bears to the Commitment then in effect.

         "REGISTER" is defined in Section 14.13(c).

         "REGULATION T" means Regulation T of the Board of Governors of the
Federal Reserve System, as amended.

         "REGULATION U" means Regulation U of the Board of Governors of the
Federal Reserve System, as amended.

         "REGULATION X" means Regulation X of the Board of Governors of the
Federal Reserve System, as amended.

         "RELEASE" means any spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, dumping, disposal,
deposit, dispersal, migrating, or other movement into the air, ground, or
surface water, or soil.

         "REPORTABLE EVENT" shall have the meaning specified in Section 4043 of
ERISA or the regulations issued thereunder in connection with an Employee Plan,
excluding events for which the notice requirement is waived under applicable
PBGC regulations other than those events described in Sections 4043.21, 4043.24,
and 4043.28 of such regulations, including each such provision as it may
subsequently be renumbered.

         "REPORTING ENTITIES" is defined in Section 8.6.

         "REPRESENTATIVES" means representatives, officers, directors,
employees, attorneys, and agents of a Person.

         "REQUIRED LENDERS" means (a) on any date of determination on and after
the Closing Date and prior to the initial Borrowing Date under the Loan
Documents, those Lenders holding 51% or more of the Commitment; (b) on any date
of determination on and after the initial Borrowing Date under the Loan
Documents and prior to the Termination Date for the Facility, those Lenders
holding 51% of the Commitment; and (c) on any date of determination on or after
the Termination Date for the Facility, those Lenders holding 51% or more of the
Principal Debt.

         "RESPONSIBLE OFFICER" means the chief executive officer, chief
financial officer, senior vice president, or treasurer of Borrower, or, for all
purposes under the Loan Documents, any other officer designated from time to
time by the Partnership Policy Committee of Borrower, which designated officer
is acceptable to Administrative Agent.

         "RIGHTS" means rights, remedies, powers, privileges, and benefits.

         "ROLLING PERIOD" means, on any date of determination, the most recent
four fiscal quarters ended on March 31, June 30, September 30, or December 31
(as the case may be).

                                      -14-
<PAGE>

         "S&P" means Standard and Poor's Rating Services, a division of
McGraw-Hill Companies, Inc.

         "SCHEDULE" means, unless specified otherwise, a schedule attached to
this Agreement, as the same maybe supplemented and modified from time to time in
accordance with the terms of the Loan Documents.

         "SENIOR NOTE INDENTURES" means the 2010 Senior Note Indenture and/or
the 2011 Senior Note Indenture, as the case may be.

         "SENIOR NOTES" means the 2010 Senior Notes and/or the 2011 Senior
Notes, as the case may be.

         "SUBSIDIARY" of any Person means (a) any entity of which an aggregate
of more than 50% (in number of votes) of the stock is owned of record or
beneficially, directly or indirectly, by such Person, or (b) any partnership
(limited or general) of which such Person shall, directly or indirectly, at any
time be the controlling general partner determined in accordance with GAAP or
own fifty percent (50%) or more of the issued and outstanding partnership
interests.

         "TAXES" means, for any Person, taxes, assessments, or other
governmental charges or levies imposed upon such Person, its income, or any of
its properties, franchises, or assets.

         "TERMINATION DATE" means, the earlier of (i) November 24, 2007, and
(ii) the effective date of any other termination, cancellation, or acceleration
of all commitments to lend under the Facility.

         "TYPE" means any type of Borrowing determined with respect to the
interest option applicable thereto.

         "VIKING" means Viking Gas Transmission Company, a Delaware corporation.

         "VIKING INDENTURE" means that certain Indenture, Assignment and
Security Agreement, dated as of November 1, 1993, between Viking as Issuer and
Norwest Bank Minnesota, National Association as Trustee, as amended by
Supplemental Indenture No. 1, dated as of November 1, 1996, as amended by
Supplemental Indenture No. 2, dated as of December 20, 1996, as amended by
Supplemental Indenture No. 3, dated as of October 15, 1997, as amended by
Supplemental Indenture No. 4, dated as of October 27, 1999 as amended from time
to time, provided that the effect of such amendment shall not be to (a) increase
the principal amount of, or the rate of interest on, Debt authorized thereunder;
(b) change the dates upon which payments of principal or interest are due on any
Debt authorized thereunder other than to postpone such dates; (c) change or add
any covenant, default or event of default therein, other than to make any such
covenant, default or event of default provision less restrictive; (d) change the
redemption or prepayment provisions relating to Debt authorized thereunder,
other than to waive such provisions or to reduce the amounts payable thereunder;
(e) grant any additional security or collateral to secure payment of Debt
authorized thereunder; or (f) change or amend any other term if such change or
amendment would materially increase the obligations of Viking thereunder or
confer additional material rights on the holder of any Debt issued thereunder in
a manner adverse to Lenders.

                                      -15-
<PAGE>

         "VOTING STOCK" means securities (as such term is defined in Section
2(1) of the Securities Act of 1933, as amended) of any class or classes, the
holders of which are ordinarily, in the absence of contingencies, entitled to
elect a majority of the corporate directors (or Persons performing similar
functions).

         SECTION 1.2 NUMBER AND GENDER OF WORDS; OTHER REFERENCES.

         Unless otherwise specified in the Loan Documents, (a) where
appropriate, the singular includes the plural and vice versa, and words of any
gender include each other gender, (b) heading and caption references may not be
construed in interpreting provisions, (c) monetary references are to currency of
the United States of America, (d) section, paragraph, annex, schedule, exhibit,
and similar references are to the particular Loan Document in which they are
used, (e) references to "telecopy," "facsimile," "fax," or similar terms are to
facsimile or telecopy transmissions, (f) references to "including" mean
including without limiting the generality of any description preceding that
word, (g) the rule of construction that references to general items that follow
references to specific items are limited to the same type or character of those
specific items is not applicable in the Loan Documents, (h) references to any
Person include that Person's heirs, personal representatives, successors,
trustees, receivers, and permitted assigns, (i) references to any Law include
every amendment or supplement to it, rule and regulation adopted under it, and
successor or replacement for it, and (j) references to any Loan Document or
other document include every renewal and extension of it, amendment and
supplement to it, and restatement, replacement or substitution for it.

         SECTION 1.3 ACCOUNTING PRINCIPLES.

         All accounting and financial terms used in the Loan Documents and the
compliance with each financial covenant therein shall be determined in
accordance with GAAP, and, all accounting principles shall be applied on a
consistent basis so that the accounting principles in a current period are
comparable in all material respects to those applied during the preceding
comparable period.

                                   ARTICLE II
                              BORROWING PROVISIONS

         SECTION 2.1 FACILITY.

         Each Lender severally, but not jointly, agrees to lend to Borrower such
Lender's Commitment Percentage of one or more Borrowings under the Facility not
to exceed such Lender's Committed Sum under the Facility, which Borrowings may
be repaid and reborrowed from time to time in accordance with the terms and
provisions of the Loan Documents; provided that, (a) each such Borrowing must
occur on a Business Day and no later than the Business Day immediately preceding
the Termination Date for the Facility; (b) each such Borrowing shall be in an
amount not less than $5,000,000 or a greater integral multiple of $1,000,000;
and (c) on any date of determination, the Commitment Usage shall never exceed
the Commitment.

         SECTION 2.2 LC SUBFACILITY.

                                      -16-
<PAGE>

         (a)      CONDITIONS. Subject to the terms and conditions of this
Agreement and applicable Law, Administrative Agent agrees to issue LCs
(denominated in Dollars) upon Borrower's application therefor by delivering to
Administrative Agent a properly completed LC Request and an LC Agreement with
respect thereto no later than 11:00 a.m. Atlanta, Georgia time three Business
Days before such LC is to be issued; provided that, (i) on any date of
determination and after giving effect to any LC to be issued on such date, the
Commitment Usage shall never exceed the Commitment then in effect, (ii) on any
date of determination and after giving effect to any LC to be issued on such
date, the LC Exposure shall never exceed $50,000,000 (as such commitment under
the LC Subfacility may be reduced or canceled as herein provided), (iii) at the
time of issuance of such LC, no Default or Potential Default shall have occurred
and be continuing and the conditions precedent set forth in Section 7.2 shall
have been satisfied or waived in accordance herewith and (iv) each LC must
expire no later than the earlier of the 30th day prior to the Termination Date
or one year from its issuance.

         (b)      PARTICIPATIONS. Immediately upon the issuance by
Administrative Agent of any LC, Administrative Agent shall be deemed to have
sold and transferred to each other Lender, and each other such Lender shall be
deemed irrevocably and unconditionally to have purchased and received from
Administrative Agent, without recourse or warranty, an undivided interest and
participation, to the extent of such Lender's Commitment Percentage (based upon
the Facility), in such LC, the LC Agreement related thereto, and all Rights of
Administrative Agent in respect thereof (other than Rights to receive certain
fees provided for in Section 5.4(b)).

         (c)      REIMBURSEMENT OBLIGATION. To induce Administrative Agent to
issue and maintain LCs and to induce Lenders to participate in issued LCs,
Borrower agrees to pay or reimburse Administrative Agent (i) on the date on
which any draft is presented under any LC, the amount of any draft paid or to be
paid by Administrative Agent and (ii) promptly, upon demand, the amount of any
fees (in addition to the fees described in Article 5) which Administrative Agent
customarily charges to a Person similarly situated in the ordinary course of its
business for amending LC Agreements, for honoring drafts under letters of
credit, and taking similar action in connection with letters of credit. If
Borrower has not reimbursed Administrative Agent for any drafts paid or to be
paid within 24 hours of demand therefor by Administrative Agent, Administrative
Agent is hereby irrevocably authorized to fund such reimbursement obligations as
a Base Rate Borrowing under the Facility to the extent of availability under the
Facility and if the conditions precedent in this Agreement for such a Borrowing
(other than any notice requirements or minimum funding amounts) have, to
Administrative Agent's knowledge, been satisfied. The proceeds of such Borrowing
under the Facility shall be advanced directly to Administrative Agent in payment
of Borrower's unpaid reimbursement obligation. If for any reason, funds cannot
be advanced under the Facility, then Borrower's reimbursement obligation shall
continue to be due and payable. Borrower's obligations under this Section 2.2(c)
shall be absolute and unconditional under any and all circumstances and
irrespective of any setoff, counterclaim, or defense to payment which Borrower
may have at any time against Administrative Agent or any other Person. From the
date that Administrative Agent pays a draft under an LC until the related
reimbursement obligation of Borrower is paid or funded by proceeds of a
Borrowing, (x) unpaid reimbursement obligations which are funded pursuant to a
Base Rate Borrowing shall accrue interest at the rate then applicable to Base
Rate Borrowings, and (y) unpaid reimbursement obligations which are

                                      -17-
<PAGE>

not so funded shall accrue interest at the Default Rate, which accrued interest
shall be payable on demand.

         (d)      GENERAL. Administrative Agent shall promptly notify Borrower
of the date and amount of any draft presented for honor under any LC (but
failure to give any such notice shall not affect Borrower's obligations under
this Agreement). Administrative Agent shall pay the requested amount upon
presentment of a draft for honor unless such presentment on its face does not
comply with the terms of the applicable LC. When making payment, Administrative
Agent may disregard (i) any default or potential default that exists under any
other agreement and (ii) the obligations under any other agreement that have or
have not been performed by the beneficiary or any other Person (and
Administrative Agent shall not be liable for any obligation of any Person
thereunder). Borrower's reimbursement obligations to Administrative Agent and
Lenders, and each Lender's obligations to Administrative Agent, under this
Section 2.2 are absolute and unconditional irrespective of, and Administrative
Agent is not responsible for, (i) the validity, enforceability, sufficiency,
accuracy, or genuineness of documents or endorsements which appear appropriate
on their face (even if they are in any respect invalid, unenforceable,
insufficient, inaccurate, fraudulent, or forged), (ii) any dispute by Borrower
or any of its Subsidiaries with Borrower's or any of its Subsidiaries' claims,
setoffs, defenses, counterclaims, or other Rights against Administrative Lender,
any Lender, or any other Person, or (iii) the occurrence of any Potential
Default or Default. However, nothing in this Section 2.2 constitutes a waiver of
the Rights of Borrower or any Lender to assert any claim or defense based upon
the gross negligence or willful misconduct of Administrative Agent. To the
extent any Lender has funded its ratable share of any draft under an LC, then
Administrative Agent shall promptly distribute reimbursement payments received
from Borrower to such Lender according to its ratable share. In the event any
payment by Borrower received by Administrative Agent with respect to an LC and
distributed to Lenders on account of their participations therein is thereafter
set aside, avoided, or recovered from Administrative Agent in connection with
any receivership, liquidation, or bankruptcy proceeding, each Lender which
received such distribution shall, upon demand by Administrative Agent,
contribute such Lender's ratable portion of the amount set aside, avoided, or
recovered, together with interest at the rate required to be paid by
Administrative Agent upon the amount required to be repaid by it.

         (e)      OBLIGATION OF LENDERS. If Borrower fails to reimburse
Administrative Agent as provided in Section 2.2(c) within twenty-four (24) hours
of the demand therefor by Administrative Agent and funds cannot be advanced
under the Facility to satisfy the reimbursement obligations, then Administrative
Agent shall promptly notify each Lender of Borrower's failure, of the date and
amount of the draft paid, and of such Lender's Commitment Percentage thereof.
Each Lender shall promptly and unconditionally fund its participation interest
in such unreimbursed draft by making available to Administrative Agent in
immediately available funds such Lender's Commitment Percentage (based upon the
Facility) of the unreimbursed draft. Funds are due and payable to Administrative
Agent on or before the close of business on the Business Day when Administrative
Agent gives notice to each Lender of Borrower's reimbursement failure (if given
prior to 2:00 p.m., Atlanta, Georgia time) or on the next succeeding Business
Day (if notice was given after 2:00 p.m., Atlanta, Georgia time). All amounts
payable by any Lender shall accrue interest at the Federal Funds Rate from the
day the applicable draft is paid by Administrative Agent to (but not including)
the date the amount is paid by Lender to Administrative Agent.

                                      -18-
<PAGE>

         (f)      DUTIES OF ADMINISTRATIVE AGENT AS ISSUING LENDER.
Administrative Agent agrees with each Lender that it will exercise and give the
same care and attention to each LC as it gives to its other letters of credit.
Administrative Agent's sole liability to each Lender with respect to such LCs
(other than liability arising from the gross negligence or willful misconduct of
Administrative Agent) shall be to distribute promptly to each Lender who has
acquired a participating interest therein such Lender's ratable portion of any
payments made to Administrative Agent by Borrower pursuant to Section 2.2(d).
Each Lender and Borrower agree that, in paying any draw under any LC,
Administrative Agent shall not have any responsibility to obtain any document
(other than any documents required by the respective LC) or to ascertain or
inquire as to any document's validity, enforceability, sufficiency, accuracy, or
genuineness or the authority of any Person delivering any such document.
Administrative Agent, Lenders, and their respective Representatives shall not be
liable to any other Lender or Borrower or any of its Subsidiaries for any LCs
use or for any beneficiary's acts or omissions.

         (g)      CASH COLLATERAL. On the Termination Date for the Facility, or
on any date that the LC Exposure exceeds the then-effective commitment under the
LC Subfacility, or upon any demand by Administrative Agent upon the occurrence
and during the continuance of a Default, Borrower shall provide to
Administrative Agent, for the benefit of Lenders, (i) cash collateral in Dollars
in an amount equal to 110% of the LC Exposure existing on such date, such cash
and all interest thereon shall constitute cash collateral for all LCs, and (ii)
such additional cash collateral as Administrative Agent may from time to time
require, so that the cash collateral amount shall at all times equal or exceed
110% the LC Exposure. Any cash collateral deposited under this clause (g), and
all interest earned thereon, shall be deposited into a Letter of Credit Cash
Collateral Account.

         (h)      LETTER OF CREDIT CASH COLLATERAL ACCOUNT.

                  (i)      Borrower hereby pledges and grants a security
         interest in and lien on the Letter of Credit Cash Collateral Account
         and all funds, cash and instruments at any time on deposit or held
         therein to the Administrative Agent for and on behalf of Lenders as
         security for the Obligation. The Letter of Credit Cash Collateral
         Account shall be under the exclusive dominion and control of the
         Administrative Agent. The Administrative Agent may, at any time during
         the continuation of a Default without notice to Borrower, apply funds
         then held in the Letter of Credit Cash Collateral Account to the
         payment of the Obligation in respect of LCs (and, if no LCs are
         outstanding or the face amount thereof is less than the amount on
         deposit in the Cash Collateral Account, to other amounts owed under
         this Agreement).

                  (ii)     The rate of interest earned on the Letter of Credit
         Cash Collateral Account shall be comparable to the rates paid by
         Administrative Agent on other similar accounts as in effect time to
         time; provided, however, that Administrative Agent shall not be
         obligated to pay interest on said account during the continuation of a
         Default.

                  (iii)    There shall be no release to Borrower of funds from
         the Letter of Credit Cash Collateral Account at any time during the
         continuance of a Potential Default or a Default.

                                      -19-
<PAGE>

                  (iv)     Borrower agrees to pay to SunTrust Bank all customary
         fees, costs and expenses which SunTrust Bank incurs in connection with
         opening and maintaining the Letter of Credit Cash Collateral Account.

         (i)      INDEMNIFICATION. BORROWER SHALL PROTECT, INDEMNIFY, PAY, AND
SAVE ADMINISTRATIVE AGENT AND EACH LENDER HARMLESS FROM AND AGAINST ANY AND ALL
CLAIMS, DEMANDS, LIABILITIES, DAMAGES, OR LOSSES OF, OR OWED TO THIRD PARTIES
(INCLUDING ANY OF THE FOREGOING ARISING FROM THE NEGLIGENCE OF ADMINISTRATIVE
AGENT, LENDERS, OR THEIR RESPECTIVE REPRESENTATIVES), AND ANY AND ALL RELATED
COSTS, CHARGES, AND EXPENSES (INCLUDING REASONABLE ATTORNEYS' FEES), WHICH
ADMINISTRATIVE AGENT, OR ANY LENDER MAY INCUR OR BE SUBJECT TO AS A CONSEQUENCE,
DIRECT OR INDIRECT, OF (A) THE ISSUANCE OF ANY LC, (B) ANY DISPUTE ABOUT AN LC,
OR (C) THE FAILURE OF ADMINISTRATIVE AGENT TO HONOR A DRAFT UNDER SUCH LC AS A
RESULT OF ANY ACT OR OMISSION (WHETHER RIGHT OR WRONG) OF ANY PRESENT OR FUTURE
GOVERNMENTAL AUTHORITY. HOWEVER, NO PERSON IS ENTITLED TO INDEMNITY HEREUNDER
FOR ITS OWN GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. THE FOREGOING INDEMNITY
PROVISIONS SHALL SURVIVE THE SATISFACTION AND PAYMENT OF THE OBLIGATION AND
TERMINATION OF THIS AGREEMENT.

         (j)      LC AGREEMENTS. Although referenced in any LC, terms of any
particular agreement or other obligation to the beneficiary are not incorporated
into this Agreement in any manner. The fees and other amounts payable with
respect to each LC are as provided in this Agreement, drafts under any LC shall
be deemed part of the Obligation, and in the event of any conflict between the
terms of this Agreement and any LC Agreement, the terms of this Agreement shall
be controlling.

         SECTION 2.3 TERMINATIONS OR REDUCTIONS OF COMMITMENTS.

         (a)      VOLUNTARY COMMITMENT REDUCTION. Without premium or penalty,
and upon giving not less than three Business Days prior written and irrevocable
notice to Administrative Agent, Borrower may terminate in whole or in part the
unused portion of the Commitment, or the commitment under the LC Subfacility;
provided that: (i) each partial termination of the Commitment shall be in an
amount of not less than $5,000,000 or a greater integral multiple of $1,000,000;
each partial termination of the commitment under the LC Subfacility shall be in
an amount of not less than $1,000,000 or a greater integral multiple of
$500,000; and (ii) on any date of determination, the amount of the Commitment
may not be reduced below the Commitment Usage, and the commitment under the LC
Subfacility shall not be reduced below the LC Exposure. At the time of any
commitment termination under this Section 2.3, Borrower shall pay to
Administrative Agent, for the account of each Lender any amounts that may then
be due under Section 3.3(c), all accrued and unpaid fees then due and payable
under this Agreement, the interest attributable to the amount of that reduction,
and any related Consequential Loss. Any part of the Commitment or the commitment
under the LC Subfacility that is terminated may not be reinstated.

                                      -20-
<PAGE>

         (b)      ADDITIONAL REDUCTIONS. The commitment under the LC Subfacility
shall be reduced from time to time on the date of any mandatory or voluntary
reduction of the Commitment by the amount, if any, by which such LC Subfacility
exceeds the Commitment after giving effect to such reduction of the Commitment.

         (c)      RATABLE ALLOCATION OF COMMITMENT REDUCTIONS. Each reduction of
the Commitment under this Section 2.3 shall be allocated among Lenders in
accordance with their respective Commitment Percentages under the Facility.

                  SECTION 2.4 BORROWING PROCEDURE.

                  The following procedures apply to all Borrowings:

         (a)      BORROWING REQUEST. Borrower may request a Borrowing by making
or delivering a Borrowing Notice to Administrative Agent requesting that Lenders
fund a Borrowing on a certain date (the "BORROWING DATE"), which Borrowing
Notice (i) shall be irrevocable and binding on Borrower, (ii) shall specify the
Facility or LC Subfacility, (iii) shall specify the Borrowing Date, amount,
Type, and (for a Borrowing comprised of Eurodollar Rate Borrowings) Interest
Period, and (iv) must be received by Administrative Agent no later than 11:00
a.m. Atlanta, Georgia time on the third Business Day preceding the Borrowing
Date for any Eurodollar Rate Borrowing or on the requested Borrowing Date (which
shall be a Business Day for any Base Rate Borrowing. Administrative Agent shall
timely notify each Lender with respect to each Borrowing Notice.

         (b)      FUNDING. Each Lender shall remit its Commitment Percentage for
the Facility of each requested Borrowing to Administrative Agent's office in
Atlanta, Georgia, in funds which are or will be available for immediate use by
Administrative Agent by 2:00 p.m. Atlanta, Georgia time on the applicable
Borrowing Date. Subject to receipt of such funds, Administrative Agent shall
(unless to its actual knowledge any of the conditions precedent therefor have
not been satisfied by Borrower or waived by the requisite Lenders under Section
14.11) make such funds available to Borrower by causing such funds to be
deposited to Borrower's account as designated to Administrative Agent by
Borrower.

         (c)      FUNDING ASSUMED. Absent contrary written notice from a Lender,
Administrative Agent may assume that each Lender has made its Commitment
Percentage of the requested Borrowing available to Administrative Agent on the
applicable Borrowing Date, and Administrative Agent may, in reliance upon such
assumption (but shall not be required to), make available to Borrower a
corresponding amount. If a Lender fails to make its Commitment Percentage of any
requested Borrowing available to Administrative Agent on the applicable
Borrowing Date, Administrative Agent may recover the applicable amount on
demand, (i) from that Lender together with interest, commencing on the Borrowing
Date and ending on (but excluding) the date Administrative Agent recovers the
amount from that Lender, at an annual interest rate equal to the Federal Funds
Rate, or (ii) if that Lender fails to pay its amount upon demand, then from
Borrower. No Lender is responsible for the failure of any other Lender to make
its Commitment Percentage of any Borrowing available as required by Section
2.4(b); however, failure of any Lender to make its Commitment Percentage of any
Borrowing so

                                      -21-
<PAGE>

available does not excuse any other Lender from making its Commitment Percentage
of any Borrowing so available.

         SECTION 2.5 RESERVED.

         SECTION 2.6 INCREASE OF COMMITMENTS; ADDITIONAL LENDERS.

         (a)      So long as no Potential Default or Default has occurred and is
continuing, from time to time after the Closing Date, Borrower may, upon at
least 30 days' written notice to the Administrative Agent, who shall promptly
notify each Lender of such notice, propose to increase the Commitment by
$25,000,000 to a maximum amount not to exceed $300,000,000 (the amount of any
such increase, the "Additional Commitment Amount"). Each Lender shall have the
right for a period of 15 days following receipt of such notice, to elect by
written notice to Borrower and the Administrative Agent to increase its
Committed Sum by a principal amount equal to its Commitment Percentage of the
Additional Commitment Amount. No Lender (or any successor thereto) shall have
any obligation to increase its Committed Sum or its other obligations under this
Agreement and the other Loan Documents, and any decision by a Lender to increase
its Committed Sum shall be made in its sole discretion independently from any
other Lender.

         (b)      If any Lender shall not elect to increase its Committed Sum
pursuant to subsection (a) of this Section, Borrower may designate another bank
or other financial institution (which may be, but need not be, one or more of
the existing Lenders) which at the time agrees to, in the case of any such
Person that is an existing Lender, increase its Committed Sum and in the case of
any other such Person (an "Additional Lender"), become a party to this
Agreement; provided, however, that any new bank or financial institution must be
acceptable to the Administrative Agent, which acceptance will not be
unreasonably withheld or delayed. The sum of the increases in the Committed Sums
of the existing Lenders pursuant to this subsection (b) plus the Committed Sums
of the Additional Lenders shall not in the aggregate exceed the unsubscribed
amount of the Additional Commitment Amount.

         (c)      An increase in the Commitment pursuant to this Section 2.6
shall become effective upon the receipt by the Administrative Agent of an
agreement in form and substance satisfactory to the Administrative Agent signed
by Borrower, by each Additional Lender and by each other Lender whose Committed
Sum is to be increased, setting forth the new Committed Sums of such Lenders and
Additional Lenders and setting forth the agreement of each Additional Lender to
become a party to this Agreement and to be bound by all the terms and provisions
hereof, together with such evidence of appropriate partnership authorization on
the part of Borrower with respect to the increase in the Commitment and such
opinions of counsel for Borrower with respect to the increase in the Commitment
as the Administrative Agent may reasonably request.

         (d)      Upon the acceptance of any such agreement by the
Administrative Agent, the Commitment shall automatically be increased by the
amount of the Committed Sums added through such agreement and Schedule 2.1 shall
automatically be deemed amended to reflect the Committed Sums of all Lenders
after giving effect to the addition of such Committed Sums.

                                      -22-
<PAGE>

         (e)      Upon any increase in the Commitment pursuant to this Section
2.6 that is not pro rata among all Lenders, (x) within five Business Days, in
the case of any Base Rate Borrowing then outstanding, and at the end of the then
current Interest Period with respect thereto, in the case of any Eurodollar Rate
Borrowing then outstanding, Borrower shall prepay such Borrowings in their
entirety and, to the extent Borrower elects to do so and subject to the
conditions specified in Article VII, Borrower shall reborrow Borrowings from
Lenders in proportion to their respective Commitment Percentage after giving
effect to such increase, until such time as all outstanding Borrowings are held
by Lenders in such proportion and (y) effective upon such increase, the amount
of the participations held by each Lender in each LC then outstanding shall be
adjusted such that, after giving effect to such adjustments, Lenders shall hold
participations in each such LC in the proportion its Commitment Percentage after
giving effect to such increase.

                                   ARTICLE III
                                TERMS OF PAYMENT

         SECTION 3.1 LOAN ACCOUNTS, NOTES, AND PAYMENTS.

         (a)      LOAN ACCOUNTS. The Principal Debt owed to each Lender shall be
evidenced by one or more loan accounts or records maintained by such Lender in
the ordinary course of business. The loan accounts or records maintained by
Administrative Agent (including, without limitation, the Register) and each
Lender shall be prima facie evidence absent manifest error of the amount of the
Borrowings made by Borrower from each Lender under this Agreement (and the LC
Subfacility hereunder) and the interest and principal payments thereon. Any
failure to so record or any error in doing so shall not, however, limit or
otherwise affect the obligation of Borrower under the Loan Documents to pay any
amount owing with respect to the Obligation.

         (b)      NOTES. Upon the request of any Lender, made through
Administrative Agent, the Commitment amount of such Lender may be evidenced by a
Note.

         (c)      PAYMENT. All payments of principal, interest, and other
amounts to be made by Borrower under this Agreement and the other Loan Documents
shall be made to Administrative Agent at its office in Atlanta, Georgia in
Dollars and in funds which are or will be available for immediate use by
Administrative Agent by 1:00 p.m., Atlanta, Georgia time on the day due, without
setoff, deduction, or counterclaim. Payments made after 1:00 p.m., Atlanta,
Georgia, time shall be deemed made on the Business Day next following.
Administrative Agent shall pay to each Lender any payment of principal,
interest, or other amount to which such Lender is entitled hereunder on the same
day Administrative Agent shall have received the same from Borrower; provided
such payment is received by Administrative Agent prior to 1:00 p.m., Atlanta,
Georgia time, and otherwise before 1:00 p.m., Atlanta, Georgia time on the
Business Day next following.

         (d)      PAYMENT ASSUMED. Unless Administrative Agent has received
notice from Borrower prior to the date on which any payment is due under this
Agreement that Borrower will not make that payment in full, Administrative Agent
may assume that Borrower has made the full payment due and Administrative Agent
may, in reliance upon that assumption, cause to be

                                      -23-
<PAGE>

distributed to the appropriate Lender on that date the amount then due to such
Lenders. If and to the extent Borrower does not make the full payment due to
Administrative Agent, each Lender shall repay to Administrative Agent on demand
the amount distributed to that Lender by Administrative Agent together with
interest for each day from the date that Lender received payment from
Administrative Agent until the date that Lender repays Administrative Agent
(unless such repayment is made on the same day as such distribution), at an
annual interest rate equal to the Federal Funds Rate.

         SECTION 3.2 INTEREST AND PRINCIPAL PAYMENTS.

         (a)      INTEREST. Accrued interest on each Eurodollar Rate Borrowing
is due and payable on the last day of its respective Interest Period and on the
Termination Date for the Facility; provided that, if any Interest Period is
greater than three months, then accrued interest is also due and payable on the
three month anniversary of the date on which such Interest Period commences and
on each three month anniversary thereafter, as well as on the last day of such
Interest Period. Accrued interest on each Base Rate Borrowing shall be due and
payable on each March 31, June 30, September 30, and December 31, and on the
Termination Date for the Facility. Notwithstanding the foregoing, interest
accrued at the Default Rate shall be due and payable on demand.

         (b)      PRINCIPAL DEBT. The Principal Debt is due and payable on the
Termination Date.

         SECTION 3.3 PREPAYMENTS.

         (a)      OPTIONAL PREPAYMENTS. Except as set forth herein, after giving
Administrative Agent advance written notice of the intent to prepay, Borrower
may voluntarily prepay all or any part of the Principal Debt, from time to time
and at any time, in whole or in part, without premium or penalty; provided that:
(i) such notice must be received by Administrative Agent by 1:00 p.m., Atlanta,
Georgia time, on or before the date of prepayment of any Borrowing; (ii) each
such partial prepayment must be in a minimum amount of at least $5,000,000 or a
greater integral multiple of $1,000,000 thereof or such lesser amount as may be
outstanding under the Facility; (iii) any Eurodollar Rate Borrowing may only be
prepaid at the end of an applicable Interest Period (unless Borrower pays the
amount of any Consequential Loss); and (iv) Borrower shall pay any related
Consequential Loss within ten (10) days after demand therefor. Conversions under
Section 3.11 are not prepayments. Each notice of prepayment shall specify the
prepayment date, the applicable loan hereunder of Principal Debt being prepaid,
and the Type of Borrowing(s) and amount(s) of such Borrowing(s) to be prepaid
and shall constitute a binding obligation of Borrower to make a prepayment on
the date stated therein, together with (unless such prepayment is made with
respect to a Base Rate Borrowing) accrued and unpaid interest to the date of
such payment on the aggregate principal amount prepaid. Any voluntary prepayment
of the Principal Debt shall be applied to the Principal Debt and shall be
allocated Pro Rata to each Lender. Unless a Default or Potential Default has
occurred and is continuing (or would arise as a result thereof), any payment or
prepayment of the Principal Debt may be reborrowed by Borrower, subject to the
terms and conditions of the Loan Documents.

         (b)      MANDATORY PAYMENTS/REDUCTIONS. On any date of determination if
the Commitment Usage exceeds the Commitment then in effect, then Borrower shall
make a

                                      -24-
<PAGE>

mandatory prepayment of the Principal Debt, in at least the amount of such
excess, together with (x) all accrued and unpaid interest on the principal
amount so prepaid and (y) any Consequential Loss arising as a result thereof;
provided that, on any such reduction date, if no Principal Debt is then
outstanding, but the LC Exposure exceeds the Commitment, then Borrower shall
provide to Administrative Agent, for the benefit of Lenders, cash collateral in
Dollars for deposit into the Letter of Credit Cash Collateral Account in an
amount at least equal to 110% such excess. All mandatory prepayments or
commitment reductions under the Facility hereunder shall be allocated among
Lenders in accordance with their respective Commitment Percentages under the
Facility.

         (c)      MANDATORY PREPAYMENTS OF INTEREST/CONSEQUENTIAL LOSS. All
prepayments under this Section 3.3 shall be made, together with accrued interest
to the date of such prepayment on the principal amount prepaid, together with
any Consequential Loss arising as a result thereof.

         SECTION 3.4 INTEREST OPTIONS.

         Except that the Eurodollar Rate may not be selected when a Default or
Potential Default exists and except as otherwise provided in this Agreement,
Borrowings bear interest at a rate per annum equal to the lesser of (a) as to
the respective Type of Borrowing (as designated by Borrower in accordance with
this Agreement), the Base Rate, plus the Applicable Margin for Base Rate
Borrowings, or the Eurodollar Rate plus the Applicable Margin for Eurodollar
Rate Borrowings, and (b) the Maximum Rate. Each change in the Base Rate or the
Maximum Rate, subject to the terms of this Agreement, will become effective,
without notice to Borrower or any other Person, upon the effective date of such
change.

         SECTION 3.5 QUOTATION OF RATES.

         It is hereby acknowledged that an appropriately designated
Representative of Borrower may call Administrative Agent on or before the date
on which a Borrowing Notice is to be delivered by Borrower in order to receive
an indication of the rates then in effect, but such indicated rates shall
neither be binding upon Administrative Agent or Lenders nor affect the rate of
interest which thereafter is actually in effect when the Borrowing Notice is
given or on the Borrowing Date.

         SECTION 3.6 DEFAULT RATE.

         While any Default exists or after acceleration, Borrower shall pay
interest on the principal amount of all Borrowings at the Default Rate until
paid, regardless whether such payment is made before or after entry of a
judgment.

         SECTION 3.7 INTEREST RECAPTURE.

         If the designated rate applicable to any Borrowing exceeds the Maximum
Rate, the rate of interest on such Borrowing shall be limited to the Maximum
Rate, but any subsequent reductions in such designated rate shall not reduce the
rate of interest thereon below the Maximum Rate until the total amount of
interest accrued thereon equals the amount of interest which would have accrued
thereon if such designated rate had at all times been in effect. In the event
that at maturity (stated or by acceleration), or at final payment of the
Principal Debt, the

                                      -25-
<PAGE>

total amount of interest paid or accrued is less than the amount of interest
which would have accrued if such designated rates had at all times been in
effect, then, at such time and to the extent permitted by Law, Borrower shall
pay an amount equal to the difference between (a) the lesser of the amount of
interest which would have accrued if such designated rates had at all times been
in effect and the amount of interest which would have accrued if the Maximum
Rate had at all times been in effect, and (b) the amount of interest actually
paid or accrued on the Principal Debt.

         SECTION 3.8 INTEREST CALCULATIONS.

         Interest will be calculated on the basis of actual number of days
(including the first day but excluding the last day) elapsed but computed as if
each calendar year consisted of 360 days in the case of an Eurodollar Rate
Borrowing (unless the calculation would result in an interest rate greater than
the Maximum Rate, in which event interest will be calculated on the basis of a
year of 365 or 366 days, as the case may be) and 365 or 366 days, as the case
may be, in the case of a Base Rate Borrowing. All interest rate determinations
and calculations by Administrative Agent are conclusive and binding absent
manifest error.

         SECTION 3.9 MAXIMUM RATE.

         Regardless of any provision contained in any Loan Document, neither
Administrative Agent nor any Lender shall ever be entitled to contract for,
charge, take, reserve, receive, or apply, as interest on all or any part of the
Obligation, any amount in excess of the Maximum Rate, and, if Lenders ever do
so, then such excess shall be deemed a partial prepayment of principal and
treated hereunder as such and any remaining excess shall be refunded to
Borrower. In determining if the interest paid or payable exceeds the Maximum
Rate, Borrower and Lenders shall, to the maximum extent permitted under
applicable Law, (a) treat all Borrowings as but a single extension of credit
(and Lenders and Borrower agree that such is the case and that provision herein
for multiple Borrowings is for convenience only), (b) characterize any
nonprincipal payment as an expense, fee, or premium rather than as interest, (c)
exclude voluntary prepayments and the effects thereof, and (d) amortize,
prorate, allocate, and spread the total amount of interest throughout the entire
contemplated term of the Obligation. However, if the Obligation is paid and
performed in full prior to the end of the full contemplated term thereof, and if
the interest received for the actual period of existence thereof exceeds the
Maximum Amount, Lenders shall refund such excess, and, in such event, Lenders
shall not, to the extent permitted by Law, be subject to any penalties provided
by any Laws for contracting for, charging, taking, reserving, or receiving
interest in excess of the Maximum Amount.

         SECTION 3.10 INTEREST PERIODS.

         When Borrower requests any Eurodollar Rate Borrowing, Borrower may
elect the interest period (each an "INTEREST PERIOD") applicable thereto, which
shall be, at Borrower's option and subject to availability, one, two, three, or
six months; provided, however, that: (a) the initial Interest Period for a
Eurodollar Rate Borrowing shall commence on the date of such Borrowing
(including the date of any conversion thereto), and each Interest Period
occurring thereafter in respect of such Borrowing shall commence on the day on
which the next preceding Interest Period applicable thereto expires; (b) if any
Interest Period for a Eurodollar Rate Borrowing

                                      -26-
<PAGE>

begins on a day for which there is no numerically corresponding Business Day in
the calendar month at the end of such Interest Period, such Interest Period
shall end on the next Business Day immediately following what otherwise would
have been such numerically corresponding day in the calendar month at the end of
such Interest Period (unless such date would be in a different calendar month
from what would have been the month at the end of such Interest Period, or
unless there is no numerically corresponding day in the calendar month at the
end of the Interest Period; whereupon, such Interest Period shall end on the
last Business Day in the calendar month at the end of such Interest Period); (c)
no Interest Period may be chosen with respect to any portion of the Principal
Debt which would extend beyond the scheduled repayment date (including any dates
on which mandatory prepayments are required to be made) for such portion of the
Principal Debt; and (d) no more than an aggregate of five (5) Interest Periods
shall be in effect at one time.

         SECTION 3.11 CONVERSIONS.

         Borrower may (a) convert a Eurodollar Rate Borrowing on the last day of
the applicable Interest Period to a Base Rate Borrowing, (b) convert a Base Rate
Borrowing at any time to a Eurodollar Rate Borrowing, and (c) elect a new
Interest Period (in the case of a Eurodollar Rate Borrowing), by giving a
Conversion Notice of such intent to Administrative Agent no later than 11:00
a.m. Atlanta, Georgia time on the third Business Day prior to the date of
conversion or the last day of the Interest Period, as the case may be (in the
case of a conversion to a Eurodollar Rate Borrowing or an election of a new
Interest Period), and no later than 11:00 a.m. Atlanta, Georgia time on the last
Business Day of the Interest Period (in the case of a conversion to a Base Rate
Borrowing); provided that, the principal amount converted to, or continued as, a
Eurodollar Rate Borrowing shall be in an amount not less than $5,000,000 or a
greater integral multiple of $1,000,000 (or such lesser amount as may be
outstanding under the Facility). Administrative Agent shall timely notify each
Lender with respect to each Conversion Notice. Absent Borrower's Conversion
Notice or election of a new Interest Period, a Eurodollar Rate Borrowing shall
be deemed converted to a Base Rate Borrowing effective as of the expiration of
the Interest Period applicable thereto. No Eurodollar Rate Borrowing may be
either made or continued as a Eurodollar Rate Borrowing, and no Base Rate
Borrowing may be converted to a Eurodollar Rate Borrowing, if the interest rate
for such Eurodollar Rate Borrowing would exceed the Maximum Rate. The right to
convert from a Base Rate Borrowing to a Eurodollar Rate Borrowing, or to
continue as a Eurodollar Rate Borrowing shall not be available if a Default or
Potential Default has occurred and is continuing.

         SECTION 3.12 ORDER OF APPLICATION.

         (a)      NO DEFAULT. If no Default or Potential Default exists and if
no order of application is otherwise specified in Section 3.3 or otherwise in
the Loan Documents, payments and prepayments of the Obligation shall be applied
first to fees, second to accrued interest then due and payable on the Principal
Debt, and then to the remaining Obligation in the order and manner as Borrower
may direct.

         (b)      DEFAULT. If a Default or Potential Default exists (or if
Borrower fails to give directions as permitted under Section 3.12(a)), any
payment or prepayment (including proceeds from the exercise of any Rights) shall
be applied to the Obligation in the following order: (i) to

                                      -27-
<PAGE>

the ratable payment of all fees, expenses, and indemnities for which the
Administrative Agent or Lenders have not been paid or reimbursed in accordance
with the Loan Documents (as used in this Section 3.12(b)(i), a "RATABLE PAYMENT"
for any Lender or Administrative Agent shall be, on any date of determination,
that proportion which the portion of the total fees, expenses, and indemnities
owed to such Lender or Administrative Agent bears to the total aggregate fees
and indemnities owed to all Lenders and the Administrative Agent on such date of
determination); (ii) to the ratable payment of accrued and unpaid interest on
the Principal Debt (as used in this Section 3.12(b)(ii), "RATABLE PAYMENT"
means, for any Lender, on any date of determination, that proportion which the
accrued and unpaid interest on the Principal Debt owed to such Lender bears to
the total accrued and unpaid interest on the Principal Debt owed to all
Lenders); (iii) to the ratable payment of any reimbursement obligation with
respect to any LC issued pursuant to the Agreement which is due and payable and
which remains unfunded by any Borrowing under the Facility; provided that, such
payments shall be allocated ratably among the issuer of the LC and Lenders which
have funded their participations in such LC; (iv) to the ratable payment of the
Principal Debt (as used in this Section 3.12(b)(iv), "RATABLE PAYMENT" means for
any Lender, on any date of determination, that proportion which the Principal
Debt owed to such Lender bears to the Principal Debt owed to all Lenders); (v)
to provide cash collateral in an amount equal to 110% of the LC Exposure then
existing in accordance with Section 2.2(g); and (vi) to the payment of the
remaining Obligation in the order and manner Required Lenders deem appropriate.
Subject to the provisions of Article 12 and provided that Administrative Agent
shall not in any event be bound to inquire into or to determine the validity,
scope, or priority of any interest or entitlement of any Lender and may suspend
all payments or seek appropriate relief (including, without limitation,
instructions from Required Lenders or an action in the nature of interpleader)
in the event of any doubt or dispute as to any apportionment or distribution
contemplated hereby, Administrative Agent shall promptly distribute such amounts
to each Lender in accordance with the Agreement and the related Loan Documents.

         SECTION 3.13 SHARING OF PAYMENTS, ETC.

         If any Lender shall obtain any payment or prepayment with respect to
the Obligation (whether voluntary, involuntary, or otherwise, including, without
limitation, as a result of exercising its Rights under Section 3.14) which is in
excess of its share of any such payment in accordance with the relevant Rights
of Lenders under the Loan Documents, then such Lender shall purchase from the
other Lenders such participations as shall be necessary to cause such purchasing
Lender to share the excess payment with each other Lender in accordance with the
relevant Rights under the Loan Documents. If all or any portion of such excess
payment is subsequently recovered from such purchasing Lender, then the purchase
shall be rescinded and the purchase price restored to the extent of such
recovery. Borrower agrees that any Lender purchasing a participation from
another Lender pursuant to this Section may, to the fullest extent permitted by
Law, exercise all of its Rights of payment (including the Right of offset) with
respect to such participation as fully as if such Lender were the direct
creditor of Borrower in the amount of such participation.

         SECTION 3.14 OFFSET.

         If a Default exists, each Lender shall be entitled to exercise (for the
benefit of all Lenders in accordance with Section 3.13) the Rights of offset
and/or banker's Lien against each and every

                                      -28-
<PAGE>

account and other property, or any interest therein, which any Loan Party may
now or hereafter have with, or which is now or hereafter in the possession of,
such Lender to the extent of the full amount of the Obligation.

         SECTION 3.15 BOOKING BORROWINGS.

         To the extent permitted by Law, any Lender may make, carry, or transfer
its Borrowings at, to, or for the account of any of its branch offices or the
office of any of its Affiliates; provided that, no Affiliate shall be entitled
to receive any greater payment under Article 4 than the transferor Lender would
have been entitled to receive with respect to such Borrowings. In the event a
Lender shall transfer its Borrowings to or make its Borrowings from any office
other than that designated on Schedule 13.3, it shall notify the Administrative
Agent and the Administrative Agent shall provide a copy of such notice to
Borrower; provided, however, that the failure of a Lender or of Administrative
Agent to provide notice under this Section shall not relieve Borrower from any
obligations under this Agreement.

                                   ARTICLE IV
                             CHANGE IN CIRCUMSTANCES

         SECTION 4.1 INCREASED COST AND REDUCED RETURN.

         (a)      CHANGES IN LAW. If, after the date hereof, the adoption of any
applicable Law or any change in any applicable Law or any change in the
interpretation or administration thereof by any Governmental Authority, or
compliance by any Lender (or its Applicable Lending Office) with any request or
directive (whether or not having the force of law) of any such Governmental
Authority:

                  (i)      shall subject such Lender (or its Applicable Lending
         Office) to any Tax or other charge with respect to any Eurodollar Rate
         Borrowing, its Notes, or its obligation to loan Eurodollar Rate
         Borrowings, or change the basis of taxation of any amounts payable to
         such Lender (or its Applicable Lending Office) under the Loan Documents
         in respect of any Eurodollar Rate Borrowings (other than Taxes imposed
         on the overall net income of such Lender by the jurisdiction in which
         such Lender has its principal office or such Applicable Lending
         Office);

                  (ii)     shall impose, modify, or deem applicable any reserve,
         special deposit, assessment, or similar requirement relating to any
         extensions of credit or other assets of, or any deposits with or other
         liabilities or commitments of, such Lender (or its Applicable Lending
         Office), including the commitment of such Lender hereunder; or

                  (iii)    shall impose on such Lender (or its Applicable
         Lending Office) or the London interbank market any other condition
         affecting the Loan Documents or any of such extensions of credit or
         liabilities or commitments;

and the result of any of the foregoing is to increase the cost to such Lender
(or its Applicable Lending Office) of making, converting into, continuing, or
maintaining any Eurodollar Rate Borrowings or to reduce any sum received or
receivable by such Lender (or its Applicable Lending Office) under the Loan
Documents with respect to any Eurodollar Rate Borrowing, then

                                      -29-
<PAGE>

Borrower shall pay to such Lender within 15 days after demand such amount or
amounts as will compensate such Lender for such increased cost or reduction. If
any Lender requests compensation by Borrower under this Section 4.1(a), Borrower
may, by notice to such Lender (with a copy to Administrative Agent), suspend the
obligation of such Lender to loan or continue Borrowings of the Type with
respect to which such compensation is requested, or to convert Borrowings of any
other Type into Borrowings of such Type, until the event or condition giving
rise to such request ceases to be in effect (in which case the provisions of
Section 4.4 shall be applicable); provided, that such suspension shall not
affect the Right of such Lender to receive the compensation so requested.

         (b)      CAPITAL ADEQUACY. If, after the date hereof, any Lender shall
have determined that the adoption of any applicable Law regarding capital
adequacy or any change therein or in the interpretation or administration
thereof by any Governmental Authority charged with the interpretation or
administration thereof, or any request or directive regarding capital adequacy
(whether or not having the force of law) of any such Governmental Authority has
or would have the effect of reducing the rate of return on the capital of such
Lender or any corporation controlling such Lender as a consequence of such
Lender's obligations hereunder to a level below that which such Lender or such
corporation could have achieved but for such adoption, change, request, or
directive (taking into consideration its policies with respect to capital
adequacy), then from time to time within 15 days after demand Borrower shall pay
to such Lender such additional amount or amounts as will compensate such Lender
for such reduction.

         (c)      CHANGES IN APPLICABLE LENDING OFFICE; COMPENSATION STATEMENT.
Each Lender shall promptly notify Borrower and Administrative Agent of any event
of which it has knowledge, occurring after the date hereof, which will entitle
such Lender to compensation pursuant to this Section and will designate a
different Applicable Lending Office if such designation will avoid the need for,
or reduce the amount of, such compensation and will not, in the judgment of such
Lender, be otherwise disadvantageous to it. Any Lender claiming compensation
under this Section shall furnish to Borrower and Administrative Agent a
statement setting forth the additional amount or amounts to be paid to it
hereunder and calculations in reasonable detail which shall be conclusive in the
absence of manifest error. In determining such amount, such Lender may use any
reasonable averaging and attribution methods. Borrower shall not be obligated to
compensate any Lender pursuant to this Section 4.1 for any amounts attributable
to a period more than 90 days prior to the giving of notice by such Lender to
Borrower of its request for compensation under this Section 4.1.

         SECTION 4.2 LIMITATION ON TYPES OF LOANS.

         If on or prior to the first day of any Interest Period for any
Eurodollar Rate Borrowing:

         (a)      INABILITY TO DETERMINE EURODOLLAR RATE. Administrative Agent
determines (which determination shall be conclusive) that by reason of
circumstances affecting the relevant market, adequate and reasonable means do
not exist for ascertaining the Eurodollar Rate for such Interest Period; or

                                      -30-
<PAGE>

         (b)      COST OF FUNDS. Required Lenders determine (which determination
shall be conclusive) and notify Administrative Agent that the Eurodollar Rate
will not adequately and fairly reflect the cost to Lenders of funding Eurodollar
Rate Borrowings for such Interest Period;

then Administrative Agent shall give Borrower prompt notice thereof specifying
the relevant amounts or periods, and so long as such condition remains in
effect, Lenders shall be under no obligation to fund additional Eurodollar Rate
Borrowings, continue Eurodollar Rate Borrowings, or to convert Base Rate
Borrowings into Eurodollar Rate Borrowings, and Borrower shall, on the last
day(s) of the then current Interest Period(s) for the outstanding Eurodollar
Rate Borrowings, either prepay such Borrowings or convert such Borrowings into
Base Rate Borrowings in accordance with the terms of this Agreement.

         SECTION 4.3 ILLEGALITY.

         Notwithstanding any other provision of the Loan Documents, in the event
that it becomes unlawful for any Lender or its Applicable Lending Office to
make, maintain, or fund Eurodollar Rate Borrowings hereunder, then such Lender
shall promptly notify Borrower thereof and such Lender's obligation to make or
continue Eurodollar Rate Borrowings and to convert other Base Rate Borrowings
into Eurodollar Rate Borrowings shall be suspended until such time as such
Lender may again make, maintain, and fund Eurodollar Rate Borrowings (in which
case the provisions of Section 4.4 shall be applicable).

         SECTION 4.4 TREATMENT OF AFFECTED LOANS.

         If the obligation of any Lender to fund Eurodollar Rate Borrowings or
to continue, or to convert Base Rate Borrowings into Eurodollar Rate Borrowings,
shall be suspended pursuant to Sections 4.1, 4.2, or 4.3 hereof, such Lender's
Eurodollar Rate Borrowings shall be automatically converted into Base Rate
Borrowings on the last day(s) of the then current Interest Period(s) for
Eurodollar Rate Borrowings (or, in the case of a conversion required by Section
4.3 hereof, on such earlier date as such Lender may specify to Borrower with a
copy to Administrative Agent) and, unless and until such Lender gives notice as
provided below that the circumstances specified in Sections 4.1, 4.2, or 4.3
hereof that gave rise to such conversion no longer exist:

         (a)      to the extent that such Lender's Eurodollar Rate Borrowings
have been so converted, all payments and prepayments of principal that would
otherwise be applied to such Lender's Eurodollar Rate Borrowings shall be
applied instead to its Base Rate Borrowings; and

         (b)      all Borrowings that would otherwise be made or continued by
such Lender as Eurodollar Rate Borrowings shall be made or continued instead as
Base Rate Borrowings, and all Borrowings of such Lender that would otherwise be
converted into Eurodollar Rate Borrowings shall be converted instead into (or
shall remain as) Base Rate Borrowings.

If such Lender gives notice to Borrower (with a copy to Administrative Agent)
that the circumstances specified in Sections 4.1, 4.2, or 4.3 hereof that gave
rise to the conversion of such Lender's Eurodollar Rate Borrowings pursuant to
this Section 4.4 no longer exist (which such Lender agrees to do promptly upon
such circumstances ceasing to exist) at a time when Eurodollar Rate Borrowings
made by other Lenders are outstanding, such Lender's Base Rate

                                      -31-
<PAGE>

Borrowings shall be automatically converted, on the first day(s) of the next
succeeding Interest Period(s) for such outstanding Eurodollar Rate Borrowings,
to the extent necessary so that, after giving effect thereto, all Eurodollar
Rate Borrowings held by Lenders and by such Lender are held pro rata (as to
principal amounts, Types, and Interest Periods) in accordance with their
respective Committed Sums.

         SECTION 4.5 COMPENSATION.

         Upon the request of any Lender, Borrower shall pay to such Lender such
amount or amounts as shall be sufficient (in the reasonable opinion of such
Lender) to compensate it for any loss, cost, or expense (excluding loss of
anticipated profits) incurred by it as a result of:

         (a)      any payment, prepayment, or conversion of a Eurodollar Rate
Borrowing for any reason (including, without limitation, the acceleration of the
loan pursuant to Section 12.1) on a date other than the last day of the Interest
Period for such Borrowing; or

         (b)      any failure by Borrower for any reason (including, without
limitation, the failure of any condition precedent specified in Section 7.2 to
be satisfied) to borrow, convert, continue, or prepay a Eurodollar Rate
Borrowing on the date for such borrowing, conversion, continuation, or
prepayment specified in the relevant Borrowing Notice, prepayment, continuation,
or conversion under this Agreement.

         SECTION 4.6 TAXES.

         (a)      GENERAL. Any and all payments by Borrower to or for the
account of any Lender or Administrative Agent hereunder or under any other Loan
Document shall be made free and clear of and without deduction for any and all
present or future Taxes, excluding, in the case of each Lender and
Administrative Agent, Taxes imposed on its income and franchise Taxes imposed on
it by the jurisdiction under the laws of which such Lender (or its Applicable
Lending Office) or Administrative Agent (as the case may be) is organized, or
any political subdivision thereof. If Borrower shall be required by law to
deduct any Taxes from or in respect of any sum payable under any Loan Document
to any Lender or Administrative Agent, (i) the sum payable shall be increased as
necessary so that after making all required deductions (including deductions
applicable to additional sums payable under this Section 4.6) such Lender or
Administrative Agent receives an amount equal to the sum it would have received
had no such deductions been made, (ii) Borrower shall make such deductions,
(iii) Borrower shall pay the full amount deducted to the relevant taxation
authority or other authority in accordance with applicable law, and (iv)
Borrower shall furnish to Administrative Agent, at its address listed in
Schedule 2.1, the original or a certified copy of a receipt evidencing payment
thereof.

         (b)      STAMP AND DOCUMENTARY TAXES. In addition, Borrower agrees to
pay any and all present or future stamp or documentary taxes and any other
excise or property taxes or charges or similar levies which arise from any
payment made under any Loan Document or from the execution or delivery of, or
otherwise with respect to, any Loan Document (hereinafter referred to as "OTHER
TAXES"), other than any such taxes, charges or levies resulting from an
assignment or participation pursuant to Section 14.13 by a Lender of all or any
portion of its interest in this Agreement or any other Loan Document ("EXCLUDED
TAXES").

                                      -32-
<PAGE>

         (c)      INDEMNIFICATION FOR TAXES. Borrower agrees to indemnify each
Lender and Administrative Agent for the full amount of Taxes, excluding, in the
case of each Lender and Administrative Agent, (i) Excluded Taxes, (ii) Taxes
imposed on its income and (iii) franchise Taxes imposed on it by the
jurisdiction under the laws of which such Lender (or its Applicable Lending
Office) or Administrative Agent (as the case may be) is organized, or any
political subdivision thereof and Other Taxes (including, without limitation,
any Taxes or Other Taxes imposed or asserted by any jurisdiction on amounts
payable under this Section 4.6) paid by such Lender or Administrative Agent (as
the case may be) and any liability (including penalties, interest, and expenses)
arising therefrom or with respect thereto.

         (d)      WITHHOLDING TAX FORMS. Each Lender organized under the Laws of
a jurisdiction outside the United States, on or prior to the Closing Date in the
case of each Lender listed on the signature pages hereof and on or prior to the
date on which it becomes a Lender in the case of each other Lender, and from
time to time thereafter if requested in writing by Borrower or Administrative
Agent (but only so long as such Lender remains lawfully able to do so), shall
provide Borrower and Administrative Agent with (i) if such Lender is a "bank"
within the meaning of Section 881(c)(3)(A) of the Code, Internal Revenue Service
Form W-8 ECI or W-8 BEN, as appropriate, or any successor form prescribed by the
Internal Revenue Service, certifying that such Lender is entitled to benefits
under an income tax treaty to which the United States is a party which reduces
the rate of withholding tax on payments of interest or certifying that the
income receivable pursuant to the Loan Documents is effectively connected with
the conduct of a trade or business in the United States, or (ii) if such Lender
is not a "bank" within the meaning of Section 881(c)(3)(A) of the Code and
intends to claim an exemption from United States withholding tax under Section
871(h) or 881(c) of the Code with respect to payments of "portfolio interest," a
Form W-8, or any successor form prescribed by the Internal Revenue Service, and
a certificate representing that such Lender is not a bank for purposes of
Section 881(c) of the Code, is not a 10-percent shareholder (within the meaning
of Section 871(h)(3)(B) of the Code) of Borrower, and is not a controlled
foreign corporation related to Borrower (within the meaning of Section 864(d)(4)
of the Code). Each Lender which so delivers a W-8, Form W-8 ECI or W-8 BEN
further undertakes to deliver to Borrower and Administrative Agent additional
forms (or a successor form) on or before the date such form expires or becomes
obsolete or after the occurrence of any event requiring a change in the most
recent form so delivered by it, in each case certifying that such Lender is
entitled to receive payments from Borrower under any Loan Document without
deduction or withholding (or at a reduced rate of deduction or withholding) of
any United States federal income taxes, unless an event (including without
limitation any change in treaty, law, or regulation) has occurred prior to the
date on which any such delivery would otherwise be required which renders all
such forms inapplicable or which would prevent such Lender from duly completing
and delivering any such form with respect to it, and such Lender advises
Borrower and Administrative Agent that it is not capable of receiving such
payments without any deduction or withholding of United States federal income
tax.

         (e)      FAILURE TO PROVIDE WITHHOLDING FORMS; CHANGES IN TAX LAWS. For
any period with respect to which a Lender has failed to provide Borrower and
Administrative Agent with the appropriate form pursuant to Section 4.6(d)
(unless such failure is due to a change in Law occurring subsequent to the date
on which a form originally was required to be provided), such Lender shall not
be entitled to indemnification under Section 4.6(a) or 4.6(b) with respect to

                                      -33-
<PAGE>

Taxes imposed by the United States; provided, however, that should a Lender,
which is otherwise exempt from or subject to a reduced rate of withholding tax,
become subject to Taxes because of its failure to deliver a form required
hereunder, Borrower shall take such steps as such Lender shall reasonably
request to assist such Lender to recover such Taxes.

         (f)      CHANGE IN APPLICABLE LENDING OFFICE. If Borrower is required
to pay additional amounts to or for the account of any Lender pursuant to this
Section 4.6, then such Lender will agree to use reasonable efforts to change the
jurisdiction of its Applicable Lending Office so as to eliminate or reduce any
such additional payment which may thereafter accrue if such change, in the
judgment of such Lender, is not otherwise disadvantageous to such Lender.

         (g)      TAX PAYMENT RECEIPT. Within thirty (30) days after the date of
any payment of Taxes, Borrower shall furnish to Administrative Agent the
original or a certified copy of a receipt evidencing such payment.

         (h)      SURVIVAL. Without prejudice to the survival of any other
agreement of Borrower hereunder, the agreements and obligations of Borrower
contained in this Section 4.6 shall survive the termination of the Commitment
and the payment in full of the Obligation.

                                    ARTICLE V
                                      FEES

         SECTION 5.1 TREATMENT OF FEES.

         Except as otherwise provided by Law, the fees described in this Article
5: (a) do not constitute compensation for the use, detention, or forbearance of
money, (b) are in addition to, and not in lieu of, interest and expenses
otherwise described in the Loan Documents, (c) shall be payable in accordance
with Section 3.1(c), (d) shall be non-refundable (subject to the provisions of
Section 3.9, if applicable), (e) shall, to the fullest extent permitted by Law,
bear interest, if not paid when due, at the Default Rate, and (f) shall be
calculated on the basis of actual number of days (including the first day but
excluding the last day) elapsed, but computed as if each calendar year consisted
of 360 days, unless such computation would result in interest being computed in
excess of the Maximum Rate in which event such computation shall be made on the
basis of a year of 365 or 366 days, as the case may be.

         SECTION 5.2 FEES OF ADMINISTRATIVE AGENT AND ARRANGER.

         Borrower shall pay to Arranger, solely for its accounts, the fees
described in that certain separate letter agreement dated October 17, 2003,
among Borrower and Arranger. Borrower shall pay to Administrative Agent, solely
for its accounts, the fees described in that certain separate letter agreement
dated as of the date hereof, among Borrower and Administrative Agent.

         SECTION 5.3 FACILITY FEES.

         Following the Closing Date, Borrower shall pay to Administrative Agent,
for the Pro Rata account of Lenders, a facility fee, calculated daily from the
Closing Date but payable in installments in arrears each March 31, June 30,
September 30, and December 31 and on the Termination Date for the Facility,
commencing December 31, 2003. On any day of

                                      -34-
<PAGE>

determination, the facility fee shall be an amount equal to the Applicable
Amount for the facility fee multiplied by the Commitment on such day (regardless
of usage). Each such installment shall be calculated in accordance with Section
5.1(f).

         SECTION 5.4 LC FEES.

         As an inducement for the issuance (including, without limitation, any
extension) of each LC, Borrower agrees to pay to Administrative Agent:

         (a)      For the account of each Lender, according to each Lender's
Commitment Percentage under the Facility, a letter of credit fee payable
quarterly in arrears for so long as each such LC is outstanding, on the last
Business Day of each March, June, September, and December and on the expiry date
of the LC. The issuance fee for each LC or any extension thereof shall be in an
amount equal to the product of (a) the letter of credit fee set forth in the
definition of Applicable Amount in effect on the date of determination of such
fee (calculated on a per annum basis) multiplied by (b) the stated amount of
such LC. If there is any change in the Applicable Amount during any period, the
stated amount of such LC shall be multiplied by the Applicable Amount separately
for each such period that such Applicable Amount was in effect.

         (b)      For the account of Administrative Agent, as the issuer of LCs,
payable on the date of issuance of any LC (or any extension thereof) a fronting
fee equal to one-eighth of one percent (0.125%) of the face amount of such LC
(or extensions thereof). In addition, Borrower shall pay to Administrative
Agent, for its individual account, standard administrative charges for LC
amendments.

                                   ARTICLE VI
                                    GUARANTY

         SECTION 6.1 GUARANTY.

         As an inducement to the Administrative Agent and Lenders to enter into
this Agreement, Borrower shall cause Intermediate Partnership and, to the extent
required to do so under any Guaranty, any Holding Subsidiary (as defined in such
Guaranty) to execute and deliver to Administrative Agent a Guaranty
substantially in the form and upon the terms of Exhibit C, providing for the
guaranty of payment and performance of the Obligation.

                                   ARTICLE VII
                              CONDITIONS PRECEDENT

         SECTION 7.1 CONDITIONS PRECEDENT TO CLOSING.

         This Agreement shall not become effective, and Lenders shall not be
obligated to advance any Borrowing or issue any LC, unless Administrative Agent
has received all of the agreements, documents, instruments, and other items
described on Schedule 7.1.

         SECTION 7.2 CONDITIONS PRECEDENT TO EACH BORROWING.

                                      -35-
<PAGE>

         In addition to the conditions stated in Section 7.1, Lenders will not
be obligated to fund (as opposed to continue or convert) any Borrowing, and
Administrative Agent will not be obligated to issue any LC, as the case may be,
unless on the date of such Borrowing or issuance (and after giving effect
thereto), as the case may be: (a) Administrative Agent shall have timely
received therefor a Borrowing Notice or a LC Request (together with the
applicable LC Agreement), as the case may be; (b) Administrative Agent shall
have received the LC fronting fees provided for in Section 5.4(b) hereof; (c)
all of the representations and warranties of any Loan Party set forth in the
Loan Documents are true and correct in all material respects (except such
representations and warranties which expressly refer to an earlier date, which
are true and correct in all material respects as of such earlier date); (d) no
Default or Potential Default shall have occurred and be continuing; and (e) the
funding of such Borrowings and issuance of such LC, as the case may be, is
permitted by Law. Each Borrowing Notice and LC Request delivered to
Administrative Agent shall constitute the representation and warranty by
Borrower to Administrative Agent that, as of the Borrowing Date or the date of
issuance of the request LC, as the case may be, the statements above are true
and correct in all respects. Each condition precedent in this Agreement is
material to the transactions contemplated in this Agreement, and time is of the
essence in respect of each thereof. Subject to the prior approval of Required
Lenders, Lenders may fund any Borrowing, and Administrative Agent may issue any
LC, without all conditions being satisfied, but, to the extent permitted by Law,
the same shall not be deemed to be a waiver of the requirement that each such
condition precedent be satisfied as a prerequisite for any subsequent funding or
issuance, unless Required Lenders specifically waive each such item in writing
with respect to such subsequent funding or issuance.

                                  ARTICLE VIII
                         REPRESENTATIONS AND WARRANTIES

         Borrower represents and warrants to Administrative Agent and Lenders as
follows:

         SECTION 8.1 PURPOSE OF CREDIT FACILITY.

         (a)      Borrower will use all proceeds of Borrowings for one or more
of the following (or will loan such proceeds to, or make capital contributions
to, Intermediate Partnership to so use such proceeds) (i) to repay the Debt
existing under the Existing Credit Agreement; (ii) to finance capital
expenditures and non-hostile acquisitions; (iii) to finance investments
permitted hereunder; (iv) for working capital; and (v) for general business
purposes. No proceeds of any Borrowing will be used to make any Distribution
with respect to the Limited Partnership Units or General Partners' interests in
Borrower, or to make any Distribution with respect to partnership interests in
Intermediate Partnership.

         (b)      Borrower is not engaged principally, or as one of its
important activities, in the business of extending credit for the purpose of
purchasing or carrying any "margin stock" within the meaning of Regulation U. No
part of the proceeds of any Borrowing will be used, directly or indirectly, for
a purpose which violates any Law, including, without limitation, the provisions
of Regulations T, U or X (as enacted by the Board of Governors of the Federal
Reserve System, as amended).

         SECTION 8.2 EXISTENCE, GOOD STANDING, AUTHORITY, AND AUTHORIZATIONS.

                                      -36-
<PAGE>

         Each of the Loan Parties and each Subsidiary thereof is duly organized,
validly existing, and in good standing under the Laws of its jurisdiction of
organization. Each of the Loan Parties and its Subsidiaries is duly qualified to
transact business and is in good standing in each jurisdiction where the nature
and extent of its business and properties require the same, except to the extent
failure to so qualify or be in good standing is not reasonably likely, in the
aggregate, to result in a Material Adverse Event. Each of the Loan Parties, and
each Subsidiary thereof, possesses all Authorizations necessary or required in
the conduct of its respective business(es), except to the extent that failure to
possess such Authorization(s) is not reasonably likely, in the aggregate, to
result in a Material Adverse Event. No authorization, consent, approval, waiver,
license, or formal exemptions from, nor any filing, declaration, or registration
with, any Governmental Authority (federal, state, or local), non-governmental
entity, or Person under the terms of contracts or otherwise, is required by
reason of or in connection with the execution and performance of the Loan
Documents by the Loan Parties or their respective Subsidiaries.

         SECTION 8.3 SUBSIDIARIES.

         Borrower has no direct Subsidiaries except as disclosed on Schedule
8.3. As of the Closing Date, Intermediate Partnership has no Subsidiaries except
as disclosed on Schedule 8.3. As of the Closing Date, the number and percentage
of shares or partnership and other equity interests in each Subsidiary, and the
ownership thereof, are accurately set forth on Schedule 8.3 attached hereto. All
such partnership and other equity interests are validly issued under the terms
of the applicable Constituent Documents of the issuer and applicable Law.

         SECTION 8.4 AUTHORIZATION AND NO CONTRAVENTION.

         The execution and delivery by each Loan Party of each Loan Document to
which it is a party and the performance by such Loan Party of its obligations
thereunder (a) are within its partnership power; (b) will have been duly
authorized by all necessary partnership action when such Loan Document is
executed and delivered (c) require no action by or in respect of, or filing
with, any Governmental Authority, which action or filing has not been taken or
made on or prior to the Closing Date (or if later, the date of execution and
delivery of such Loan Document); (d) will not violate any provision of the
partnership agreement of such Loan Party, (e) will not violate any provision of
Law applicable to it; (f) will not violate any material written or oral
agreements, contracts, commitments, or understandings to which it is a party,
other than such violations which could not be a Material Adverse Event; and (g)
will not result in the creation or imposition of any Lien on any asset of any
Loan Party.

         SECTION 8.5 BINDING EFFECT.

         Upon execution and delivery by all parties thereto, each Loan Document
will constitute a legal, valid, and binding obligation of each Loan Party party
thereto, enforceable against each such Loan Party in accordance with its terms,
except as enforceability may be limited by applicable Debtor Relief Laws and
general principles of equity.

         SECTION 8.6 FINANCIAL STATEMENTS.

         (a)      The Current Financials were prepared in accordance with GAAP
and present fairly, in all material respects, the consolidated financial
condition, results of operations, and

                                      -37-
<PAGE>

cash flows of the Loan Parties and Subsidiaries thereof covered thereby
("REPORTING ENTITIES") as of and for the portion of the fiscal year ending on
the date or dates thereof (subject only to normal year-end audit adjustments for
interim statements). There were no material liabilities, direct or indirect,
fixed or contingent, of the Reporting Entities as of the date or dates of the
Current Financials which are required under GAAP to be reflected therein or in
the notes thereto, and are not so reflected.

         (b)      Since December 31, 2002, there has been no Material Adverse
Event. For the purposes hereof, Borrower's write-off of goodwill and other
assets required pursuant to FAS 142 and FAS 144 which was recorded by Borrower
in the fiscal quarter ended September 30, 2003 shall not be considered a
Material Adverse Event.

         SECTION 8.7 LITIGATION, CLAIMS, INVESTIGATIONS.

         No Loan Party is subject to, or aware of the threat of, any Litigation
which is reasonably likely to be determined adversely to any Loan Party, or any
Subsidiary thereof, and, if so adversely determined, could (individually or
collectively with other Litigation) be a Material Adverse Event. There are no
formal complaints, suits, claims, investigations, or proceedings initiated at or
by any Governmental Authority pending or threatened by or against any Loan
Party, or any Subsidiary thereof, which could reasonably be expected to result
in a Material Adverse Event, nor any judgments, decrees, or orders of any
Governmental Authority outstanding against any Loan Party, or any Subsidiary
thereof, that could reasonably be expected to result in a Material Adverse
Event.

         SECTION 8.8 TAXES.

         All Tax returns of each Loan Party and each Subsidiary thereof required
to be filed have been filed (or extensions have been granted) prior to
delinquency, and all Taxes imposed upon each Loan Party and each Subsidiary
thereof which are due and payable have been paid prior to delinquency, other
than Taxes or charges which are being diligently contested in good faith by
appropriate proceedings and for which adequate reserves in accordance with GAAP
shall have been set aside on its books.

         SECTION 8.9 ENVIRONMENTAL MATTERS.

         No Loan Party (a) knows of any environmental condition or circumstance,
such as the presence or Release of any Hazardous Substance, on any property
presently or previously owned by any Loan Party and any Subsidiary thereof that
could reasonably be expected to be a Material Adverse Event, (b) knows of any
violation by any Loan Party, any Subsidiary thereof of any Environmental Law,
except for such violations that could not reasonably be expected to be a
Material Adverse Event, or (c) knows that any Loan Party and any Subsidiary
thereof is under any obligation to remedy any violation of any Environmental
Law, except for such obligations that could not reasonably be expected to be a
Material Adverse Event.

         SECTION 8.10 EMPLOYEE BENEFIT PLANS.

         (a) No Employee Plan has incurred an "accumulated funding deficiency"
(as defined in Section 302 of ERISA and Section 412 of the Code), (b) no Loan
Party or any Subsidiary or

                                      -38-
<PAGE>

ERISA Affiliate thereof has incurred material liability to the PBGC or with
respect to an Employee Plan, which liability is currently due and remains unpaid
under Title IV of ERISA, (c) each Employee Plan maintained or contributed to by
a Loan Party or any Subsidiary thereof has complied in all material respects,
both in form and operation, with ERISA and the Code to the extent applicable
thereto, (d) no ERISA Event has occurred or is reasonably expected to occur with
respect to any Employee Plan or Multiemployer Plan which, individually or
collectively with all other ERISA Events then existing, could reasonably be
expected to be a Material Adverse Event, and (e) the present value of all
accrued benefits under each Employee Plan (based on actuarial assumptions used
for funding purposes in the most recent actuarial valuation prepared by the
Employee Plan's actuary with respect to such Employee Plan) did not, as of the
last annual actuarial valuation date for such Employee Plan, exceed the
then-current value of the assets of such Employee Plan in such an amount which
could reasonably be expected to result in a Material Adverse Event.

         SECTION 8.11 PROPERTIES; LIENS.

         Each Loan Party has good and indefeasible title to all its property
reflected on the Current Financials and each of its Subsidiaries has sufficient
title to permit such Subsidiary to operate its facilities. Except for Permitted
Liens, there is no Lien on any property of any Loan Party, and the execution,
delivery, performance, or observance of the Loan Documents will not require or
result in the creation of any Lien on such property.

         SECTION 8.12 GOVERNMENT REGULATIONS.

         No Loan Party or any of their respective Subsidiaries are subject to,
or such entities are exempt from, regulation as a "holding company" or a
"subsidiary company" of a "holding company", or an "affiliate" of a "holding
company" or of a "subsidiary company" of a "holding company", within the meaning
of the Public Utility Holding Company Act of 1935, as amended ("PUHCA"). No Loan
Party or Subsidiary thereof is subject to regulation under the Investment
Company Act of 1940, as amended, or any other Law (other than Regulations T, U,
and X of the Board of Governors of the Federal Reserve System and the
requirements of any public service commission) which regulates the incurrence of
Debt.

         SECTION 8.13 TRANSACTIONS WITH AFFILIATES.

         No Loan Party or any Subsidiary thereof is a party to a material
transaction with any of its Affiliates (excluding (i) transactions between or
among such Loan Parties or any Subsidiary thereof, (ii) the Operating Agreement,
dated February 28, 1980, by and between NBPC and Northern Plains, (iii) the
Operating Agreement, dated April 1, 2001, by and between Midwestern Gas
Transmission Company and Northern Plains, (iv) the Operating Agreement, dated
January 17, 2003, by and between Viking Gas Transmission Company and Northern
Plains and (v) the Administrative Services Agreement by and between NBP Services
Corporation, Borrower and Intermediate Partnership), other than transactions
upon fair and reasonable terms not materially less favorable than such entity
could obtain or could become entitled to in an arm's-length transaction with a
Person that was not its Affiliate.

         SECTION 8.14 MATERIAL AGREEMENTS.

                                      -39-
<PAGE>

         No Loan Party or any Subsidiary thereof is in default with respect to
any material agreements, contracts, commitments, or understandings which could
reasonably be expected to be a Material Adverse Event.

         SECTION 8.15 INSURANCE.

         Each Loan Party and each Subsidiary thereof maintains, with financially
sound, responsible, and reputable insurance companies or associations, insurance
concerning its properties and businesses against such casualties and
contingencies and of such types and in such amounts (and with self-insurance,
co-insurance and deductibles) as is customary in the case of same or similar
businesses.

         SECTION 8.16 COMPLIANCE WITH LAWS.

         No Loan Party or any Subsidiary thereof is in violation of any Laws
(including, without limitation, Environmental Laws), other than such violations
which could not, individually or collectively, reasonably be expected to be a
Material Adverse Event. No Loan Party or any Subsidiary thereof has received
notice alleging any noncompliance with any Laws, except for such noncompliance
which no longer exists, or which could not reasonably be expected to be a
Material Adverse Event.

         SECTION 8.17 REGULATION U.

         "Margin Stock" (as defined in Regulation U) constitutes less than 25%
of those assets of the Loan Parties which are subject to any limitation on sale,
pledge, or other restrictions hereunder.

         SECTION 8.18 FULL DISCLOSURE.

         All information heretofore furnished by any Loan Party to any Lender or
Administrative Agent in connection with the Loan Documents was, and all such
information hereafter furnished by any Loan Party to any Lender or
Administrative Agent will be, taken as a whole, true and accurate in all
material respects or based on reasonable estimates on the date as of which such
information is stated or certified.

         SECTION 8.19 NO DEFAULT.

         No Default or Potential Default has occurred and is continuing or will
arise as a result of the execution of the Loan Documents or of any Borrowing
hereunder.

         SECTION 8.20 LABOR RELATIONS.

         There are no strikes, lockouts or other material labor disputes or
grievances against Borrower or any of its Subsidiaries, or, to Borrower's
knowledge, threatened against or affecting Borrower or any of its Subsidiaries,
and no significant unfair labor practice, charges or grievances are pending
against Borrower or any of its Subsidiaries, or to Borrower's knowledge,
threatened against any of them before any Governmental Authority.

                                      -40-
<PAGE>

         SECTION 8.21 SOLVENCY.

         As of the Closing Date, after giving effect to the execution and
delivery of the Loan Documents and the making of any Borrowings under this
Agreement on the Closing Date, the Borrower and its Subsidiaries, taken as a
whole, will not be "insolvent" within the meaning of such term as defined in
Section 101 of Title 11 of the United States Code, as amended from time to time,
or be unable to pay their debts generally as such debts become due, or have an
unreasonably small capital to engage in any business or transaction, whether
current or contemplated.

                                   ARTICLE IX
                              AFFIRMATIVE COVENANTS

         Each of Borrower, and Guarantor, by its execution and delivery of a
Guaranty, covenants and agrees to perform, observe, and comply with each of the
following covenants from the Closing Date and so long thereafter as Lenders are
committed to fund Borrowings and Administrative Agent is committed to issue LCs
under this Agreement and thereafter until the payment in full of the Principal
Debt (and termination of outstanding LCs, if any) and payment in full of all
other interest, fees, and other amounts of the Obligation then due and owing,
unless Borrower receives a prior written consent to the contrary by
Administrative Agent as authorized by Required Lenders:

         SECTION 9.1 USE OF PROCEEDS.

         Borrower shall, and shall cause each of its Subsidiaries to, use the
proceeds of Borrowings only for the purposes represented in Section 8.1(a).

         SECTION 9.2 BOOKS AND RECORDS.

         The Loan Parties shall, and shall cause each of their Subsidiaries to,
maintain books, records, and accounts necessary to prepare financial statements
in all material respects in accordance with GAAP.

         SECTION 9.3 ITEMS TO BE FURNISHED.

         Borrower shall cause the following to be furnished to Administrative
Agent for delivery to Lenders:

         (a)      Promptly after preparation, and no later than 60 days after
the last day of each of the first three fiscal quarters of Borrower, balance
sheets and statements of earnings and cash flow ("FINANCIAL STATEMENTS") showing
the consolidated financial condition and results of operations calculated for
Borrower and its Subsidiaries, for such fiscal quarter and for the period from
the beginning of the then-current fiscal year to such last day, and each
accompanied by a Compliance Certificate.

         (b)      Promptly after preparation, and no later than 120 days after
the last day of each fiscal year of Borrower, Financial Statements showing the
consolidated financial condition and

                                      -41-
<PAGE>

results of operations for Borrower and its Subsidiaries, as of, and for the year
ended on, such day, each accompanied by:

                  (i)      the unqualified opinion of a firm of
         nationally-recognized independent certified public accountants, based
         on an audit using generally accepted auditing standards, that such
         Financial Statements were prepared in accordance with GAAP and present
         fairly the consolidated financial condition and results of operations
         of Borrower; and

                  (ii)     a Compliance Certificate.

         (c)      Promptly upon receipt thereof, and in any event within ten
(10) Business Days after receipt thereof, copies of all auditor's annual
management letters delivered to Borrower.

         (d)      Notice, promptly (but in any event within five (5) Business
Days) after any Loan Party knows or has reason to know of (i) a Default or
Potential Default specifying the nature thereof and what action any Loan Party
or any Subsidiary thereof has taken, is taking, or proposes to take with respect
thereto, (ii) any other event or circumstance that results in, or could
reasonably be expected to result in, a Material Adverse Event, or (iii) the
filing or commencement of any action, suit or proceeding by or before any
arbitrator or Governmental Authority against or, to the knowledge of Borrower,
affecting any Loan Party or any Subsidiary of any Loan Party that, if adversely
determined, could reasonably be expected to result in a Material Adverse Event.

         (e)      Promptly after the filing thereof, a true, correct, and
complete copy of each Form 10-K, Form 10-Q, and Form 8-K filed by or on behalf
of any Loan Party or any Subsidiary thereof with the Securities and Exchange
Commission, and of all material reports or filings filed by or on behalf of any
Loan Party with any Governmental Authority.

         (f)      Promptly upon request therefor by Administrative Agent or
Lenders, such information (not otherwise required to be furnished under the Loan
Documents) respecting the business affairs, assets, and liabilities of the Loan
Parties or Subsidiary thereof, and such opinions, certifications, and documents,
in addition to those mentioned in this Agreement, as reasonably requested.

         SECTION 9.4 INSPECTIONS.

         Upon reasonable notice, the Loan Parties shall allow, and shall cause
their Subsidiaries to allow, Administrative Agent or any Lender (or their
respective Representatives) to inspect any of their properties, to review
reports, files, and other records and to make and take away copies thereof, to
conduct tests or investigations, and to discuss any of their respective affairs,
conditions, and finances with other creditors, directors, officers, employees,
other representatives, and independent accountants of the Loan Parties and their
Subsidiaries, from time to time, during reasonable business hours.

         SECTION 9.5 TAXES.

                                      -42-
<PAGE>

         Each Loan Party shall, and shall cause each of its Subsidiaries to,
promptly pay when due any and all Taxes other than Taxes the applicability,
amount, or validity of which is being contested in good faith by lawful
proceedings diligently conducted, and against which reserve or other provision
required by GAAP has been made, and in respect of which levy and execution of
any lien securing same have been and continue to be stayed.

         SECTION 9.6 PAYMENT OF OBLIGATIONS.

         Borrower shall pay the Obligation in accordance with the terms and
provisions of the Loan Documents. Each Loan Party shall, and shall cause its
Subsidiaries to, promptly pay (or renew and extend) all of its material
obligations as the same become due (unless such obligations other than the
Obligation are being contested in good faith by appropriate proceedings).

         SECTION 9.7 MAINTENANCE OF EXISTENCE, ASSETS, AND BUSINESS.

         Except as otherwise permitted by Section 10.9, each Loan Party shall,
and shall cause each of its Subsidiaries to, at all times: (a) maintain its
existence and good standing in the jurisdiction of its organization and its
authority to transact business in all other jurisdictions where the nature of
its business so requires; (b) maintain all licenses, permits, and franchises
necessary for the normal conduct of its business; (c) keep all of its assets
which are useful in and necessary to its business in good working order and
condition (ordinary wear and tear excepted) and make all necessary repairs
thereto and replacements thereof; and (d) do all things necessary to obtain,
renew, extend, and continue in effect all Authorizations which may at any time
and from time to time be necessary for the Loan Parties and Subsidiaries thereof
to operate their businesses in compliance with applicable Law; except in the
case of each of clauses (a) through (d), where the failure to so renew, extend,
or continue in effect could not reasonably be expected to be a Material Adverse
Event.

         SECTION 9.8 COMPLIANCE WITH LAWS, ETC.

         The Loan Parties will comply, and will cause each of its Subsidiaries
to comply, in all material respects with all applicable Laws (including
Environmental Laws and ERISA) and contractual obligations except where the
failure to so comply will not reasonably be expected to cause a Material Adverse
Event.

         SECTION 9.9 INSURANCE.

         Each Loan Party will, and will cause each of its Subsidiaries to,
maintain or cause to be maintained with responsible insurance companies
insurance with respect to its properties and business against such casualties
and contingencies and of such types and in such amounts as is consistent with
prudent industry practice and will, upon request of the Administrative Agent,
furnish to each Lender at reasonable intervals a certificate of insurance
setting forth the nature and extent of all insurance maintained by Borrower in
accordance with this Section.

         SECTION 9.10 PRESERVATION AND PROTECTION OF RIGHTS.

         Each Loan Party shall perform such acts and duly authorize, execute,
acknowledge, deliver, file, and record any additional agreements, documents,
instruments, and certificates as

                                      -43-
<PAGE>

Administrative Agent or Required Lenders may reasonably deem necessary or
appropriate in order to preserve and protect the Rights of Administrative Agent
and Lenders under any Loan Document.

         SECTION 9.11 PARI PASSU STATUS.

         Each Loan Party will ensure the claims and rights of Lenders against it
under this Agreement and each other Loan Document will not be subordinate to,
and will rank at all times at least pari passu with, all other unsecured Debt of
such Loan Party.

         SECTION 9.12 MAINTENANCE OF TAX STATUS.

         Borrower shall take all action necessary to prevent Borrower,
Intermediate Partnership or NBPC from being, and will take no action which would
have the effect of causing any of Borrower, Intermediate Partnership or NBPC to
be, treated as an association taxable as a corporation or otherwise to be taxed
as an entity for federal income tax purposes.

                                    ARTICLE X
                               NEGATIVE COVENANTS

         Each of Borrower, and Guarantor, by its execution and delivery of a
Guaranty, covenants and agrees to perform, observe, and comply with each of the
following covenants from the Closing Date and so long thereafter as Lenders are
committed to fund Borrowings and Administrative Agent is committed to issue LCs
under this Agreement and thereafter until the payment in full of the Principal
Debt (and termination of outstanding LCs, if any) and payment in full of all
other interest, fees, and other amounts of the Obligation then due and owing,
unless Borrower receives a prior written consent to the contrary by
Administrative Agent as authorized by Required Lenders:

         SECTION 10.1 DEBT AND GUARANTIES.

         No Subsidiary of Borrower shall, directly or indirectly, create, incur,
or suffer to exist any direct, indirect, fixed, or contingent liability for any
Debt, other than:

         (a)      The Obligation and Guaranties thereof;

         (b)      Viking's $32,000,000 Secured Notes, 6.40% Series A Due October
31, 2008, $5,400,000 Secured Notes, 7.10% Series B due November 30, 2011,
$14,000,000 Secured Notes, 7.31% Series C due September 30, 2012, and
$20,000,000 Secured Notes, 8.04% Series D due September 30, 2014, all issued
pursuant to the Viking Indenture;

         (c)      Trade Debt for goods furnished or services rendered in the
ordinary course of business and payable in accordance with customary trade terms
that are not more than 90 days past due;

         (d)      Endorsements of checks or drafts in the ordinary course of
business;

                                      -44-
<PAGE>

         (e)      Debt of NBPC described on Schedule 10.1 and other Debt of
NBPC, so long as the NBPC Leverage Ratio does not exceed 4.50 to 1.0;

         (f)      Other Debt of Subsidiaries (excluding Debt otherwise permitted
in this Section 10.1) which does not exceed $35,000,000 outstanding at any time
in the aggregate;

         (g)      Debt of Subsidiaries resulting from loans made by Borrower to
Intermediate Partnership, loans by Intermediate Partnership to another
Subsidiary or other loans by a Subsidiary to another Subsidiary; provided,
however, that any Debt of Intermediate Partnership resulting from loans made by
any Subsidiary to Intermediate Partnership shall be subordinated on terms and
conditions satisfactory to Administrative Agent and the Required Lenders in
right of payment to its obligations under the Guaranty; and

         (h)      The guaranty by Intermediate Partnership of Borrower's
obligations under the Senior Notes;

provided, however, no Debt otherwise permitted under this Section 10.1 shall be
permitted if, after giving effect to the incurrence thereof, any Default or
Potential Default shall have occurred and be continuing.

         SECTION 10.2 LIENS.

         No Loan Party shall, or permit any of its Subsidiaries (except NBPC)
to, directly or indirectly, create, incur, or suffer or permit to be created or
incurred or to exist any Lien upon any of its assets, except:

         (a)      Liens existing as a result of any Capital Lease, to the extent
permitted pursuant to Section 10.1;

         (b)      Liens for taxes, assessments or other governmental charges or
levies not at the time delinquent or thereafter payable without penalty or being
diligently contested in good faith by appropriate proceedings and for which
adequate reserves in accordance with GAAP shall have been set aside on its
books;

         (c)      Liens of carriers, operators, warehousemen, mechanics,
materialmen and landlords, and statutory Liens of producers of hydrocarbons,
incurred in the ordinary course of business for sums not overdue or being
diligently contested in good faith by appropriate proceedings and for which
adequate reserves in accordance with GAAP shall have been set aside on its
books;

         (d)      Deposits in the ordinary course of business in connection with
workmen's compensation, unemployment insurance or other forms of governmental
insurance or benefits, or to secure performance of tenders, statutory
obligations, leases and contracts (other than for borrowed money) entered into
in the ordinary course of business or to secure obligations on surety or appeal
bonds;

                                      -45-
<PAGE>

         (e)      Judgment Liens in existence less than 30 days after the entry
thereof or with respect to which execution has been stayed or the payment of
which is covered in full (subject to a customary deductible) by insurance
maintained with responsible insurance companies;

         (f)      Liens on the limited liability company interests in Fort
Union, L.L.C. which are owned by Crestone Powder River L.L.C., a Delaware
limited liability company, which Liens secure amounts owed under the Fort Union
Project Finance Documents;

         (g)      Liens on the limited liability company interests in Lost
Creek, L.L.C. which are owned by Crestone Wind River, L.L.C., a Delaware limited
liability company, which Liens secure amounts owed under the Lost Creek Project
Finance Documents;

         (h)      Liens in favor of the Administrative Agent or any Lender,
under Section 2.2(h); and

         (i)      Liens securing the Debt described in Section 10.1(b) in the
"Collateral" as such term is defined and described in the Granting Clauses of
the Viking Indenture.

         SECTION 10.3 TRANSACTIONS WITH AFFILIATES.

         No Loan Party shall, or permit any of its Subsidiaries to, enter into
any transaction with any of its Affiliates, other than transactions upon fair
and reasonable terms not less favorable than such Loan Party or Subsidiary could
obtain or could become entitled to in an arm's-length transaction with a Person
that was not its Affiliate.

         SECTION 10.4 ASSIGNMENT.

         No Loan Party shall assign or transfer any of its Rights, duties, or
obligations under any of the Loan Documents.

         SECTION 10.5 GOVERNMENT REGULATIONS.

         No Loan Party will conduct its business in such a way that it will
become subject to regulation under the Investment Company Act of 1940, as
amended, the Public Utility Holding Company Act of 1935, as amended, the Federal
Power Act, as amended, or any other Law (other than Regulations T, U, and X of
the Board of Governors of the Federal Reserve System) which regulates the
incurrence of Debt.

         SECTION 10.6 MERGERS; SALE OF ASSETS.

         (a)      No Loan Party will, nor will it permit any Subsidiary to,
merge into or consolidate with any other Person, or permit any other Person to
merge into or consolidate with it, or sell, transfer, lease or otherwise dispose
of (in one transaction or in a series of transactions) all (or substantially
all) of its assets, or all or substantially all of the stock of or other equity
interest in any of its Subsidiaries (in each case, whether now owned or
hereafter acquired), unless: (i) at the time thereof and immediately after
giving effect thereto no Default or Potential Default shall have occurred and be
continuing, (ii) if Borrower is involved in any such transaction, Borrower is
the surviving entity or the recipient of any such sale, transfer, lease or other
disposition of

                                      -46-
<PAGE>

assets, and if any other Loan Party is involved in any such transaction a Loan
Party is the surviving entity or the recipient of any such sale, transfer, lease
or other disposition of assets; provided, however, that in no event shall any
such merger, consolidation, sale, transfer, lease or other disposition whether
or not otherwise permitted by this Section 10.6 have the effect of releasing any
Loan Party from any of its obligations and liabilities under this Agreement. The
Loan Parties will not permit NBPC to merge or consolidate with or into any other
Person, or sell, assign, lease or otherwise dispose of (whether in one
transaction or in a series of transactions) all or substantially all of its
business and assets (whether now owned or hereafter acquired) to, any Person,
except pursuant to Section 14 or Section 15 (to the extent it applies to a
merger pursuant to Section 14) of NBPC's Partnership Agreement.

         (b)      The Loan Parties shall not permit NBPC to lease, sell or
otherwise dispose of its assets to any other Person except: (i) sales of
inventory and other assets in the ordinary course of business, (ii) leases,
sales or other dispositions of its assets that, together with all other assets
of NBPC previously leased, sold or disposed of (other than disposed of pursuant
to this Section 10.6(b)) during the twelve-month period ending with the month in
which any such lease, sale or other disposition occurs, do not constitute a
substantial portion of the assets of NBPC, (iii) sales of assets which are
concurrently leased back, (iv) dispositions of assets which are obsolete or no
longer used or useful in the business of NBPC, and (v) as permitted by the last
sentence of 10.6(a).

         SECTION 10.7 LOAN AND INVESTMENTS.

         Borrower shall not purchase or acquire or make any commitment to
purchase or acquire, any capital stock, equity interest, or any obligations or
other securities of, or any interest in, any Person, or commit to make any
Acquisitions, or make or commit to make any advance, loan, extension of credit
or capital contribution to or any other investment in, any Person including any
Affiliate of Borrower (together, "INVESTMENTS"), except for:

         (a)      Investments held by Borrower in the form of cash equivalents
or short-term marketable securities; and

         (b)      Investments in and through Intermediate Partnership permitted
by Section 10.9.

         SECTION 10.8 DISTRIBUTIONS.

         Borrower will not declare, pay or make any Distribution (in cash,
property or obligations) on any interests (now or hereafter outstanding) in
Borrower or apply any of its funds, property or assets to the purchase of any
partnership interests in Borrower; provided, that at any time during which no
Default or Potential Default has occurred and is continuing, Borrower (a) may
make Distributions on the Limited Partnership Units and General Partners'
interests in accordance with the Partnership Agreement and (b) may purchase its
partnership interests provided that the aggregate purchase price therefor does
not exceed $20,000,000 in the aggregate during the term of this Agreement.

         SECTION 10.9 LIMITATION ON BUSINESS ACTIVITIES.

                                      -47-
<PAGE>

         Borrower shall not engage in any business activity except the ownership
of a limited partner interest in Intermediate Partnership and such activities as
may be incidental or related thereto. Intermediate Partnership shall not, and
the Loan Parties shall not permit any of their Subsidiaries to, engage, directly
or indirectly, in any business activity except (a) existing business activities
consisting of the ownership and operation of natural gas pipelines, coal slurry
pipelines, natural gas gathering facilities, midstream gas processing
facilities, extension and expansion of such pipelines and facilities and related
facilities, services related to the transportation, marketing and processing of
natural gas and coal slurry and such activities as may be incidental or related
to the aforementioned and (b) new business activities in the area of storage,
exploration, development, production, processing, refining, transportation or
marketing of gas, oil, coal or products thereof, provided the gross income of
such activities allows Borrower to meet the exception in Section 7704 of the
Code.

         SECTION 10.10 CERTAIN AMENDMENTS TO CASH DISTRIBUTION POLICIES AND
PARTNERSHIP AGREEMENTS.

         Each Loan Party agrees that it shall not consent to, vote in favor of
or permit any amendment of (a) the cash distribution policies of NBPC or
Intermediate Partnership in any manner which would result in a Material Adverse
Event with respect to any Loan Party or materially adversely affect the rights
and remedies of Lenders under and in connection with this Agreement, the Notes
or any other Loan Document; or (b) the Partnership Agreement, the Northern
Border Partnership Agreement or the Intermediate Partnership Agreement in any
manner which would (i) have a material adverse effect on the rights and remedies
of Lenders under and in connection with this Agreement, the Notes or any other
Loan Document; or (ii) result in a Material Adverse Event.

         SECTION 10.11 RESTRICTIVE AGREEMENTS, ETC.

         Except as set forth in Section 5.09 of the Viking Indenture, no Loan
Party will, nor will it permit any of its Material Subsidiaries to, enter into
any agreement restricting the ability of any Material Subsidiary to make any
payments, directly or indirectly, to a Loan Party by way of distributions,
advances, repayments of loans or advances, reimbursements of management and
other intercompany charges, expenses and accruals or other returns on
investments, or any other agreement or arrangement which restricts the ability
of any such Material Subsidiary to make any payment, directly or indirectly, to
a Loan Party or to guarantee Debt of a Loan Party.

         SECTION 10.12 EMPLOYEE BENEFIT PLANS.

         No Loan Party shall, or shall permit any of its ERISA Affiliates to,
permit any breach of any of the provisions described in Section 8.10 to exist or
occur.

         SECTION 10.13 INTEREST COVERAGE RATIO.

         As of the last day of each fiscal quarter of Borrower, Borrower shall
not permit the ratio of Consolidated EBITDA of Borrower to Consolidated Interest
Expense of Borrower for the Rolling Period ending on such date to be 3.00:1.00
or lower.

         SECTION 10.14 CONSOLIDATED LEVERAGE RATIO.

                                      -48-
<PAGE>

         As of the last day of each fiscal quarter of Borrower, Borrower shall
not permit the ratio of Consolidated Total Debt to Adjusted Consolidated EBITDA
for the Rolling Period ending on such date to be greater than 4.50 to 1.00 (the
"Required Threshold"); provided, however, that if Borrower consummates one or
more Acquisitions permitted hereunder in which the aggregate purchase price of
all such Acquisitions is $25,000,000 or more, then the Required Threshold shall
be increased to 5.00 to 1.00 for the first two full fiscal reporting periods
during any 12-month period immediately following the consummation of such
Acquisitions.

                                   ARTICLE XI
                                     DEFAULT

         The term "DEFAULT" means the occurrence of any one or more of the
following events:

         SECTION 11.1 PAYMENT OF OBLIGATION.

         The failure of Borrower to pay (a) any amount of principal of any
Borrowing or any reimbursement obligation in respect of a drawing under an LC
when the same becomes due (whether by its terms, by acceleration, or as
otherwise provided in the Loan Documents); or (b) within five (5) days after the
same becomes due, any interest, fee or any other amount payable hereunder or
under any other Loan Document.

         SECTION 11.2 COVENANTS.

         The failure or refusal of Borrower (and, if applicable, any other Loan
Party or Subsidiary of any Loan Party) to punctually and properly perform,
observe, and comply with:

         (a)      Any covenant, agreement, or condition contained in Section
9.7, Sections 10.1 through 10.14 or any reporting requirement contained in
Section 9.3(d); and

         (b)      Any other covenant, agreement, or condition contained in any
Loan Document (other than the covenants to pay the Obligation set forth in
Section 11.1 and the covenants in Section 11.2(a)), and such failure or refusal
continues for 30 days after the earlier of (i) the date upon which a Responsible
Officer (or, in the case of a failure or refusal of Guarantor to perform,
observe or comply, an officer of Guarantor) knew or reasonably should have known
of such failure or refusal, or (ii) the date upon which written notice thereof
is given to Borrower (or, if applicable, Guarantor) by the Administrative Agent
or any Lender.

         SECTION 11.3 DEBTOR RELIEF.

         Any Loan Party or any Material Subsidiary thereof (a) fails to pay, or
admits in writing its inability to pay its Debts generally as they become due,
(b) voluntarily seeks, consents to, or acquiesces in the benefit of any Debtor
Relief Law, other than as a creditor or claimant, (c) becomes a party to or is
made the subject of any proceeding provided for by any Debtor Relief Law, other
than as a creditor or claimant, (unless, in the event such proceeding is
involuntary, the petition instituting same is dismissed within 60 days after its
filing), (d) makes a general assignment for the benefit of creditors or (e)
takes any corporate action to authorize any of the foregoing.

                                      -49-
<PAGE>

         SECTION 11.4 JUDGMENTS AND ATTACHMENTS.

         Any Loan Party or any Material Subsidiary thereof fails, within 60 days
after entry, to pay, bond, or otherwise discharge any judgment or order for the
payment of money in excess of $15,000,000 (individually or collectively) or any
warrant of attachment, sequestration, or similar proceeding against any of their
respective assets having a value (individually or collectively) of $15,000,000
which is not stayed on appeal.

         SECTION 11.5 MISREPRESENTATION.

         Any representation or warranty made herein or in any Loan Document
shall at any time prove to have been incorrect in any material respect when
made.

         SECTION 11.6 CHANGE OF CONTROL.

         A Change of Control shall occur.

         SECTION 11.7 DEFAULT UNDER OTHER DEBT AND AGREEMENTS.

         (a)      A default shall occur in the payment when due (subject to any
applicable notice requirement or grace period), whether by acceleration or
otherwise, of any Debt (other than Debt described in Section 11.1) of any Loan
Party or any of its Material Subsidiaries having a principal amount (including
undrawn or committed or available amounts), individually or in the aggregate, in
excess of $15,000,000, or a default shall occur in the performance or observance
of any covenant, or obligation with respect to such Debt, or any other event
shall occur or condition exist under any agreement relating to such Debt the
effect of which default, condition or event is to cause, or to permit the holder
or holders of such Debt (or any trustee or agent for such holders) to cause
(with the giving of notice if required or lapse of time or both), such Debt to
become due and payable prior to its expressed maturity (whether by acceleration,
redemption, repurchase or otherwise); provided, that no Default will result from
a Rating Decline Offer (as such term is defined in the Senior Note Indentures),
or the event causing such offer, under the Senior Notes unless one or more
holders of Senior Note(s) elect to exercise its or their rights to have all or
any portion of their Senior Notes repurchased by Borrower.

         (b)      A Loan Party or any of its Subsidiaries shall: (i) default in
making any payment, delivery or exchange, or in the performance of any of its
other obligations, under one or more agreements or instruments (individually or
collectively) governing or otherwise relating to one or more Derivative
Transactions, which default shall have resulted in early termination,
liquidation or other similar payments in an aggregate amount in excess of
$15,000,000 becoming, or becoming capable at such time (after giving effect to
any applicable notice requirement or grace period) of being declared or
designated, due and payable by a Loan Party, or one or more of its Subsidiaries;
or (ii) default (after giving effect to any applicable notice requirement or
grace period) in making any payment or delivery due on the last payment,
delivery or exchange date of, or on the early termination or liquidation of, one
or more Derivative Transactions and such default relates to one or more payments
or deliveries of cash or property having an aggregate value in excess of
$15,000,000.

         SECTION 11.8 EMPLOYEE BENEFIT PLANS.

                                      -50-
<PAGE>

         (a)      Any Loan Party or ERISA Affiliate shall fail to pay when due
an amount or amounts for which it is liable under Title IV of ERISA, which
aggregate unpaid amounts for all such entities exceed $15,000,000 in the
aggregate; or

         (b)      an ERISA Event shall occur or exist with respect to any
Employee Plan or Multiemployer Plan, and as a result of such ERISA Event and all
other ERISA Events then-existing, the aggregate liabilities incurred (or in the
reasonable judgment of Required Lenders, likely to be incurred) of the Loan
Parties and the ERISA Affiliates to any Employee Plan, Multiemployer Plan, or
the PBGC (or any combination thereof) shall exceed $15,000,000.

         SECTION 11.9 VALIDITY AND ENFORCEABILITY OF LOAN DOCUMENTS.

         Any Loan Document shall, at any time after its execution and delivery
and for any reason, cease to be in full force and effect in any material respect
or be declared to be null and void (other than in accordance with the terms
hereof or thereof) or the validity or enforceability thereof be contested by any
Loan Party thereto or any Loan Party shall deny in writing that it has any or
any further liability or obligations under any Loan Document to which it is a
party.

         SECTION 11.10 ENVIRONMENTAL LIABILITY.

         If any event or condition shall occur or exist with respect to any
activity or substance regulated under the Environmental Law and, as a result of
such event or condition, any Loan Party or any of their respective Subsidiaries
shall have incurred or in the opinion of the Required Lenders will be reasonably
likely to incur a liability in excess of $15,000,000 during any consecutive
twelve (12) month period.

         SECTION 11.11 DISSOLUTION.

         Any Loan Party or NBPC shall dissolve, liquidate, or otherwise
terminate their existence, except, with respect to NBPC, pursuant to Section 14
or Section 15 (to the extent it applies to a merger pursuant to Section 14) of
NBPC's Partnership Agreement.

                                   ARTICLE XII
                               RIGHTS AND REMEDIES

         SECTION 12.1 REMEDIES UPON DEFAULT.

         (a)      DEBTOR RELIEF. If a Default exists under Section 11.3(b) or
11.3(c), the commitment to extend credit hereunder shall automatically terminate
and the entire unpaid balance of the Obligation shall automatically become due
and payable without any action or notice of any kind whatsoever, and Borrower
shall be required to deposit cash collateral in the Letter of Credit Cash
Collateral Account in an amount equal to 110% of the LC Exposure then existing
in accordance with Section 2.2(g).

         (b)      OTHER DEFAULTS. If any Default exists, Administrative Agent
may (and, subject to the terms of Article 13, shall upon the request of Required
Lenders) or Required Lenders may, do any one or more of the following: (i) if
the maturity of the Obligation has not already been accelerated under Section
12.1(a), declare the entire unpaid balance of the Obligation, or any part

                                      -51-
<PAGE>

thereof, immediately due and payable, whereupon it shall be due and payable;
(ii) terminate the commitments of Lenders to extend credit hereunder; (iii)
reduce any claim to judgment; (iv) to the extent permitted by Law, exercise (or
request each Lender to, and each Lender shall be entitled to, exercise) the
Rights of offset or banker's Lien against the interest of each Loan Party in and
to every account and other property of any Loan Party which are in the
possession of Administrative Agent or any Lender to the extent of the full
amount of the Obligation (to the extent permitted by Law, each Loan Party being
deemed directly obligated to each Lender in the full amount of the Obligation
for such purposes); (v) if the maturity of the Obligation has not already been
accelerated under Section 12.1(a), demand Borrower to deposit cash collateral in
the Letter of Credit Cash Collateral Account in an amount equal to 110% of the
LC Exposure then existing in accordance with Section 2.2(g); and (vi) exercise
any and all other legal or equitable Rights afforded by the Loan Documents, the
Laws of the State of New York, or any other applicable jurisdiction as
Administrative Agent or Required Lenders (as the case may be) shall deem
appropriate, or otherwise, including, but not limited to, the Right to bring
suit or other proceedings before any Governmental Authority either for specific
performance of any covenant or condition contained in any of the Loan Documents
or in aid of the exercise of any Right granted to Administrative Agent or any
Lender in any of the Loan Documents.

         SECTION 12.2 LOAN PARTY WAIVERS.

         To the extent permitted by Law, the Loan Parties hereby waive
presentment and demand for payment, protest, notice of intention to accelerate,
notice of acceleration, and notice of protest and nonpayment, and agree that
their respective liability with respect to the Obligation (or any part thereof)
shall not be affected by any renewal or extension in the time of payment of the
Obligation (or any part thereof), by any indulgence, or by any release or change
in any security for the payment of the Obligation (or any part thereof).

         SECTION 12.3 PERFORMANCE BY ADMINISTRATIVE AGENT.

         If any covenant, duty, or agreement of any Loan Party is not performed
in accordance with the terms of the Loan Documents, after the occurrence and
during the continuance of a Default, Administrative Agent may, at its option
(but subject to the approval of Required Lenders), perform or attempt to perform
such covenant, duty, or agreement on behalf of such Loan Party. In such event,
any amount expended by Administrative Agent in such performance or attempted
performance shall be payable by the Loan Parties, jointly and severally, to
Administrative Agent on demand, shall become part of the Obligation, and shall
bear interest at the Default Rate from the date of such expenditure by
Administrative Agent until paid. Notwithstanding the foregoing, it is expressly
understood that Administrative Agent does not assume, and shall never have,
except by its express written consent, any liability or responsibility for the
performance of any covenant, duty, or agreement of any Loan Party.

         SECTION 12.4 DELEGATION OF DUTIES AND RIGHTS.

         Lenders may perform any of their duties or exercise any of their Rights
under the Loan Documents by or through their respective Representatives.

         SECTION 12.5 NOT IN CONTROL.

                                      -52-
<PAGE>

         Except with respect to the Letter of Credit Cash Collateral Account,
nothing in any Loan Document shall, or shall be deemed to (a) give
Administrative Agent or any Lender the Right to exercise control over the assets
(including real property), affairs, or management of any Loan Party or any
Subsidiary thereof, (b) preclude or interfere with compliance by any Loan Party
or any Subsidiary thereof with any Law, or (c) require any act or omission by
any Loan Party or any Subsidiary thereof that may be harmful to Persons or
property. Any "Material Adverse Event" or other materiality qualifier in any
representation, warranty, covenant, or other provision of any Loan Document is
included for credit documentation purposes only and shall not, and shall not be
deemed to, mean that Administrative Agent or any Lender acquiesces in any
non-compliance by any Loan Party or any Subsidiary thereof with any Law or
document, or that Administrative Agent or any Lender does not expect the Loan
Parties and their respective Subsidiaries to promptly, diligently, and
continuously carry out all appropriate removal, remediation, and termination
activities required or appropriate in accordance with all Environmental Laws.
The Administrative Agent and Lenders have no fiduciary relationship with or
fiduciary duty to any Loan Party or any Subsidiary thereof arising out of or in
connection with the Loan Documents, and the relationship between the
Administrative Agent and Lenders, on the one hand, and Loan Parties, on the
other hand, in connection with the Loan Documents is solely that of debtor and
creditor. The power of the Administrative Agent and Lenders under the Loan
Documents is limited to the Rights provided in the Loan Documents, which Rights
exist solely to assure payment and performance of the Obligation and may be
exercised in a manner calculated by the Administrative Agent and Lenders in
their respective good faith business judgment.

         SECTION 12.6 COURSE OF DEALING.

         The acceptance by Administrative Agent or Lenders at any time and from
time to time of partial payment on the Obligation shall not be deemed to be a
waiver of any Default then existing. No waiver by Administrative Agent, Required
Lenders, or Lenders of any Default shall be deemed to be a waiver of any other
then-existing or subsequent Default. No delay or omission by Administrative
Agent, Required Lenders, or Lenders in exercising any Right under the Loan
Documents shall impair such Right or be construed as a waiver thereof or any
acquiescence therein, nor shall any single or partial exercise of any such Right
preclude other or further exercise thereof, or the exercise of any other Right
under the Loan Documents or otherwise.

         SECTION 12.7 CUMULATIVE RIGHTS.

         All Rights available to Administrative Agent and Lenders under the Loan
Documents are cumulative of and in addition to all other Rights granted to
Administrative Agent and Lenders at law or in equity, whether or not the
Obligation is due and payable and whether or not Administrative Agent or Lenders
have instituted any suit for collection, foreclosure, or other action in
connection with the Loan Documents.

         SECTION 12.8 APPLICATION OF PROCEEDS.

                                      -53-
<PAGE>

         Any and all proceeds ever received by Administrative Agent or Lenders
from the exercise of any Rights pertaining to the Obligation shall be applied to
the Obligation in the order and manner set forth in Section 3.12.

         SECTION 12.9 CERTAIN PROCEEDINGS.

         Each Loan Party will promptly execute and deliver, or cause the
execution and delivery of, all applications, certificates, instruments,
registration statements, and all other documents and papers Administrative Agent
or Lenders may reasonably request in connection with the obtaining of any
consent, approval, registration, qualification, permit, license, or
Authorization of any Governmental Authority or other Person necessary or
appropriate for the effective exercise of any Rights under the Loan Documents.

         SECTION 12.10 EXPENDITURES BY LENDERS.

         Borrower shall promptly pay within fifteen (15) Business Days after
request therefor (a) all reasonable costs, fees, and expenses paid or incurred
by Administrative Agent and Arranger, incident to any Loan Document (including,
but not limited to, the reasonable fees and expenses of counsel to
Administrative Agent and Arranger in connection with the negotiation,
preparation, delivery, execution, coordination and administration of the Loan
Documents and any related amendment, waiver, or consent) and (b) all costs and
expenses of Lenders and Administrative Agent incurred by Administrative Agent or
any Lender in connection with the enforcement of the obligations of any Loan
Party arising under the Loan Documents (including, without limitation, costs and
expenses incurred in connection with any workout or bankruptcy) or the exercise
of any Rights arising under the Loan Documents (including, but not limited to,
reasonable attorneys' fees, court costs and other costs of collection), all of
which shall be a part of the Obligation and shall bear interest at the Default
Rate from the date due until the date repaid.

         SECTION 12.11 INDEMNIFICATION.

         BORROWER AND EACH OTHER LOAN PARTY (BY EXECUTION OF A GUARANTY) AGREES
TO INDEMNIFY AND HOLD HARMLESS EACH AGENT, ARRANGER, AND EACH LENDER AND EACH OF
THEIR RESPECTIVE AFFILIATES AND THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES,
AGENTS, ATTORNEYS, AND ADVISORS (EACH, AN "INDEMNIFIED PARTY") FROM AND AGAINST
ANY AND ALL CLAIMS, DAMAGES, LOSSES, LIABILITIES (INCLUDING, WITHOUT LIMITATION,
ANY ENVIRONMENTAL LIABILITIES), COSTS, AND EXPENSES (INCLUDING, WITHOUT
LIMITATION, ATTORNEYS' FEES) THAT MAY BE INCURRED BY OR ASSERTED OR AWARDED
AGAINST ANY INDEMNIFIED PARTY, IN EACH CASE ARISING OUT OF OR IN CONNECTION WITH
OR BY REASON OF (INCLUDING, WITHOUT LIMITATION, IN CONNECTION WITH ANY
INVESTIGATION, LITIGATION, OR PROCEEDING OR PREPARATION OF DEFENSE IN CONNECTION
THEREWITH) THE LOAN DOCUMENTS, ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN OR
THE ACTUAL OR PROPOSED USE OF THE PROCEEDS OF THE BORROWINGS (INCLUDING ANY OF
THE FOREGOING ARISING FROM THE NEGLIGENCE OF THE INDEMNIFIED PARTY), EXCEPT TO
THE EXTENT SUCH

                                      -54-
<PAGE>

CLAIM, DAMAGE, LOSS, LIABILITY, COST, OR EXPENSE IS FOUND IN A FINAL,
NON-APPEALABLE JUDGMENT BY A COURT OF COMPETENT JURISDICTION TO HAVE RESULTED
FROM SUCH INDEMNIFIED PARTY'S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. IN THE
CASE OF AN INVESTIGATION, LITIGATION OR OTHER PROCEEDING TO WHICH THE INDEMNITY
IN THIS SECTION 12.11 APPLIES, SUCH INDEMNITY SHALL BE EFFECTIVE WHETHER OR NOT
SUCH INVESTIGATION, LITIGATION OR PROCEEDING IS BROUGHT BY BORROWER, ITS
DIRECTORS, SHAREHOLDERS OR CREDITORS OR AN INDEMNIFIED PARTY OR ANY OTHER PERSON
OR ANY INDEMNIFIED PARTY IS OTHERWISE A PARTY THERETO AND WHETHER OR NOT THE
TRANSACTIONS CONTEMPLATED HEREBY ARE CONSUMMATED. BORROWER AND EACH OTHER LOAN
PARTY (BY EXECUTION OF A GUARANTY) AGREE NOT TO ASSERT ANY CLAIM AGAINST ANY
INDEMNIFIED PARTY ON ANY THEORY OF LIABILITY, FOR SPECIAL, INDIRECT,
CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING OUT OF OR OTHERWISE RELATING TO THE
LOAN DOCUMENTS, ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN OR THE ACTUAL OR
PROPOSED USE OF THE PROCEEDS OF THE BORROWINGS. WITHOUT PREJUDICE TO THE
SURVIVAL OF ANY OTHER AGREEMENT OF BORROWER OR GUARANTORS HEREUNDER, THE
AGREEMENTS AND OBLIGATIONS OF THE LOAN PARTIES CONTAINED IN THIS SECTION 12.11
SHALL SURVIVE THE PAYMENT IN FULL OF THE BORROWINGS AND ALL OTHER AMOUNTS
PAYABLE UNDER THE LOAN DOCUMENTS.

                                      -55-
<PAGE>

                                  ARTICLE XIII
                             AGREEMENT AMONG LENDERS

         SECTION 13.1 ADMINISTRATIVE AGENT.

         (a)      APPOINTMENT OF ADMINISTRATIVE AGENT. Each Lender hereby
appoints SunTrust Bank (and SunTrust Bank hereby accepts such appointment) as
its agent hereunder, in its name and on its behalf: (i) to act for and on behalf
of such Lender in and under all Loan Documents as provided therein; (ii) to
arrange the means whereby the funds of Lenders are to be made available to
Borrower under the Loan Documents; (iii) to take such action as may be requested
by any Lender under the Loan Documents (when such Lender is entitled to make
such request under the Loan Documents and after such requesting Lender has
obtained the concurrence of such other Lenders as may be required under the Loan
Documents); (iv) to receive all documents and items to be furnished to Lenders
under the Loan Documents; (v) to timely distribute, and Administrative Agent
agrees to so distribute, to each Lender all material information, requests,
documents, and items received from Borrower under the Loan Documents; (vi) to
promptly distribute to each Lender its ratable part of each payment or
prepayment (whether voluntary, as proceeds of collateral upon or after
foreclosure, as proceeds of insurance thereon, or otherwise) in accordance with
the terms of the Loan Documents; (vii) to deliver to the appropriate Persons
requests, demands, approvals, and consents received from Lenders; and (viii) to
execute, on behalf of Lenders, such releases or other documents or instruments
as are permitted by the Loan Documents or as directed by Lenders from time to
time; provided, however, Administrative Agent shall not be required to take any
action which exposes Administrative Agent to personal liability or which is
contrary to the Loan Documents or applicable Law.

         (b)      RESIGNATION OF ADMINISTRATIVE AGENT; SUCCESSOR ADMINISTRATIVE
AGENTS. Administrative Agent may resign at any time as Administrative Agent
under the Loan Documents by giving written notice thereof to Lenders and to
Borrower. Should the initial or any successor Administrative Agent ever cease to
be a party hereto or should the initial or any successor Administrative Agent
ever resign as Administrative Agent, then Required Lenders shall elect the
successor Administrative Agent from among Lenders (other than the resigning
Administrative Agent). If no successor Administrative Agent shall have been so
appointed by Required Lenders, within 30 days after the retiring Administrative
Agent's giving of notice of resignation, then the retiring Administrative Agent
may, on behalf of Lenders, appoint a successor Administrative Agent, which shall
be a commercial bank having a combined capital and surplus of at least
$1,000,000,000. Unless a Default or Potential Default has occurred and is
continuing, any such successor Administrative Agent appointed under this Section
shall be subject to Borrower's approval, which approval shall not be
unreasonably withheld or delayed. Upon the acceptance of any appointment as
Administrative Agent under the Loan Documents by a successor Administrative
Agent, such successor Administrative Agent shall thereupon succeed to and become
vested with all the Rights of the retiring Administrative Agent, and the
retiring Administrative Agent shall be discharged from its duties and
obligations of Administrative Agent under the Loan Documents (provided, however,
that when used in connection with LCs issued and outstanding prior to the
appointment of the successor Administrative Agent, "ADMINISTRATIVE AGENT" shall
continue to refer solely to the bank that issued the outstanding LC; provided
further that any LCs issued or renewed after the appointment of any successor
Administrative Agent shall be issued by such successor Administrative Agent),
and each Lender

                                      -56-
<PAGE>

shall execute such documents as any Lender may reasonably request to reflect
such change in and under the Loan Documents. After any retiring Administrative
Agent's resignation as Administrative Agent under the Loan Documents, the
provisions of this Article 13 shall inure to its benefit as to any actions taken
or omitted to be taken by it while it was Administrative Agent under the Loan
Documents.

         (c)      ADMINISTRATIVE AGENT AS A LENDER; NON-FIDUCIARY.
Administrative Agent, in its capacity as a Lender, shall have the same Rights
under the Loan Documents as any other Lender and may exercise the same as though
it were not acting as Administrative Agent; the term "LENDER" shall, unless the
context otherwise indicates, include Administrative Agent and any issuer of an
LC hereunder; and any resignation, or removal of by Administrative Agent
hereunder shall not impair or otherwise affect any Rights which it has or may
have in its capacity as an individual Lender. Each Lender and Borrower agree
that Administrative Agent is not a fiduciary for Lenders or for Borrower but
simply is acting in the capacity described herein to alleviate administrative
burdens for both Borrower and Lenders, that Administrative Agent has no duties
or responsibilities to Lenders or Borrower except those expressly set forth
herein, and that Administrative Agent in its capacity as a Lender has all Rights
of any other Lender.

         (d)      OTHER ACTIVITIES OF ADMINISTRATIVE AGENT. Administrative Agent
and its Affiliates may now or hereafter be engaged in one or more loan, letter
of credit, leasing, or other financing transactions with Borrower, act as
trustee or depositary for Borrower, or otherwise be engaged in other
transactions with Borrower (collectively, the "OTHER ACTIVITIES") not the
subject of the Loan Documents. Without limiting the Rights of Lenders
specifically set forth in the Loan Documents, Administrative Agent and its
Affiliates shall not be responsible to account to Lenders for such other
activities, and no Lender shall have any interest in any other activities, any
present or future guaranties by or for the account of Borrower which are not
contemplated or included in the Loan Documents, any present or future offset
exercised by Administrative Agent and its Affiliates in respect of such other
activities, any present or future property taken as security for any such other
activities, or any property now or hereafter in the possession or control of
Administrative Agent or its Affiliates which may be or become security for the
obligations of Borrower arising under the Loan Documents by reason of the
general description of indebtedness secured or of property contained in any
other agreements, documents or instruments related to any such other activities;
provided that, if any payments in respect of such guaranties or such property or
the proceeds thereof shall be applied to reduction of the Obligation arising
under the Loan Documents, then each Lender shall be entitled to share in such
application ratably.

         SECTION 13.2 EXPENSES.

         Upon demand by Administrative Agent, each Lender shall pay its ratable
portion of any expenses (including, without limitation, court costs, attorneys'
fees, and other costs of collection) incurred by Administrative Agent in
connection with any of the Loan Documents if and to the extent Administrative
Agent does not receive reimbursement therefor from other sources within 60 days
after incurred; provided that, each Lender shall be entitled to receive its
ratable portion of any reimbursement for such expenses, or part thereof, which
Administrative Agent subsequently receives from such other sources.

                                      -57-
<PAGE>

         SECTION 13.3 PROPORTIONATE ABSORPTION OF LOSSES.

         Except as otherwise provided in the Loan Documents, nothing in the Loan
Documents shall be deemed to give any Lender any advantage over any other Lender
insofar as the Obligation arising under the Loan Documents is concerned, or to
relieve any Lender from absorbing its ratable portion of any losses sustained
with respect to the Obligation (except to the extent such losses result from
unilateral actions or inactions of any Lender that are not made in accordance
with the terms and provisions of the Loan Documents).

         SECTION 13.4 DELEGATION OF DUTIES; RELIANCE.

         Administrative Agent may perform any of its duties or exercise any of
its Rights under the Loan Documents by or through its Representatives.
Administrative Agent and its Representatives shall (a) be entitled to rely upon
(and shall be protected in relying upon) any writing, resolution, notice,
consent, certificate, affidavit, letter, cablegram, telecopy, telegram, telex or
teletype message, statement, order, or other documents or conversation believed
by it or them to be genuine and correct and to have been signed or made by the
proper Person and, with respect to legal matters, upon opinion of counsel
selected by Administrative Agent, (b) be entitled to deem and treat each Lender
as the owner and holder of the Obligation owed to such Lender for all purposes
until, subject to Section 14.13, written notice of the assignment or transfer
thereof shall have been given to and received by Administrative Agent (and any
request, authorization, consent, or approval of any Lender shall be conclusive
and binding on each subsequent holder, assignee, or transferee of the Obligation
owed to such Lender or portion thereof until such notice is given and received),
(c) not be deemed to have notice of the occurrence of a Default or Potential
Default unless a responsible officer of Administrative Agent, who handles
matters associated with the Loan Documents and transactions thereunder, has
received written notice from a Lender or Borrower and stating that such notice
is a "Notice of Default," and (d) be entitled to consult with legal counsel
(including counsel for Borrower), independent accountants, and other experts
selected by Administrative Agent and shall not be liable for any action taken or
omitted to be taken in good faith by it in accordance with the advice of such
counsel, accountants or experts.

         SECTION 13.5 LIMITATION OF LIABILITY.

         (a)      GENERAL. Neither the Administrative Agent nor any of its
Representatives shall be liable for any action taken or omitted to be taken by
it under the Loan Documents in good faith and reasonably believed by it to be
within the discretion or power conferred upon it by the Loan Documents or be
responsible for the consequences of any error of judgment, except to the extent
arising from its gross negligence, or willful misconduct; and neither the
Administrative Agent nor any of its Representatives has a fiduciary relationship
with any Lender by virtue of the Loan Documents (provided that, nothing herein
shall negate the obligation of Administrative Agent to account for funds
received by it for the account of any Lender).

         (b)      NON-DISCRETIONARY ACTIONS; INDEMNIFICATION. Unless indemnified
to its satisfaction against loss, cost, liability, and expense, the
Administrative Agent shall not be compelled to do any act under the Loan
Documents or to take any action toward the execution or enforcement of the
powers thereby created or to prosecute or defend any suit in respect of the

                                      -58-
<PAGE>

Loan Documents. If Administrative Agent requests instructions from Lenders or
Required Lenders, as the case may be, with respect to any act or action
(including, but not limited to, any failure to act) in connection with any Loan
Document, Administrative Agent shall be entitled (but shall not be required) to
refrain (without incurring any liability to any Person by so refraining) from
such act or action unless and until it has received such instructions. Except
where action of Required Lenders or all Lenders is required in the Loan
Documents, Administrative Agent may act hereunder in its own discretion without
requesting instructions. In no event, however, shall Administrative Agent or any
of its respective Representatives be required to take any action which it or
they determine could incur for it or them criminal or onerous civil liability.
Without limiting the generality of the foregoing, no Lender shall have any right
of action against Administrative Agent as a result of Administrative Agent's
acting or refraining from acting hereunder in accordance with the instructions
of Required Lenders (or all Lenders if required in the Loan Documents).

         (c)      INDEPENDENT CREDIT DECISION. The Administrative Agent shall
not be responsible in any manner to any Lender or any Participant for, and each
Lender represents and warrants that it has not relied upon Administrative Agent
in respect of, (i) the creditworthiness of any Loan Party and the risks involved
to such Lender, (ii) the effectiveness, enforceability, genuineness, validity,
or the due execution of any Loan Document, (iii) any representation, warranty,
document, certificate, report, or statement made therein or furnished thereunder
or in connection therewith, or (iv) observation of or compliance with any of the
terms, covenants, or conditions of any Loan Document on the part of any Loan
Party. Each Lender agrees to indemnify Administrative Agent and its respective
Representatives and hold them harmless from and against (but limited to such
Lender's Pro Rata Part of) any and all liabilities, obligations, losses,
damages, penalties, actions, judgments, suits, costs, expenses, and
disbursements of any kind or nature whatsoever which may be imposed on, asserted
against, or incurred by them in any way relating to or arising out of the Loan
Documents or any action taken or omitted by them under the Loan Documents
(including any of the foregoing arising from the negligence of Administrative
Agent or its Representatives), to the extent Administrative Agent and its
respective Representatives are not reimbursed for such amounts by any Loan Party
(provided that, Administrative Agent and its respective Representatives shall
not have the right to be indemnified hereunder for its or their own gross
negligence, or willful misconduct).

         SECTION 13.6 DEFAULT.

         (a)      Upon the occurrence and continuance of a Default, Lenders
agree to promptly confer in good faith upon reasonable prior notice in order
that Required Lenders or Lenders, as the case may be, may agree upon a course of
action for the enforcement of the Rights of Lenders; and Administrative Agent
shall be entitled to refrain from taking any action (without incurring any
liability to any Person for so refraining) unless and until Administrative Agent
shall have received instructions from Required Lenders or Lenders, as herein
required. All Rights of action under the Loan Documents, if any, hereunder may
be enforced by Administrative Agent and any suit or proceeding instituted by
Administrative Agent in furtherance of such enforcement shall be brought in its
name as Administrative Agent without the necessity of joining as plaintiffs or
defendants any other Lender, and the recovery of any judgment shall be for the
benefit of Lenders subject to the expenses of Administrative Agent. In actions
with respect to any property of Borrower, Administrative Agent is acting for the
ratable benefit of each Lender. Any and all

                                      -59-
<PAGE>

agreements to subordinate (whether made heretofore or hereafter) other
indebtedness or obligations of Borrower to the Obligation shall be construed as
being for the ratable benefit of each Lender.

         (b)      Except to the extent unanimity is required hereunder, each
Lender agrees that any action taken by the Required Lenders in accordance with
the provisions of the Loan Documents, and the exercise by the Required Lenders
of the powers set forth herein or therein, together with such other powers as
are reasonably incidental thereto, shall be authorized and binding upon all of
Lenders.

         SECTION 13.7 LIMITATION OF LIABILITY.

         To the extent permitted by Law, (a) Administrative Agent (acting in its
agent capacity) shall not incur any liability to any Lender or Participant
except for acts or omissions resulting from its own gross negligence or willful
misconduct, and (b) neither Administrative Agent nor any Lender or Participant
shall incur any liability to any other Person for any act or omission of the
Administrative Agent or any Lender or Participant.

         SECTION 13.8 RELATIONSHIP OF LENDERS.

         Nothing herein shall be construed as creating a partnership or joint
venture among the Administrative Agent and Lenders.

         SECTION 13.9 BENEFITS OF AGREEMENT.

         None of the provisions of this Article 13 (other than Borrower's right
to consent to a successor agent as set forth in Section 13.1(b)) shall inure to
the benefit of any Loan Party, Guarantor, or any other Person other than
Lenders; consequently, no Loan Party or any other Person shall be entitled to
rely upon, or to raise as a defense, in any manner whatsoever, the failure of
the Administrative Agent or any Lender to comply with such provisions.

         SECTION 13.10 AGENTS.

         None of the Persons identified in this Agreement or on the cover page
as "Syndication Agent," "Documentation Agent" or "Lead Arranger" shall have any
Rights, powers, obligations, liabilities, responsibilities, or duties under the
Loan Documents other than those applicable to all Lenders as such. Without
limiting the foregoing, none of the Persons so identified as a "Syndication
Agent," "Documentation Agent" or "Lead Arranger" shall have or be deemed to have
any fiduciary relationship with any Lender. Any Person that is a "Syndication
Agent," "Documentation Agent" or "Lead Arranger" may voluntarily relinquish its
title by giving written notice thereof to Administrative Agent and Borrower.
Upon such relinquishments, a successor "Syndication Agent," "Documentation
Agent" or "Lead Arranger" may be appointed upon the mutual agreement of Borrower
and Administrative Agent.

         SECTION 13.11 OBLIGATIONS SEVERAL.

         The obligations of Lenders hereunder are several, and each Lender
hereunder shall not be responsible for the obligations of the other Lenders
hereunder, nor will the failure of one Lender

                                      -60-
<PAGE>

to perform any of its obligations hereunder relieve the other Lenders from the
performance of their respective obligations hereunder.

                                   ARTICLE XIV
                                  MISCELLANEOUS

         SECTION 14.1 HEADINGS.

         The headings, captions, and arrangements used in any of the Loan
Documents are, unless specified otherwise, for convenience only and shall not be
deemed to limit, amplify, or modify the terms of the Loan Documents, nor affect
the meaning thereof.

         SECTION 14.2 NONBUSINESS DAYS.

         In any case where any payment or action is due under any Loan Document
on a day which is not a Business Day, such payment or action may be delayed
until the next-succeeding Business Day, but interest and fees shall continue to
accrue in respect of any payment to which it is applicable until such payment is
in fact made; provided that, if, in the case of any such payment in respect of a
Eurodollar Rate Borrowing, the next-succeeding Business Day is in the next
calendar month, then such payment shall be made on the next-preceding Business
Day.

         SECTION 14.3 COMMUNICATIONS.

         Unless specifically otherwise provided, whenever any Loan Document
requires or permits any consent, approval, notice, request, or demand from one
party to another, such communication must be in writing (which may be by telex
or telecopy) to be effective and shall be deemed to have been given (a) if by
telecopy, when transmitted to the telecopy number for such party during normal
business hours on a Business Day (and all such communications sent by telecopy
shall be confirmed promptly thereafter by personal delivery or mailing in
accordance with the provisions of this Section; provided, that any requirement
in this parenthetical shall not affect the date on which such telecopy shall be
deemed to have been delivered), (b) if by mail, on the third Business Day after
it is enclosed in an envelope, properly addressed to such party, properly
stamped, sealed, and deposited in the appropriate official postal service, or
(c) if by any other means, when actually delivered to such party. Until changed
by notice pursuant hereto, the address (and telecopy numbers) for Administrative
Agent and each Lender is set forth on Schedule 14.3, and for each Loan Party is
the address set forth by Borrower's signature on the signature page of this
Agreement and for each Guarantor is the address set forth by such Guarantor's
signature on the signature page of its Guaranty.

         SECTION 14.4 FORM AND NUMBER OF DOCUMENTS.

         Each agreement, document, instrument, or other writing to be furnished
under any provision of the Loan Documents must be in form and substance and in
such number of counterparts as may be reasonably satisfactory to Administrative
Agent and its counsel.

         SECTION 14.5 EXCEPTIONS TO COVENANTS.

                                      -61-
<PAGE>

         No Loan Party shall take any action or fail to take any action which is
permitted as an exception to any of the covenants contained in any Loan Document
if such action or omission would result in the breach of any other covenant
contained in any of the Loan Documents.

         SECTION 14.6 SURVIVAL.

         All covenants, agreements, undertakings, representations, and
warranties made in any of the Loan Documents shall survive all closings under
the Loan Documents and, except as otherwise indicated, shall not be affected by
any investigation made by any party. All rights of, and provisions relating to,
reimbursement and indemnification of Administrative Agent or any Lender (and any
other provision of the Loan Documents that expressly provides for such survival)
shall survive termination of this Agreement and payment in full of the
Obligation.

         SECTION 14.7 GOVERNING LAW.

         THE LAWS OF THE STATE OF NEW YORK, AND THE APPLICABLE FEDERAL LAWS OF
THE UNITED STATES OF AMERICA, SHALL GOVERN THE VALIDITY, CONSTRUCTION,
ENFORCEMENT AND INTERPRETATION OF THE LOAN DOCUMENTS.

         SECTION 14.8 INVALID PROVISIONS.

         If any provision in any Loan Document is held to be illegal, invalid,
or unenforceable, such provision shall be fully severable; the appropriate Loan
Document shall be construed and enforced as if such provision had never
comprised a part thereof; and the remaining provisions thereof shall remain in
full force and effect and shall not be affected by such provision or by its
severance therefrom. Administrative Agent, Lenders, and each Loan Party party to
such Loan Document agree to negotiate, in good faith, the terms of a replacement
provision as similar to the severed provision as may be possible and be legal,
valid, and enforceable.

         SECTION 14.9 ENTIRETY.

         THE RIGHTS AND OBLIGATIONS OF EACH LOAN PARTY, LENDERS, AND AGENTS
SHALL BE DETERMINED SOLELY FROM WRITTEN AGREEMENTS, DOCUMENTS, AND INSTRUMENTS,
AND ANY PRIOR ORAL AGREEMENTS BETWEEN SUCH PARTIES ARE SUPERSEDED BY AND MERGED
INTO SUCH WRITINGS. THIS AGREEMENT (AS AMENDED IN WRITING FROM TIME TO TIME) AND
THE OTHER WRITTEN LOAN DOCUMENTS EXECUTED BY ANY LOAN PARTY, ANY GUARANTOR, ANY
LENDER, AND/OR ANY AGENT (TOGETHER WITH ALL FEE LETTERS AS THEY RELATE TO THE
PAYMENT OF FEES AFTER THE CLOSING DATE) REPRESENT THE FINAL AGREEMENT BETWEEN
THE LOAN PARTIES, LENDERS, AND AGENTS, AND MAY NOT BE CONTRADICTED BY EVIDENCE
OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS BY SUCH PARTIES. THERE
ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN SUCH PARTIES.

         SECTION 14.10 JURISDICTION; VENUE; SERVICE OF PROCESS.

                                      -62-
<PAGE>

         EACH PARTY HERETO (INCLUDING EACH GUARANTOR BY EXECUTION OF A
GUARANTY), IN EACH CASE FOR ITSELF, ITS SUCCESSORS AND ASSIGNS, HEREBY (A)
IRREVOCABLY SUBMITS TO THE NONEXCLUSIVE JURISDICTION OF THE UNITED STATES
DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN NEW YORK COUNTY
OR THE SUPREME COURT OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY, AND
AGREES AND CONSENTS THAT SERVICE OF PROCESS MAY BE MADE UPON IT IN ANY LEGAL
PROCEEDING ARISING OUT OF OR IN CONNECTION WITH THE LOAN DOCUMENTS AND THE
OBLIGATION BY SERVICE OF PROCESS AS PROVIDED BY NEW YORK LAW, (B) IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW
OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY LITIGATION ARISING OUT OF OR IN
CONNECTION WITH THE LOAN DOCUMENTS AND THE OBLIGATION BROUGHT IN ANY SUCH COURT,
(C) IRREVOCABLY WAIVES ANY CLAIMS THAT ANY LITIGATION BROUGHT IN ANY SUCH COURT
HAS BEEN BROUGHT IN AN INCONVENIENT FORUM, AND (D) IRREVOCABLY CONSENTS TO THE
SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH
LITIGATION BY THE MAILING OF COPIES THEREOF BY CERTIFIED MAIL, RETURN RECEIPT
REQUESTED, POSTAGE PREPAID, AT ITS ADDRESS SET FORTH HEREIN. The scope of each
of the foregoing waivers is intended to be all-encompassing of any and all
disputes that may be filed in any court and that relate to the subject matter of
this transaction, including, without limitation, contract claims, tort claims,
breach of duty claims, and all other common law and statutory claims. The Loan
Parties and each other party to the Loan Documents acknowledge that this waiver
is a material inducement to the agreement of each party hereto to enter into a
business relationship, that each has already relied on this waiver in entering
into the Loan Documents, and each will continue to rely on each of such waivers
in related future dealings. The Loan Parties and each other party to the Loan
Documents warrant and represent that they have reviewed these waivers with their
legal counsel, and that they knowingly and voluntarily agree to each such waiver
following consultation with legal counsel. THE WAIVERS IN THIS SECTION 14.10 ARE
IRREVOCABLE, MEANING THAT THEY MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING,
AND THESE WAIVERS SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, SUPPLEMENTS, AND
REPLACEMENTS TO OR OF THIS OR ANY OTHER LOAN DOCUMENT.

         SECTION 14.11 AMENDMENTS, CONSENTS, CONFLICTS, AND WAIVERS.

         (a)      Except as otherwise specifically provided, this Agreement and
the other Loan Documents may be amended, modified, or waived only by an
instrument in writing executed jointly by Borrower and Required Lenders (or by
Administrative Agent acting upon directions of the Required Lenders).

         (b)      Any amendment to or consent or waiver under any Loan Document
which purports to accomplish any of the following must be by an instrument in
writing executed by Borrower and executed (or approved, as the case may be) by
each Lender affected thereby, and by Administrative Agent if affected thereby:
(i) increases the Commitment Sum of such Lender or extends such Lender's
commitment hereunder; (ii) postpones or delays any date fixed by the Loan
Documents for any payment or mandatory prepayment of all or any part of the
Obligation

                                      -63-
<PAGE>

payable to such Lender or Administrative Agent; (iii) reduces the interest rate
or decreases the amount of any payment of principal, interest, fees, or other
sums payable to Administrative Agent or any such Lender hereunder; (iv) changes
the definition of "Required Lenders"; (v) releases a Guaranty; (vi) changes this
clause (b) or any other matter specifically requiring the consent of all Lenders
hereunder; or (vii) alters the rights, duties or obligations of Administrative
Agent.

         (c)      Any conflict or ambiguity between the terms and provisions of
this Agreement and terms and provisions in any other Loan Document shall be
controlled by the terms and provisions herein.

         (d)      No course of dealing nor any failure or delay by
Administrative Agent, any Lender, or any of their respective Representatives
with respect to exercising any Right of Administrative Agent or any Lender
hereunder shall operate as a waiver thereof. A waiver must be in writing and
signed by Required Lenders (or by all Lenders, if required hereunder) to be
effective, and such waiver will be effective only in the specific instance and
for the specific purpose for which it is given.

         SECTION 14.12 MULTIPLE COUNTERPARTS.

         The Loan Documents may be executed in a number of identical
counterparts, each of which shall be deemed an original for all purposes and all
of which constitute, collectively, one agreement; but, in making proof of any
Loan Document, it shall not be necessary to produce or account for more than one
such counterpart. It is not necessary that each Lender execute the same
counterpart so long as identical counterparts are executed by Borrower, each
Lender, and Administrative Agent. This Agreement shall become effective when
counterparts hereof shall have been executed and delivered to Administrative
Agent by each Lender, Administrative Agent, and Borrower, or, when
Administrative Agent shall have received telecopied, telexed, or other evidence
satisfactory to it that such party has executed and is delivering to
Administrative Agent a counterpart hereof.

         SECTION 14.13 SUCCESSORS AND ASSIGNS; ASSIGNMENTS AND PARTICIPATIONS.

         (a)      This Agreement shall be binding upon, and inure to the benefit
of the parties hereto and their respective successors and assigns, except that
(i) Borrower may not, directly or indirectly, assign or transfer, or attempt to
assign or transfer, any of its Rights, duties, or obligations under any Loan
Documents without the express written consent of all Lenders, and (ii) except as
permitted under this Section, no Lender may transfer, pledge, assign, sell any
participation in, or otherwise encumber its portion of the Obligation.

         (b)      Each Lender may assign to one or more Eligible Assignees all
or a portion of its Rights and obligations under the Loan Documents (including,
without limitation, all or a portion of its Borrowings and its Notes to the
extent any Principal Debt owed to such assigning Lender is evidenced by a Note
or Notes); provided, however, that:

                  (i)      each such assignment shall be to an Eligible
         Assignee;

                                      -64-
<PAGE>

                  (ii)     except in the case of an assignment to another Lender
         or in the case of an assignment of all of a Lender's Rights and
         obligations under the Loan Documents, any such partial assignment under
         the Facility shall not be less than $5,000,000 unless Borrower and
         Administrative Agent consent thereto (in their sole discretion) in
         writing which may be evidenced by their acceptance and execution of the
         related Assignment and Acceptance Agreement; provided that, no partial
         assignment for the Facility (including any assignment among Lenders)
         may result in any Lender holding less than $10,000,000;

                  (iii)    the parties to such assignment (including, without
         limitation, any assignment between Lenders) shall execute and deliver
         to Administrative Agent for its acceptance an Assignment and Acceptance
         Agreement in substantially the form of Exhibit E hereto, together with
         any Notes (to the extent any Principal Debt owed to such assigning
         Lender is evidenced by a Note or Notes) subject to such assignment and
         a processing fee of $1,000; and

                  (iv)     so long as any Lender is Administrative Agent under
         this Agreement, such Lender (or an Affiliate of such Lender) shall
         retain an economic interest in the Loan Documents, will not assign all
         of its Rights, duties, or obligations under the Loan Documents, except
         to an Affiliate of such Lender, and will not enter into any Assignment
         and Acceptance Agreement that would have the effect of such Lender
         assigning all of its Rights, duties, or obligations as a Lender under
         the Loan Documents to any Person other than an Affiliate of such Lender
         unless Administrative Agent has relinquished such title in accordance
         with Section 13.1.

Upon execution, delivery, and acceptance of such Assignment and Acceptance
Agreement, the assignee thereunder, if not already a party hereto, shall become
a party hereto and, to the extent of such assignment, have the obligations,
Rights, and benefits of a Lender under the Loan Documents and the assigning
Lender shall, to the extent of such assignment, relinquish its Rights and be
released from its obligations under the Loan Documents; provided, however, the
assigning Lender shall retain any indemnity rights hereunder for the period
prior to such assignment. Upon the consummation of any assignment pursuant to
this Section, but only upon the request of the assignor or assignee made through
Administrative Agent, Borrower shall issue appropriate Notes to the assignor and
the assignee, reflecting such Assignment and Acceptance. If the assignee is not
incorporated under the laws of the United States of America or a state thereof,
it shall deliver to Borrower and Administrative Agent certification as to
exemption from deduction or withholding of Taxes in accordance with Section 4.6.

         (c)      Administrative Agent shall maintain at its address referred to
in Section 14.3 a copy of each Assignment and Acceptance Agreement delivered to
and accepted by it and a register for the recordation of the names and addresses
of Lenders and the Commitment Percentage, and principal amount of the Borrowings
owing to, each Lender from time to time (the "REGISTER"). The entries in the
Register shall be conclusive and binding for all purposes, absent manifest
error, and Borrower, Administrative Agent and Lenders may treat each Person
whose name is recorded in the Register as a Lender hereunder for all purposes of
the Loan Documents. The Register shall be available for inspection by Borrower
or any Lender at any reasonable time and from time to time upon reasonable prior
notice. Upon the consummation of any assignment in accordance with this Section
14.13, Schedule 2.1 shall automatically be

                                      -65-
<PAGE>

deemed amended (to the extent required) by Administrative Agent to reflect the
name, address, and, where appropriate, respective Committed Sums under the
Facility (as the case may be) of the assignor and assignee.

         (d)      Upon its receipt of an Assignment and Acceptance Agreement
executed by the parties thereto, together with any Notes (to the extent any
Principal Debt owed to such assigning Lender is evidenced by a Note or Notes)
subject to such assignment and payment of the processing fee, Administrative
Agent shall, if such Assignment and Acceptance has been completed and is in
substantially the form of Exhibit E hereto, promptly (i) accept such Assignment
and Acceptance Agreement, (ii) record the information contained therein in the
Register, and (iii) give notice thereof to the parties thereto.

         (e)      Subject to the provisions of this Section and in accordance
with applicable Law, any Lender may, in the ordinary course of its commercial
banking business and in accordance with applicable Law, at any time sell to one
or more Persons (each a "PARTICIPANT") participating interests in its portion of
the Obligation. In the event of any such sale to a Participant, (i) such Lender
shall remain a "Lender" under the Loan Documents and the Participant shall not
constitute a "Lender" hereunder, (ii) such Lender's obligations under the Loan
Documents shall remain unchanged, (iii) such Lender shall remain solely
responsible for the performance thereof, (iv) such Lender shall remain the
holder of its share of the Principal Debt for all purposes under the Loan
Documents, (v) Borrower and Administrative Agent shall continue to deal solely
and directly with such Lender in connection with such Lender's Rights and
obligations under the Loan Documents, and (vi) such Lender shall be solely
responsible for any withholding taxes or any filing or reporting requirements
relating to such participation and shall hold Borrower and Administrative Agent
and their respective successors, permitted assigns, officers, directors,
employees, agents, and representatives harmless against the same. Participants
shall have no Rights under the Loan Documents, other than certain voting Rights
as provided below. Subject to the following, each Lender shall be entitled to
obtain (on behalf of its Participants) the benefits of Article 4 with respect to
all participations in its part of the Obligation outstanding from time to time,
so long as Borrower shall not be obligated to pay any amount in excess of the
amount that would be due to such Lender under Article 4 calculated as though no
participations have been made. No Lender shall sell any participating interest
under which the Participant shall have any Rights to approve any amendment,
modification, or waiver of any Loan Document, except to the extent such
amendment, modification, or waiver extends the due date for payment of any
amount in respect of principal (other than mandatory prepayments), interest, or
fees due under the Loan Documents, reduces the interest rate or the amount of
principal or fees applicable to the Obligation (except such reductions as are
contemplated by the Loan Documents), or releases all or any substantial portion
of the Guaranties under the Loan Documents; provided that, in those cases where
a Participant is entitled to the benefits of Article 4 or a Lender grants Rights
to its Participants to approve amendments to or waivers of the Loan Documents
respecting the matters previously described in this sentence, such Lender must
include a voting mechanism in the relevant participation agreement or
agreements, as the case may be, whereby a majority of such Lender's portion of
the Obligation (whether held by such Lender or Participant) shall control the
vote for all of such Lender's portion of the Obligation. Except in the case of
the sale of a participating interest to another Lender, the relevant
participation agreement shall not permit the Participant to transfer, pledge,
assign, sell participations in, or otherwise encumber its portion of the
Obligation, unless the consent of the transferring Lender has been obtained.

                                      -66-
<PAGE>

         (f)      Notwithstanding any other provision set forth in this
Agreement, any Lender may, without notice to, or the consent of Borrower or
Administrative Agent, at any time assign and pledge all or any portion of its
Borrowings and its Notes (to the extent any Principal Debt owed to such
assigning Lender is evidenced by a Note or Notes) to any Federal Reserve Bank as
collateral security pursuant to Regulation A and any Operating Circular issued
by such Federal Reserve Bank or any Lender which is a fund may pledge all or any
portion of its Borrowings and its Notes (to the extent any Principal Debt owed
to such assigning Lender is evidenced by a Note or Notes) to its trustee in
support of its obligations to its trustee. No such assignment shall release the
assigning Lender from its obligations hereunder.

         (g)      Any Lender may furnish any information concerning the Loan
Parties in the possession of such Lender from time to time to Eligible Assignees
and Participants (including prospective Eligible Assignees and Participants),
subject to the provisions of Section 14.14.

         SECTION 14.14 CONFIDENTIALITY.

         (a)      The Administrative Agent and each Lender (each, a "LENDING
PARTY") agrees to keep confidential any information furnished or made available
to it by any Loan Party pursuant to this Agreement that is marked confidential;
provided that nothing herein shall prevent any Lending Party from disclosing
such information (a) to any other Lending Party or any affiliate of any Lending
Party, or any officer, director, employee, agent, or advisor of any Lending
Party or affiliate of any Lending Party, (b) to any other Person if reasonably
incidental to the administration of the credit facility provided herein, (c) as
required by any law, rule, or regulation, (d) upon the order of any court or
administrative agency, (e) upon the request or demand of any regulatory agency
or authority, (f) that is or becomes available to the public or that is or
becomes available to any Lending Party other than as a result of a disclosure by
any Lending Party prohibited by this Agreement, (g) in connection with any
litigation to which such Lending Party or any of its affiliates may be a party,
(h) to the extent necessary in connection with the exercise of any remedy under
this Agreement or any other Loan Document, and (i) subject to provisions
substantially similar to those contained in this Section, to any actual or
proposed Participant or Eligible Assignee. Notwithstanding anything herein or in
any other Loan Document to the contrary, any party to this Agreement (and any
employee, representative, or other agent of any party to this Agreement or any
other Loan Document) may disclose to any and all Persons, without limitation of
any kind, the tax treatment and tax structure of the transactions contemplated
by this Agreement or any other Loan Document and all materials of any kind
(including opinions or other tax analyses) that are provided to it relating to
such tax treatment and tax structure. However, any such information relating to
the tax treatment or tax structure is required to be kept confidential to the
extent necessary to comply with any applicable federal or state securities laws.

         SECTION 14.15 DISCHARGE ONLY UPON PAYMENT IN FULL; REINSTATEMENT IN
CERTAIN CIRCUMSTANCES.

         The obligations of each Loan Party under the Loan Documents shall
remain in full force and effect until termination of the Commitment, payment in
full of the Principal Debt and of all interest, fees, and other amounts of the
Obligation then due and owing, and expiration of all LCs, except that Sections
4, 12, and 14, and any other provisions under the Loan Documents expressly

                                      -67-
<PAGE>

intended to survive by the terms hereof or by the terms of the applicable Loan
Documents, shall survive such termination. If at any time any payment of the
principal of or interest on any Note or any other amount payable by Borrower
under any Loan Document is rescinded or must be otherwise restored or returned
upon the insolvency, bankruptcy, or reorganization of Borrower or otherwise, the
obligations of each Loan Party under the Loan Documents with respect to such
payment shall be reinstated as though such payment had been due but not made at
such time.

         SECTION 14.16 NO GENERAL PARTNERS' LIABILITY.

         The Administrative Agent and Lenders agree for themselves and their
respective successors, participants and assigns, including any subsequent holder
of any Note, that any claim against Borrower which may arise under any Loan
Document shall be made only against and shall be limited to the assets of
Borrower, except to the extent Intermediate Partnership may have obligations
with respect to such claim pursuant to the terms of its Guaranty, and that no
judgment, order or execution entered in any suit, action or proceeding, whether
legal or equitable, on this Agreement, such Note or any of the other Loan
Documents shall be obtained or enforced against any General Partner or its
assets for the purpose of obtaining satisfaction and payment of such Note, the
Debt evidenced thereby, any other Obligation or any claims arising thereunder or
under this Agreement or any other Loan Document, any right to proceed against
the General Partners individually or their respective Representatives or assets
being hereby expressly waived, renounced and remitted by the Administrative
Agent and Lenders for themselves and their respective successors, participants
and assigns. Nothing in this Section 14.16, however, shall be construed so as to
prevent the Administrative Agent, any Lender or any other holder of any Note
from commencing any action, suit or proceeding with respect to or causing legal
papers to be served upon any General Partner for the purpose of obtaining
jurisdiction over Borrower.

                  [remainder of page intentionally left blank]

                                      -68-
<PAGE>

                                   NORTHERN BORDER PARTNERS, L.P.

                                   By /s/ Jerry L. Peters
                                      ------------------------------------------
                                   Name: Jerry L .Peters
                                   Title: Chief Financial and Accounting Officer

                                   Address for Notices:
                                   Mr. Jerry L. Peters
                                   Chief Financial and Accounting Officer
                                   Northern Border Partners, L.P.
                                   13710 FNB Parkway
                                   Omaha, NE 68154
                                   Telephone: 402-492-7345
                                   Telecopy: 402-492-7479

                                   with a copy to:
                                   Ms. Janet Place
                                   Vice President and General Counsel
                                   Northern Plains Natural Gas Company
                                   13710 FNB Parkway
                                   Omaha, NE 68154
                                   Telephone: 402-492-7315
                                   Telecopy: 402-492-7480

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   SUNTRUST BANK, as Administrative Agent and
                                   Lender

                                   By /s/ Mary Crawford Owen
                                      ------------------------------------------
                                      Name: Mary Crawford Owen
                                      Title: Vice President

                                   Commitment: $40,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   BMO NESBITT BURNS FINANCING, INC.,
                                   as a Lender

                                   By /s/ James Whitmore
                                      ------------------------------------------
                                      Name: James Whitmore
                                      Title: Managing Director

                                   Commitment: $29,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   WACHOVIA BANK, NATIONAL
                                   ASSOCIATION, as a Lender

                                   By /s/ Russell Clingman
                                      ------------------------------------------
                                      Name:  Russell Clingman
                                      Title: Director

                                   Commitment: $29,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   CITIBANK, N.A., as a Lender
                                   By /s/ Amy K. Pincu
                                      ------------------------------------------
                                      Name: Amy K. Pincu
                                      Title:  Attorney-In-Fact

                                   Commitment: $29,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                         BARCLAYS BANK PLC, as a Lender

                                  By /s/ Nicholas A. Bell
                                     ------------------------------------------
                                     Name: Nicholas A. Bell
                                     Title: Director Loan Transaction Management

                                  Commitment: $28,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   MIZUHO CORPORATE BANK, LTD. , as a
                                   Lender

                                   By /s/ Jun Shimmachi
                                      ------------------------------------------
                                      Name: Jun Shimmachi
                                      Title: Vice President

                                   Commitment: $25,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   ROYAL BANK OF CANADA, as a Lender

                                   By /s/ Tom J. Oberaigner
                                      ------------------------------------------
                                      Name:  Tom J. Oberaigner
                                      Title: Attorney-In-Fact

                                   Commitment: $25,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   UBS LOAN FINANCE LLC as a Lender

                                   By /s/ Josalin Fernandes
                                      ------------------------------------------
                                      Name: Josalin Fernandes
                                      Title:  Associate Director

                                   By /s/ Barbara Ezell McMichael
                                      ------------------------------------------
                                      Name: Barbara Ezell-McMichael
                                      Title: Associate Director

                                   Commitment: $25,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                                   WELLS FARGO BANK, N.A., as a Lender

                                   By /s/ Art Krasny
                                      ------------------------------------------
                                      Name: Art Krasny
                                      Title:  Relationship Manager

                                   Commitment: $25,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]
<PAGE>

                                   BANK ONE, N.A., as a Lender

                                   By _________________________________________
                                      Name:
                                      Title:

                                   Commitment: $20,000,000

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]

<PAGE>

                      [SIGNATURE PAGE TO CREDIT AGREEMENT]<PAGE>
                                                                   EXHIBIT 10.14

Confidential materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.

                              AMENDED AND RESTATED

                       COLLABORATION AND LICENSE AGREEMENT

         This Amended and Restated Collaboration and License Agreement (the
"Agreement") is executed as of the 19 day of November, 2003 and made effective
as of the 17 day of December, 2002 (the "Effective Date") between Genentech,
Inc., a Delaware corporation having its principal place of business at 1 DNA
Way, South San Francisco, California 94080 ("Genentech"), and Lexicon Genetics
Incorporated, a Delaware corporation having its principal place of business at
8800 Technology Forest Place, The Woodlands, TX 77381-1160 ("Lexicon"). The
Agreement amends and restates that certain Collaboration and License Agreement
between Genentech and Lexicon dated as of December 17, 2002 (the "Original
Agreement"). Throughout the Agreement, Genentech and Lexicon are sometimes
referred to individually as a "Party" and collectively as "Parties."

                                    RECITALS

         WHEREAS, Genentech is in the business of using human genetic
information to discover, develop, manufacture and market pharmaceutical
products; and

         WHEREAS, Lexicon possesses certain knowledge and experience in the
design, generation, and phenotypic analysis of Knock-Out Mice and ES Cell Lines;
and

         WHEREAS, Genentech desires, on the terms and conditions contained
herein, for Lexicon to generate Knock-Out Mice and ES Cell Lines for Genentech
based on human gene sequences provided by Genentech and then to analyze such
Knock-Out Mice and ES Cell Lines, and Lexicon desires, on the terms and
conditions, and for the consideration, contained herein, to undertake such
activities; and

         NOW THEREFORE, in consideration of the foregoing premises and the
mutual covenants contained in this Agreement, the Parties agree as follows:

                                   ARTICLE 1

                                   DEFINITIONS

Terms defined in this Article 1 and parenthetically elsewhere, including in the
introductory paragraph and recitals, will have the same meaning throughout this
Agreement, unless otherwise specified. Defined terms are capitalized and may be
used in the singular or plural.

                                       1
<PAGE>

1.1      "ACADEMIC COLLABORATOR" means a principal investigator, employed at a
university or other not-for-profit academic research institution that has
entered into a material transfer agreement with Genentech pursuant to Section
5.10, who is performing collaborative research with Genentech involving use of a
Knock-Out Mouse or Progeny.

1.2      "ACTUAL KNOWLEDGE" of a Party means [**].

1.3      "AFFILIATE" of a Party means any person or corporation, joint venture,
or other business entity which directly (or indirectly through one or more
intermediaries) controls, is controlled by, or is under common control with such
Party, as the case may be. For purposes of this definition only, the terms
"controls," "controlled," and "control" mean the direct or indirect ability or
power to direct or cause the direction of the management and policies of an
entity or otherwise direct the affairs of such entity, whether through ownership
of equity, voting securities, or beneficial interest, by contract, or otherwise.
Notwithstanding the foregoing, F. Hoffmann-La Roche Ltd and its affiliates shall
not be considered Affiliates of Genentech for purposes of this Agreement.

1.4      "APPLICABLE LAWS" means all applicable statutes, ordinances,
regulations, rules, or orders of any kind whatsoever of any government authority
or court of competent jurisdiction.

1.5      "BLA" means a Biologics License Application filed with the FDA in the
United States or a corresponding application filed with a governmental authority
in any other country, together with all additions, deletions and supplements
thereto.

1.6      "CALENDAR QUARTER" means a period of three (3) consecutive calendar
months ending on either March 31, June 30, September 30, or December 31.

1.7      "CALENDAR YEAR" means the respective period of a year commencing on
January 1 and ending on December 31.

1.8      "COMMERCIALLY REASONABLE EFFORTS" or "commercially reasonable efforts"
means [**]. With regard to the creation and generation of Knock-Out Mice for a
Project, such efforts shall be deemed to have been exhausted if Lexicon has
[**].

1.9      "CONFIDENTIAL INFORMATION" means Lexicon Confidential Information,
Project Confidential Information and/or Genentech Confidential Information, as
applicable.

1.10     "CONTRACT SERVICE PROVIDER" means [**].

1.11     "DERIVATIVE PROTEIN" means [**].

1.12     "DOLLARS" means United States dollars.

1.13     "EFFECTIVE DATE" has the meaning set forth in the introductory
paragraph of the Agreement.

                                       2
<PAGE>

1.14     "ES CELL LINE" means the embryonic stem cell line used to produce a
line of Knock-Out Mice containing within their genome the corresponding mutated
gene. [**]

1.15     "FDA" means the U.S. Food and Drug Administration or corresponding
governmental authority in another country.

1.16     "FIELD" means any human or animal healthcare applications including,
without limitation, the diagnosis, prevention and treatment of diseases or
conditions.

1.17     "FIRST PASS PHENOTYPIC ANALYSIS" means the tests, observations, and
analyses listed on Exhibit A that Lexicon will use Commercially Reasonable
Efforts to perform, under Section 3.3, on the Knock-Out Mice of each Project.

1.18     "FORCE MAJEURE" means acts of God, strikes, civil disturbances,
earthquakes, fires, floods, explosions, riots, war, rebellion, sabotage, acts or
failure to act of governmental authority, or any other cause beyond the
reasonable control and without negligence of the defaulting Party, provided that
the Party claiming force majeure has exerted all reasonable efforts to promptly
remedy such force majeure.

1.19     "GAAP" shall mean United States generally accepted accounting
principles, consistently applied.

1.20     "GENENTECH CONFIDENTIAL INFORMATION" means all proprietary discoveries,
trade secrets, inventions (whether or not patentable), data, materials and
information disclosed or provided by, or on behalf of, Genentech to Lexicon or
its designees in connection with this Agreement (including, but not limited to,
Genentech Gene Patents and Know-How) other than Project Confidential
Information, whether provided prior to, or after, the Effective Date and whether
provided orally, electronically, visually, or in writing, except such
discoveries, trade secrets, inventions, data, materials or information that
Lexicon can demonstrate, through its contemporaneous written records:

         (i)      was known to Lexicon or to the public prior to Genentech's
                  disclosure hereunder;

         (ii)     became known to the public, after Genentech's disclosure
                  hereunder, other than through an unauthorized act of Lexicon
                  or of any person to whom Lexicon disclosed such information;

         (iii)    was subsequently disclosed to Lexicon by a person having
                  lawful possession of, and a legal right to disclose without
                  any restrictions, such information; or

         (iv)     was developed by Lexicon without use, and independent, of
                  Genentech Confidential Information.

1.21     "GENENTECH GENE PATENTS AND KNOW HOW" means (i) all Patents which are
owned, controlled or licensed by Genentech as of the Effective Date or which are
created

                                       3
<PAGE>

or acquired by Genentech during the course of this Agreement and which claim a
Project Gene, polypeptides encoded by such genes and/or antibodies directed
toward such polypeptides and/or methods of treatment employing such genes,
polypeptides and/or antibodies (also referred to herein as a "Genentech Gene
Patent") and (ii) all Know-How which is owned, controlled or licensed by
Genentech as of the Effective Date or which is created or acquired by Genentech
during the course of this Agreement which relates to any of the Project Genes
(also referred to herein as "Genentech Gene Know-How"); provided that Genentech
Gene Patents and Know-How shall not include Project Patents and Know-How. [**]

1.22     "GROSS SALES" means, with respect to a Licensed Product, the gross
amount invoiced by Genentech, its Affiliates and Product Licensees, as
applicable, for sales of such Licensed Product to Third Persons.

1.23     "IND" means an Investigational New Drug Application filed with the FDA
in the United States, or a corresponding application filed with a regulatory
agency in any other country, together with all additions, deletions, and
supplements thereto.

1.24     "KNOCK-OUT MOUSE" means a mouse made by Lexicon pursuant to this
Agreement in which Lexicon has interrupted, disrupted, or deleted a specific
gene or portion thereof, homologous to a Project Gene, to inactivate the
function of such gene in such mouse.

1.25     "KNOW-HOW" means all proprietary information, trade secrets, techniques
and data (including Confidential Information) of a Party that are owned,
controlled or licensed by such a Party as of the Effective Date or thereafter
during the term of this Agreement, including but not limited to, discoveries,
formulae, materials, practices, methods, knowledge, processes, experience, test
data (including pharmacological, toxicological and clinical information and test
data), analytical and quality control data, marketing, pricing, distribution,
cost and sales data or descriptions. Know-How may be made prior to the Effective
Date or after the Effective Date whether or not during the course of, in
furtherance of, and as a direct result of the activities of one or more Parties
hereunder. Know-How may be made by employees of Lexicon, solely or jointly with
a Third Person, by employees of Genentech, solely or jointly with a Third
Person, or jointly by employees of Lexicon and Genentech, alone or together with
a Third Person. Know-How does not include Patents.

1.26     "LEXICON CONFIDENTIAL INFORMATION" means all proprietary discoveries,
trade secrets, inventions (whether or not patentable), data, materials, and
information disclosed or provided by, or on behalf of, Lexicon to Genentech or
its designees in connection with this Agreement (including, but not limited to,
Lexicon Knock-Out Technology), other than Project Confidential Information,
whether provided prior to, or after, the Effective Date and whether provided
orally, electronically, visually, or in writing, except such discoveries, trade
secrets, inventions, materials, data, or information that Genentech can
demonstrate, through its contemporaneous written records:

                                       4
<PAGE>

         (i)      was known to Genentech or to the public prior to Lexicon's
                  disclosure hereunder;

         (ii)     became known to the public, after Lexicon's disclosure
                  hereunder, other than through an unauthorized act of Genentech
                  or of any person to whom Genentech disclosed such information;

         (iii)    was subsequently disclosed to Genentech by a person having
                  lawful possession of, and a legal right to disclose without
                  any restrictions, such information; or

         (iv)     was developed by Genentech without use, and independent, of
                  Lexicon Confidential Information.

1.27     "LEXICON KNOCK-OUT TECHNOLOGY" means all Patents and Know How which are
(i) owned, controlled or licensed by Lexicon as of the Effective Date or created
or acquired by Lexicon during the course of this Agreement and (ii) related to a
process or method used in the creation or generation of Knock-Out or transgenic
mice, including the process for creating Knock-Out Mice [**]. "Lexicon Knock-out
Technology" shall also include (A) the Know-How consisting of the Knock-Out Mice
[**]; the Know-How consisting of ES Cell Lines; and the Know-How consisting of
biological materials (such as nucleic acid sequences, RNA, DNA, organisms,
proteins, polypeptides, plasmids and vectors) used for the creation of such
Knock-Out Mice [**], but not the Know-How related to the biological materials
and/or sequence information provided by Genentech to Lexicon or known to
Genentech (as evidenced by written records) prior to the Effective Date; and (B)
Patents claiming such Know How. [**]

1.28     "LEXICON PRE-EXISTING PATENTS AND KNOW-HOW" means all Patents ("Lexicon
Pre-Existing Patents") and Know-How ("Lexicon Pre-Existing Know-How") which are
(i) owned, controlled or licensed by Lexicon as of the Effective Date, or
involve a Project Gene for which Lexicon [**] and (ii) related to a Pre-Existing
Project, a Project Gene, a Protein Candidate or a Licensed Product, provided in
each case that Lexicon Pre-Existing Patents and Know-How shall not include (a)
Lexicon Knock-Out Technology, (b) Genentech Gene Patents and Know How, (c)
Project Patents and Know How, (d) Restricted Rights Project Patents and
Know-How, (e) general Patents that cover inventions that could be used for
products other than products under which Genentech has a license pursuant to
Article 5, including, without limitation, Patents covering manufacturing or
process inventions, or (f) that portion of any such Patent or Know-How which is
beyond the scope of the work performed by Lexicon for Projects other than
Pre-Existing Projects.

1.29     "LICENSED PRODUCT" means a pharmaceutical preparation other than a
Small Molecule Drug that is ready for administration to the ultimate consumer
and that (i) contains as the active pharmaceutical ingredient a Protein
Candidate or (ii) that directly modulates a Protein Candidate, or the gene that
encodes a Protein Candidate.

                                       5
<PAGE>

1.30     "NDA" means a New Drug Application filed with the FDA in the United
States, or a corresponding application filed with a regulatory agency in any
other country, together with all additions, deletions, and supplements thereto.

1.31     "NET SALES" means, with respect to a Licensed Product, Gross Sales of
such Licensed Product less Sales Returns and Allowances for such Licensed
Product.

1.32     "NOTE AGREEMENT" shall have the meaning set forth in Section 7.14.

1.33     [**]

1.34     [**]

1.35     "PATENT" means:

         (i)      a U.S. and corresponding foreign patent application (including
                  provisional application, division, refiling, continuation,
                  continuation-in-part, reissue and re-examination thereof); and

         (ii)     any patent (including without limitation, any substitution,
                  extension, reissue, renewal, re-examination, patent of
                  addition, supplementary protection certificate and inventors'
                  certificate) that has issued or may issue in the future from
                  any patent application described in Subsection (i).

1.36     "PHASE III CLINICAL TRIAL" means, as to a specific Licensed Product, a
controlled and lawful study in humans of the efficacy and safety of such
Licensed Product, which is prospectively designed to demonstrate statistically
whether such Licensed Product is effective and safe for use in a particular
indication in a manner sufficient to file a BLA or NDA to obtain regulatory
approval to market and sell that Licensed Product in the United States or
another country for the indication being investigated by the study, as further
defined in Federal Regulation 21 C.F.R. 312.21.

1.37     "PIPELINE PROJECT" means a Project involving a Project Gene for which
Lexicon [**].

1.38     "PRE-EXISTING PROJECT" means a Pipeline Project involving a Project
Gene for which Lexicon [**].

1.39     "PRODUCT LICENSEE" means any Third Person which enters into an
agreement with Genentech or its Affiliates involving the grant to such Third
Person of a license to sell a Licensed Product.

1.40     "PROGENY" means mice, including successive generations thereof, that
are produced or developed by Genentech, its Affiliates or Academic Collaborators
by breeding a Knock-Out Mouse with any other mouse (including, without
limitation, any other Knock-Out Mouse).

                                       6
<PAGE>

1.41     "PROJECT" has the meaning set forth in Section 3.1(e).

1.42     "PROJECT CONFIDENTIAL INFORMATION" means all discoveries, trade
secrets, inventions (whether or not patentable), data, materials, and
information created by either Party, or created jointly by both Parties, in
connection with this Agreement (including, but not limited to, Project Patents
and Project Know How) and that are created during the course of performing the
activities contemplated by this Agreement, and whether provided orally,
electronically, visually or in writing, except such discoveries, trade secrets,
inventions, materials, data, or information that a Party can demonstrate,
through its contemporaneous written records:

         (i)      was known to such Party or to the public prior to its creation
                  hereunder;

         (ii)     became known to the public, after its creation hereunder,
                  other than through an unauthorized act of such Party or of any
                  person to whom such Party disclosed such information;

         (iii)    was subsequently disclosed to such Party by a person having
                  lawful possession of, and a legal right to disclose without
                  any restrictions, such information; or

         (iv)     was developed by such Party without use, and independent, of
                  the Project Confidential Information.

1.43     "PROJECT GENE" has the meaning set forth in Section 3.1(e); provided
that a Rejected Proposed Gene shall not be a Project Gene.

1.44     "PROJECT MATERIALS" means, with respect to a Project, [**].

1.45     "PROJECT PATENTS AND KNOW-HOW" means all Patents (also referred to
herein as "Project Patents") and Know How (also referred to herein as "Project
Know How") (i) created or acquired by either Party during the course of and in
connection with this Agreement and (ii) which are based upon data and other
information reviewed by the Steering Committee related to a Project Gene or
Protein Candidate; provided in each case that Project Patents and Know How shall
not include (A) Lexicon Knock-Out Technology, (B) Genentech Gene Patents and
Know-How, (C) Lexicon Pre-Existing Patents and Know-How, (D) Restricted Rights
Project Patents and Know-How, (E) general Patents that cover inventions that
could be used for products other than a Licensed Product, including, without
limitation, Patents covering manufacturing or process inventions, or (F) any
Patent or Know-How arising from work performed not in relation to this
Agreement. [**].

1.46     "PROPOSED GENE" means a human gene sequence proposed by Genentech under
Section 3.1(a), (i) that Genentech believes is the full-length gene sequence for
a Protein and (ii) for which a patent application owned or controlled by
Genentech has been filed

                                       7
<PAGE>

claiming such full-length human gene sequence and the Protein believed to be
produced by such gene.

1.47     "PROTEIN" means [**].

1.48     "PROTEIN CANDIDATE" has the meaning set forth in Section 3.5, and shall
include Derivative Proteins.

1.49     "REGULATORY APPROVAL" means any and all approvals (including pricing
and reimbursement approvals), licenses, registrations or authorizations of any
kind of the FDA (or foreign equivalent) necessary for the marketing and sale of
a Licensed Product in any country or other regulatory jurisdiction. "Regulatory
Approval" shall include, without limitation, approval granted with respect to
any BLA, NDA or other foreign equivalent.

1.50     "REJECTED PROJECT GENE" means a Project Gene whose Protein is not
designated as a Protein Candidate under Section 3.5(c).

1.51     "REJECTED PROPOSED GENE" means a Proposed Gene (i) that is rejected
under Section 3.1(b), (c) or (d), (ii) that is removed from the collaboration
under Section 3.1(f), (iii) that is deemed a Rejected Gene pursuant to Section
3.2(a), (iv) for which the Steering Committee does not vote, under Section
3.2(b), to proceed or (v) that is designated a Rejected Proposed Gene under
Section 3.3(a).

1.52     "RESTRICTED RIGHTS PROJECT" means a Project involving a Project Gene
[**].

1.53     "RESTRICTED RIGHTS PROJECT PATENTS AND KNOW-HOW" means all Patents
(also referred to herein as "Restricted Rights Project Patents") and Know How
(also referred to herein as "Restricted Rights Project Know How") which are (i)
owned, controlled or licensed by Lexicon as of the Effective Date or created or
acquired by Lexicon during the course of and in connection with this Agreement
and (ii) which are based upon data and other information reviewed by the
Steering Committee related to a Project Gene or Protein Candidate in connection
with a Restricted Rights Project; provided in each case that Restricted Rights
Project Patents and Know How shall not include (A) Lexicon Knock-Out Technology,
(B) Genentech Gene Patents and Know-How, (C) general Patents that cover
inventions that could be used for products other than a Licensed Product,
including, without limitation, Patents covering manufacturing or process
inventions, or (D) any Patent claims or Know-How arising from work performed not
in relation to this Agreement.

1.54     "SALES RETURNS AND ALLOWANCES" means, with respect to a Licensed
Product, the sum of (a) and (b), where: (a) is a provision, [**] for sales of
such Licensed Product under GAAP as provided hereinabove for (i) cash and
quantity discounts or rebates on such Licensed Product (other than price
discounts granted at the time of invoicing and which are included in the
determination of Gross Sales), (ii) credits or allowances given

                                       8
<PAGE>

or made for rejection or return of previously sold Licensed Product or for
retroactive price reductions (including Medicare and similar types of rebates
and chargebacks), (iii) sales taxes, duties or other governmental charges levied
on or measured by the billing amount for such Licensed Product, as adjusted for
rebates and refunds, (iv) charges for freight and insurance directly related to
the distribution of such Licensed Product, to the extent included in the invoice
to the customer, and (v) credits for allowances given or made for wastage
replacement, indigent patient and any other sales programs agreed to by the
Parties for such Licensed Product; and (b) is a periodic adjustment of the
provision determined in (a) to reflect amounts actually incurred by Genentech,
its Affiliates and Product Licensees, as applicable, for items (i), (ii), (iii),
(iv) and (v) in clause (a).

1.55     "SMALL MOLECULE DRUG" means any pharmaceutical compound for the
treatment of any human or animal disease or condition, the active ingredient of
which is a synthetically prepared, or a naturally derived chemical compound
[**]; provided, however, that "Small Molecule Drug" specifically excludes any
compound which consists of or incorporates as an active ingredient a Protein, a
Derivative Protein, a nucleic acid oligomer, or an antibody or any fragment
thereof.

1.56     "STEERING COMMITTEE" means the committee established and described in
Article 2.

1.57     "THIRD PERSON" means any person or entity other than Lexicon, Genentech
or any Affiliate of Lexicon or Genentech.

                                   ARTICLE 2

                             GOVERNANCE OF RESEARCH

2.1      CREATION OF A STEERING COMMITTEE. Within [**] of the Effective Date,
the Parties shall establish a Steering Committee to oversee the Parties'
activities under Article 3 of this Agreement. The Steering Committee shall be
comprised of [**], but each Party may change its Steering Committee members at
any time by giving prior written notice to the other Party.

2.2      STEERING COMMITTEE RESPONSIBILITIES. The Steering Committee shall have
the following responsibilities, as well as any additional responsibilities
expressly set forth in this Agreement:

         (i)      receiving and reviewing reports and data received from a Party
                  from time to time as set forth herein, including without
                  limitation the submission of Proposed Genes, data related to
                  the murine homology of Proposed Genes, results of the First
                  Pass Phenotypic Analysis and [**];

                                       9
<PAGE>

         (ii)     receiving notices from the Parties as set forth herein,
                  including without limitation notices of delays or stalled
                  research pursuant to Section 3.3(a);

         (iii)    the designation of Project Genes and Protein Candidates under
                  Sections 3.1 and 3.5, respectively;

         (iv)     coordinating the activities of the Parties hereunder;

         (v)      developing and implementing a publicity strategy and policy
                  for the review and approval of press releases and publications
                  in accordance with Section 9.4;

         (vi)     settling disputes or disagreements that arise between the
                  parties as set forth in Article 13; and

         (vii)    performing such other functions as appropriate to further the
                  purposes of this Agreement, as determined by the Parties.

2.3      STEERING COMMITTEE DECISIONS. All Steering Committee decisions will be
made by [**] of all the Steering Committee's members, except as expressly stated
otherwise in this Agreement. Each Steering Committee member will have one vote,
and a Steering Committee member need not be present in order to vote; the
Steering Committee member(s) of a Party that are present for, or participating
in, a decision shall have the authority to vote on behalf of the Steering
Committee member(s) of such Party who are not present for, or participating in,
such decision.

2.4      STEERING COMMITTEE MEETINGS. Within [**] after the Effective Date, the
Steering Committee will hold an in-person organizational meeting to establish
the Committee's operating procedures. After such initial meeting, the Steering
Committee will meet at such other times as are unanimously agreed to by the
Steering Committee members, but no less than once each Calendar Quarter. Such
meetings may be in-person, via videoconference, or via teleconference, provided
that at least one meeting per Calendar Year shall be held in person. The
location of in-person Steering Committee meetings will alternate between South
San Francisco, California and The Woodlands, Texas. Each Party will bear the
expense of its respective Committee members' participation in Steering Committee
meetings. Minutes will be kept of all Steering Committee meetings.
Responsibility for keeping minutes will alternate between the Parties, beginning
with Genentech. Meeting minutes will be sent to each member of the Steering
Committee for review as soon as practicable after a meeting.

2.5      DISSOLUTION OF THE STEERING COMMITTEE. Upon the expiration of [**]
after all of the activities of Lexicon that have been approved by the Steering
Committee have been completed, the Steering Committee will have no further
responsibilities or authority under this Agreement and will be considered
dissolved by the Parties.

                                       10
<PAGE>

                                   ARTICLE 3

                             KNOCK-OUT MICE PROJECTS

3.1      GENENTECH SUBMISSION OF PROPOSED GENES.

         (a)      Initial Submission of Proposed Genes. Genentech, within [**],
will provide the Steering Committee with a written list of [**] Proposed Genes,
together with the date of Genentech's initial Patent filing with regard to each
such Proposed Gene.

         (b)      Delivery of Notice by Lexicon. Within [**] of the delivery by
Genentech of the list of Proposed Genes (or, with respect to replacement
Proposed Genes proposed by Genentech under Section 3.1(b), (c) or (f) or Section
3.2(a), within [**] of the delivery by Genentech of notice to the Steering
Committee of such replacement), Lexicon will notify the Steering Committee in
writing as to whether or not: (i) to Lexicon's Actual Knowledge, Lexicon's
conducting the activities contemplated by this Agreement with regard to such
Proposed Gene would infringe patents or other intellectual property rights under
which Lexicon is not licensed through this Agreement or otherwise; or (ii) [**].
If so, Lexicon shall additionally notify Genentech which Proposed Gene(s) are
the subject of such patents or intellectual property rights [**].

         (c)      Rejection of Proposed Genes by Lexicon; Proposal of
Replacement Proposed Genes by Genentech. Lexicon shall not be obligated to
develop, produce or deliver a Knock-Out Mouse related to a Proposed Gene where
Lexicon reasonably believes, with the advice of its counsel and the Steering
Committee, that such action would infringe the intellectual property rights of a
Third Person. Such Proposed Gene shall become a Rejected Proposed Gene and the
Steering Committee shall adopt an acceptable solution including, but not limited
to, the identification by Genentech of an alternative Proposed Gene. Lexicon
shall further have the sole right, but not the obligation, to reject any
Proposed Gene for which Lexicon reasonably believes, with the advice of its
counsel and the Steering Committee, that Genentech was not the first to file a
patent application, but only in cases where the Steering Committee reasonably
believes [**], by notice to the Steering Committee within the period specified
in Section 3.1(b), in which case Lexicon shall have the right to designate such
Proposed Gene as a Rejected Proposed Gene. In such event, Genentech shall have
the sole right, but not the obligation, to propose another Proposed Gene in the
place of such Rejected Proposed Gene for the Steering Committee's review and
approval, by notice to the Steering Committee within [**] of Lexicon's notice.

         (d)      Removal of Proposed Genes by Genentech. Within [**] of
Genentech's receipt of Lexicon's notice under Section 3.1(b), Genentech shall
inform Lexicon which, if any, of the Proposed Genes referenced in Lexicon's
notice (and not automatically deemed a Rejected Proposed Gene under Section
3.1(b)) Genentech elects to remove from the collaboration and, thereafter, all
such removed Proposed Genes shall constitute Rejected Proposed Genes. Genentech
shall have no right to propose a replacement

                                       11
<PAGE>

Proposed Gene for any Proposed Gene that it elects to remove from the
collaboration under this Section 3.1(d).

         (e)      Designation of Project Genes. Following Genentech's notice
pursuant to Section 3.1(d), the remaining Proposed Genes shall constitute
"Project Genes" (and the work performed hereunder with regard to such Project
Gene shall be deemed a corresponding "Project"), and be deemed to be submitted
to the collaboration for Lexicon to begin determining, as fully described in
Section 3.2(a), the murine gene that is homologous to each such Project Gene.
Except as set forth in this Section 3.1, Lexicon, acting through the Steering
Committee or otherwise, shall not have the ability to prevent the submission of
a Project Gene to the collaboration for Lexicon to conduct its activities under
Section 3.2(a) regarding such Project Gene. [**] following each designation of
Proposed Genes as Project Genes hereunder, Lexicon shall provide Genentech with
a list of the Projects, if any, that are Pipeline Projects and/or Pre-Existing
Projects, and the stage of each such Pipeline Project or Pre-Existing Project,
as the case may be.

         (f)      Removal and Replacement of Project Genes by Genentech. At any
time prior to [**], Genentech shall have the sole right, but not the obligation,
to remove such Project Gene and/or propose another Proposed Gene for the
Steering Committee's review and approval, by delivering notice thereof to the
Steering Committee; provided, however, that Genentech shall not be permitted to
remove more than [**] Project Genes pursuant to this Section 3.1(f); and
provided, further, that Genentech shall reimburse Lexicon for all reasonable
costs and expenses, including allocable overhead, incurred by Lexicon under this
Agreement prior to the date of Genentech's notice under this subsection 3.1(f)
in respect of the Project Gene being removed (for purposes of which, "allocable
overhead" shall mean [**]. Any such removed Project Gene shall be considered a
Rejected Proposed Gene for purposes of this Agreement.

3.2      LEXICON IDENTIFICATION OF HOMOLOGOUS MURINE GENE; STEERING COMMITTEE
REVIEW AND APPROVAL OF PROJECTS.

         (a)      Lexicon Efforts to Determine Homologous Murine Gene. For each
Project Gene submitted to the collaboration under Section 3.1(e), Lexicon will
use Commercially Reasonable Efforts to identify the homologous murine gene as
soon as practicable, and in any event within [**], after such Project Gene was
submitted to it, and will provide Genentech with [**] reports regarding its
efforts. To identify the homologous murine gene, Lexicon will use its standard
resources and, if applicable, [**]. Upon identifying what it believes to be the
homologous murine gene(s) for a Project Gene, Lexicon will provide the Steering
Committee with written evidence of such gene's (or, if applicable, genes')
homology. If Lexicon is unable to identify a homologous murine gene for a
Project Gene, Lexicon will report all of the results related to such Project
Gene obtained during the course of its search to the Steering Committee as well,
and such Project Gene shall thereafter be deemed a Rejected Proposed Gene under
this Agreement. Genentech shall have the sole right, but not the obligation, to
propose another Proposed Gene in the place of such Rejected Proposed Gene for
the Steering

                                       12
<PAGE>

Committee's review and approval, by notice to the Steering Committee within [**]
of Lexicon's report of its failure to identify a homologous murine gene.

         (b)      Steering Committee Review and Approval of Projects. The
Steering Committee will review the information provided by Lexicon under
Sections 3.2(a) with respect to a Project Gene and will confirm that Lexicon has
identified the homologous murine gene, and therefore to proceed with such
Project Gene under Section 3.3 hereof. If the Steering Committee determines that
Lexicon has not identified a homologous murine gene for a Project Gene, such
Project Gene shall thereafter be deemed a Rejected Proposed Gene under this
Agreement.

         (c)      Project Development Plan. Concurrently with its delivery of
the information contemplated by Section 3.2(a), Lexicon will provide the
Steering Committee (i) for Pipeline Projects, information (as set forth in
Exhibit A) [**], and (ii) for Projects other than Pipeline Projects, [**].

3.3      LEXICON'S CREATION AND TESTING OF KNOCK-OUT MICE AND ES CELL LINES.

         (a)      Activities Performed by Lexicon. Once the Steering Committee
approves proceeding with a Project Gene under Section 3.2(b), Lexicon, in
accordance with the recommendation from Genentech as to desired priority, will,
at Lexicon's sole expense, use Commercially Reasonable Efforts to perform the
following activities on such Project: (i) create and generate, [**] Knock-Out
Mice using the Project Gene's homologous murine gene; (ii) conduct a First Pass
Phenotypic Analysis of such Knock-Out Mice; and (iii) [**]. Lexicon agrees to
use Commercially Reasonable Efforts to perform and complete such activities on a
Project within [**] after the approval of a Project Gene by the Steering
Committee under Section 3.2(b). If a Project is delayed or stalled due to
technological or scientific difficulties, Lexicon will so notify Genentech and
the Steering Committee. The Parties will consult with each other to determine
whether such difficulties can be resolved or remedied. The Steering Committee
shall decide, based on input from Lexicon, whether such Project's problems can
be remedied within the scope of commercially reasonable efforts for such Project
or whether to terminate such Project and designate such Project Gene a Rejected
Proposed Gene. Genentech shall have the right to terminate this Agreement under
certain circumstances, as set forth in Section 10.2.

         (b)      Reports; Consultation and Site Visits. Within [**] after the
end of [**], Lexicon will provide each Steering Committee member with a written
report describing the status of its work on each Project, and, [**], Lexicon
will provide a Genentech Steering Committee member with the same [**] report
generated for Lexicon's internal purposes. Upon reasonable advance written
notice from the Steering Committee or Genentech, Lexicon will make persons
working on its behalf on a Project available during normal business hours for a
reasonable number of consultations with the Steering Committee or Genentech
regarding such Project. Such consultations will either be in-person at such
person's place of employment or via videoconference or teleconference. Upon
reasonable notice, Genentech representatives may visit during normal business

                                       13
<PAGE>

hours the facilities where Lexicon is performing services on Projects. All
Genentech representatives will be advised of, and be bound by, Genentech's
confidentiality obligations in Article 9 and will follow such security and
facility access procedures as are reasonably designated by Lexicon. Lexicon may
require that at all times the Genentech representatives be accompanied by a
Lexicon representative.

3.4      SAFEGUARDS TO PROTECT CONFIDENTIALITY OF PROJECTS.

         (a)      Lexicon hereby agrees that each person working on a Project on
its behalf (whether as an employee, subcontractor, or otherwise) has or will,
prior to commencing work on a Project, have executed an instrument:

         (i)      assigning to Lexicon all of his, her, or its rights, title,
                  and interest in inventions or intellectual property arising
                  during the course, and as a result, of his, her, or its
                  association with Lexicon; and

         (ii)     agreeing to abide by confidentiality and non-use restrictions
                  regarding Confidential Information and the existence and terms
                  of this Agreement no less stringent than Lexicon's
                  confidentiality and non-use obligations under Article 9.

Lexicon also agrees to maintain appropriate security measures no less stringent
than measures that are customary in the industry.

         (b)      Genentech hereby agrees that each person working on a Project
on its behalf (whether as an employee, subcontractor, or otherwise) has or will,
prior to commencing work on a Project, have executed an instrument:

         (i)      assigning to Genentech all of his, her, or its rights, title,
                  and interest in inventions or intellectual property arising
                  during the course, and as a result, of his, her, or its
                  association with Genentech; and

         (ii)     agreeing to abide by confidentiality and non-use restrictions
                  regarding Confidential Information and the existence and terms
                  of this Agreement no less stringent than Genentech's
                  confidentiality and non-use obligations under Article 9.

Genentech also agrees to maintain appropriate security measures no less
stringent than measures that are customary in the industry.

3.5      REVIEW OF FIRST PASS PHENOTYPIC ANALYSIS; DESIGNATION OF PROTEIN
CANDIDATES.

         (a)      Review of First Pass Phenotypic Analysis. Once Lexicon
completes the First Pass Phenotypic Analysis on each of the Project Genes, it
will submit to Genentech, through the Steering Committee, the data from such
Projects. After reviewing this information from a Project, the Steering
Committee will determine by [**], within [**]

                                       14
<PAGE>

following the submission of the First Pass Phenotypic Analysis on such Project,
whether Lexicon has [**] for such Project Gene.

         (b)      Designation of Protein Candidates. The Protein produced by
each such Project Gene for which the Steering Committee [**] votes that Lexicon
has [**] shall be designated as a "Protein Candidate." In the event that the
Steering Committee designates [**] Proteins produced by Project Genes as Protein
Candidates, then Lexicon shall have the right to designate an additional number
of Proteins produced by Project Genes as Protein Candidates, so that there are a
total of [**]; provided that Lexicon shall make such designations no later than
[**] following the submission to the Steering Committee of the last First Pass
Phenotypic Analysis to be submitted under this Agreement. Genentech shall have
the rights and obligations set forth in Article 4 and 6 with regard to such
Protein Candidates.

         (c)      Rejected Project Genes. Any Project Gene the Protein product
of which has not been designated as a Protein Candidate pursuant to subsection
(b) above, shall be deemed a Rejected Project Gene for purposes of this
Agreement. Genentech shall have the rights and obligations set forth in Articles
5 and 6 with regard to such Rejected Project Genes.

3.6      [**]

                                   ARTICLE 4

                                LICENSED PRODUCTS

4.1      GENENTECH'S EXCLUSIVE RIGHT TO DEVELOP AND COMMERCIALIZE LICENSED
PRODUCTS. Genentech shall have the sole right and responsibility for, and
control over, developing and commercializing Licensed Products; provided,
however, that with regard to Restricted Rights Projects, nothing in this Section
will be deemed to grant Genentech rights beyond the scope of the licenses
granted to Genentech (or limit the rights of Lexicon, its collaborators or
licensees) with regard to such Restricted Rights Project.

4.2      TRANSFER TO GENENTECH OF LEXICON PRE-EXISTING KNOW-HOW AND PROJECT
KNOW-HOW RELATED TO PROTEIN Candidates. Within [**] after designation of a
Protein Candidate pursuant to Section 3.5, Lexicon will provide Genentech, to
the extent not previously provided, with a copy of all Lexicon Pre-Existing
Know-How, Project Know-How and Restricted Rights Know-How related to such
Protein Candidate in Lexicon's possession or control.

4.3      GENENTECH RESPONSIBLE FOR DEVELOPMENT COSTS. Genentech shall bear
all costs and expenses associated with, and shall have sole control over,
developing and commercializing Licensed Products.

                                       15
<PAGE>

4.4      PRODUCT LICENSEES. Genentech agrees to notify Lexicon promptly of any
(sub)license that it enters into with a Product Licensee, and Genentech further
covenants that any such (sub)licence shall contain terms and conditions
consistent with Genentech's obligations under this Agreement.

                                   ARTICLE 5

                             GRANT OF LICENSE RIGHTS

5.1      EXCLUSIVE LICENSE UNDER LEXICON PRE-EXISTING PATENTS AND KNOW-HOW AND
RESTRICTED RIGHTS PROJECT PATENTS AND KNOW-HOW FOR THE RESEARCH, DEVELOPMENT AND
COMMERCIALIZATION OF LICENSED PRODUCTS. Subject to the terms of this Agreement,
Lexicon hereby grants to Genentech (i) an exclusive (even as to Lexicon),
world-wide right and license under the Lexicon Pre-Existing Patents and Know-How
and (ii), to the extent specified in the Parties' designation(s) of Restricted
Rights Project(s), an exclusive (even as to Lexicon) or non-exclusive,
world-wide right and license under the Restricted Rights Project Patents and
Know-How, in each case to research, develop, make (or have made), use, sell,
offer for sale, and import Licensed Products in the Field. Such license includes
the right to grant sublicenses of all or part of such rights without Lexicon's
consent; provided that the grant of any such sublicense shall be consistent with
the terms and conditions of this Agreement and that no such sublicense to a
Product Licensee shall relieve Genentech of primary responsibility for all
payments and royalties due to Lexicon under Article 7 with respect to Licensed
Product(s) licensed to such Product Licensee.

5.2      LICENSE UNDER LEXICON PRE-EXISTING PATENTS AND KNOW-HOW AND RESTRICTED
RIGHTS PROJECT PATENTS AND KNOW-HOW FOR THE RESEARCH, DEVELOPMENT AND
COMMERCIALIZATION OF PRODUCTS OTHER THAN LICENSED PRODUCTS IN THE FIELD. Subject
to the terms of this Agreement, Lexicon hereby grants to Genentech a
royalty-free, worldwide right and license under the Lexicon Pre-Existing Patents
and Know-How and, to the extent specified in the Parties' designation(s) of
Restricted Rights Project(s), the Restricted Rights Project Patents and Know-How
to research, develop, make (or have made), use, offer for sale, sell, and import
products (including, but not limited to Small Molecule Drugs) other than
Licensed Products for use in the Field. Such right and license (i) shall be
exclusive (even as to Lexicon) under the Lexicon Pre-Existing Patents and
Know-How with respect to products in the Field other than Small Molecule Drugs,
(ii) shall be exclusive (even as to Lexicon) or non-exclusive under the
Restricted Rights Project Patents and Know-How, to the extent specified in the
Parties' designation(s) of Restricted Rights Project(s), with respect to
products in the Field other than Small Molecule Drugs and (iii) shall be
non-exclusive with regard to Small Molecule Drugs. Lexicon hereby grants
Genentech the right to grant sublicenses under the right and license granted by
Lexicon pursuant to this Section 5.2, on a Project Gene-by-Project Gene basis;
provided, however, that with respect to a Small Molecule Drug related to a
Project Gene, without the prior written consent of Lexicon, no such sublicense
under the Lexicon Pre-Existing Patents or Know-How or Restricted Rights Project
Patents or

                                       16
<PAGE>

Know-How may be granted to any Third Person in the absence of (x) a
corresponding license or sublicense of right to a given Small Molecule Drug that
directly modulates the Protein produced by such Project Gene or Derivative
Protein thereof and discovered, researched and under bona fide commercial
development (at least through the stage of the demonstration of preclinical
efficacy in animal studies) by Genentech and (y) the license or sublicense of
Patent rights pertaining thereto owned by, licensed to or controlled by
Genentech.

5.3      LICENSE UNDER PROJECT PATENTS AND KNOW-HOW FOR THE RESEARCH,
DEVELOPMENT AND COMMERCIALIZATION OF SMALL MOLECULE DRUGS IN THE FIELD. Subject
to the terms of this Agreement, Genentech hereby grants to Lexicon a
royalty-free, non-exclusive, worldwide right and license under the Project
Patents and Know-How to research, develop, make (or have made), use, offer for
sale, sell, and import Small Molecule Drugs for use in the Field. Such right and
license shall be exclusive; provided that Genentech retains rights under the
Genentech Project Patents and Know How (i) to research, develop, make (or have
made), use, offer for sale, sell, and import Small Molecule Drugs for use in the
Field and (ii) to grant licenses to Third Persons under the Genentech Project
Patents and Know How to research, develop, make (or have made), use, offer for
sale, sell, and import Small Molecule Drugs for use in the Field in connection
with (A) a corresponding license or sublicense of right to a given Small
Molecule Drug that directly modulates the Protein produced by a Project Gene or
Derivative Protein thereof and discovered, researched and under bona fide
commercial development (at least through the stage of the demonstration of
preclinical efficacy in animal studies) by Genentech and (B) the license or
sublicense of Patent rights pertaining thereto owned by, licensed to or
controlled by Genentech. Genentech hereby grants Lexicon the right to grant
sublicenses under the right and license granted by Genentech pursuant to this
Section 5.3, subject to the restrictions, if any, on Project Materials set forth
in Section 5.5.

5.4      NON-EXCLUSIVE RESEARCH LICENSE GRANT UNDER LEXICON KNOCK-OUT TECHNOLOGY
TO KNOCK-OUT MICE AND PROGENY. Subject to the terms of this Agreement and the
restrictions, if any, on Project Materials set forth in Section 5.5, Lexicon
hereby grants to Genentech a worldwide, non-exclusive right and license under
the Lexicon Knock-Out Technology to use, breed, cross-breed and have bred and
cross-bred Knock-Out Mice and Progeny, at the internal research facilities of
Genentech and its Academic Collaborators or Contract Service Providers, for
research directed toward the discovery, identification, selection,
characterization, development or commercialization of products for use in the
Field. Except as provided in Section 5.10, Genentech agrees to use Knock-Out
Mice and Progeny solely for its own internal research purposes in accordance
with the terms and conditions of this Agreement, and not to use any Knock-Out
Mice or Progeny for any purposes for any Third Person, or to transfer, license
the use of or make available to any Third Person any Knock-Out Mice or Progeny.

5.5      [**]

                                     17
<PAGE>

5.6      [**]

5.7      RESERVATION OF RIGHTS. Notwithstanding the non-exclusive rights and
licenses granted to Genentech under Sections 5.2 and 5.4, but subject to the
exclusive rights and licenses granted to Genentech under Sections 5.1 and 5.2
[**]:

         (a)      Lexicon reserves the right under the Lexicon Knock-Out
Technology to make and use, and to permit others to use, (i) Project Materials
and (ii) other transgenic and Knock-Out Mice (including, without limitation,
transgenic and Knock-Out Mice with a mutation in the same gene as a Knock-Out
Mouse or Overexpression Mouse) and phenotypic data with respect thereto,
including the right to grant licenses with respect to any applicable
intellectual property rights for such purpose.

         (b)      Lexicon reserves the right under the Lexicon Pre-Existing
Patents and Know-How and Restricted Rights Project Patents and Know-How (i) to
discover, research, develop, make, have made, import, use, have used, offer for
sale, sell and have sold Small Molecule Drugs and (ii) to grant licenses to
Third Persons to discover, research, develop, make, have made, import, use, have
used, offer for sale, sell and have sold Small Molecule Drugs.

5.8      LIMITED LICENSE TO GENENTECH GENE KNOW-HOW. For each Project Gene,
Genentech hereby grants Lexicon a non-exclusive, royalty-free license under the
Genentech Gene Patents and Know-How related to such Project Gene solely for
Lexicon to perform the following activities under this Agreement:

         (i)      identify, under Section 3.2(a), the homologous murine gene;

         (ii)     create, under Section 3.3, Knock-Out Mice with such homologous
                  murine gene;

         (iii)    test, under Section 3.3 and, if applicable, Section 3.6, such
                  Knock-Out Mice;

         (iv)     conduct a First Pass Phenotypic Analysis on such Project Gene
                  under Section 3.3(a); and

         (v)      [**]

Lexicon has no right to sublicense under this license grant, which shall be
considered personal to Lexicon. Such license will terminate with regard to a
Project Gene upon the earliest to occur of such Project Gene becoming a Rejected
Proposed Gene, a Rejected Project Gene, a Protein Candidate, or the completion
of Lexicon's activities under this article 5.8.

5.9      NO GRANT OF OTHER TECHNOLOGY OR PATENT RIGHTS. Except as otherwise
expressly provided in this Agreement, under no circumstances shall a party
hereto, as a

                                       18
<PAGE>

result of this Agreement, obtain any ownership interest in or other right to any
technology, know-how, patents, patent applications, gene or genomic sequence
data or information, products, or biological materials of the other party,
including items owned, controlled or developed by, or licensed to, the other
party, or transferred by the other party to said party, at any time pursuant to
this Agreement.

5.10     TRANSFERS TO ACADEMIC COLLABORATOR OR CONTRACT SERVICE PROVIDERS.
Genentech shall have the right to transfer a Knock-Out Mouse or Progeny made
pursuant to this Agreement to an Academic Collaborator or Contract Service
Providers, provided that such Academic Collaborator or Contract Service
Providers shall have entered into a material transfer agreement with Genentech
containing terms relating to the transfer of such material that expressly (i)
prohibit the use of such Knock-Out Mice or Progeny thereof for any purpose other
than such Academic Collaborator's collaborative research with, or Contract
Service Provider's service for, Genentech in the Field and (ii) prohibit the
transfer of such Knock-Out Mice thereof by such Academic Collaborator or
Contract Service Provider to any Third Party. Within [**] of entering into any
such material transfer agreement, Genentech shall provide Lexicon with a copy
thereof.

5.11     LICENSE TO LEXICON ISOGENIC TECHNOLOGY. On the Effective Date, Lexicon
and Genentech shall enter into the Sublicense Agreement attached hereto as
Exhibit B.

                                   ARTICLE 6

                   REQUEST FOR AND DELIVERY OF KNOCK-OUT MICE

6.1      REQUESTS FOR PROJECT MATERIALS BY GENENTECH. During the period of [**]
following the submission to the Steering Committee of the data from the First
Pass Phenotypic Analysis for a Project Gene in accordance with Section 3.5(a),
Genentech shall have the option, subject to the terms and conditions of this
Agreement, to have Lexicon deliver to Genentech [**] the Knock-Out Mice for such
Project Gene, by delivering written notice of such request to Lexicon. During
the period beginning on the date of the submission to the Steering Committee of
the data from the First Pass Phenotypic Analysis for a Project Gene in
accordance with Section 3.5(a) and ending on [**], Genentech shall have the
option, subject to the terms and conditions of this Agreement, to have Lexicon
deliver to Genentech Project Materials and Project Know-How (to the extent not
already provided), including without limitation [**], for such Project Gene.
Genentech may also have, during such period, [**]. Lexicon shall have no further
obligation to deliver Project Materials to Genentech following such period;
provided that, following such period, Genentech may [**].

6.2      MAINTENANCE OF BACK-UP COLONIES. For a period of at least [**] after
the delivery of a particular Knock-Out Mouse requested by Genentech under
Section 6.1, Lexicon shall retain a small back-up colony of [**] such Knock-Out
Mice [**], for the purpose of replacing mice shipped to Genentech under this
Article 6 which die or are otherwise unable to breed during or within [**] after
shipment to Genentech hereunder.

                                       19
<PAGE>

Thereafter, until the expiration of six (6) months following the submission to
the Steering Committee of the data from the last First Pass Phenotypic Analysis
to be submitted under this Agreement, Lexicon shall [**], if requested by
Genentech. In the event Genentech requests that Lexicon maintain any such colony
for a period of more than [**], Genentech shall pay Lexicon a storage and
maintenance charge of [**] for such requested line of Knock-Out Mice for each
[**] that Lexicon maintains such colony at Genentech's request.

6.3      DELIVERY TERMS AND CONDITIONS. Lexicon shall be responsible for making
shipping arrangements for all Knock-Out Mice to be shipped to Genentech from
Lexicon; provided that Genentech shall be responsible for (i) paying all
shipment and delivery charges in connection therewith and (ii) obtaining, if
desired, and paying for any insurance for Knock-Out Mice shipped to Genentech
from Lexicon. Genentech shall also be responsible for complying with all
customs, regulations, veterinary handling procedures and protocols, and
obtaining any and all permits, forms or permissions that may be required for
Genentech to accept shipment of Knock-Out Mice from Lexicon. Lexicon shall ship
to Genentech [**] Knock-Out Mice, [**], promptly following its receipt of
written notice that Genentech is prepared to accept shipment. Risk of loss with
respect to any Knock-Out Mice to be transferred under this Section 6.3 shall
pass to Genentech upon delivery thereof to the shipping company designated as
specified herein. If Genentech fails to complete the necessary arrangements to
accept shipment and provide such notice within [**] after delivery of its
request for such Knock-Out Mice pursuant to Section 6.1, Genentech shall pay
Lexicon a storage and maintenance charge of [**] for such requested line of
Knock-Out Mice for each week thereafter until Lexicon receives such notice.

                                   ARTICLE 7

                                    PAYMENTS

7.1      UP-FRONT FEE. As partial consideration for the work to be performed by
Lexicon under this Agreement, Genentech shall pay Lexicon a fee of [**], which
fee shall be payable within ten (10) days of the Effective Date.

7.2      PERFORMANCE PAYMENTS. Within [**] (of achieving each of the research
milestones listed below, Genentech shall pay to Lexicon the following amounts:

         [**]

7.3      OPTION FEE. In the event Genentech exercises its option under [**] with
respect to a [**], Genentech shall pay Lexicon [**] concurrently with its
delivery of its notice exercising such option.

                                       20
<PAGE>

7.4      [**] FUNDING. To the extent the Steering Committee elects to have
Lexicon produce [**], Genentech shall pay Lexicon funding of [**] for each
additional [**], which funding shall be payable within [**] of such election.

7.5      FEE FOR [**] KNOCK-OUT MICE. In the event Genentech requests, more than
[**] following the submission to the Steering Committee of the data from the
First Pass Phenotypic Analysis for a Project Gene in accordance with Section
3.5(a), that Lexicon [**], Genentech shall pay Lexicon a fee of [**]
concurrently with its delivery of such request.

7.6      FEE FOR DELIVERY OF MATERIALS [**]. In the event Genentech requests,
after the later of (i) the date of submission to the Steering Committee of the
data from the last First Pass Phenotypic Analysis to be submitted under this
Agreement and (ii) [**] following the date of submission to the Steering
Committee of the data from the First Pass Phenotypic Analysis for a Project
Gene, that [**], Genentech shall pay Lexicon a fee of [**] within [**] of
Lexicon's notice that [**].

7.7      MILESTONE PAYMENTS. With respect to the first Licensed Product relating
to a specified Protein Candidate to achieve the following development milestones
listed below, within [**] of achieving each such development milestones,
Genentech shall pay Lexicon the following amounts:

         [**]

For purposes of clarification, with respect to each Project Gene whose Protein
is designated as a Protein Candidate, Genentech shall only be required to pay
Lexicon for each of the above development milestones once upon the first
occurrence of the respective event. All milestone payments hereunder are to be
made by wire transfer of immediately available funds. Such milestone payments
are non-refundable and non-creditable against any other payments hereunder.
Genentech shall give Lexicon written notice of the achievement of any milestone
event no later than [**] after such achievement.

7.8      ROYALTIES ON LICENSED PRODUCTS. As consideration for its exclusive
rights with respect to Licensed Products and the other rights provided and
activities performed by Lexicon hereunder, Genentech agrees to pay Lexicon a
royalty of [**] of Net Sales of each Licensed Product by Genentech, its
Affiliates and Product Licensees, on a country-by-country basis, during the
period commencing with the first sale for use or consumption by the general
public of a Product in a country after Regulatory Approval in such country and
ending on the date that is [**] from the date of such first commercial sale of
such Licensed Product in such country; provided that, in the event the worldwide
Net Sales of such Licensed Product for which a royalty is payable to Lexicon
hereunder exceeds [**] in any Calendar Year, Genentech shall pay Lexicon a
royalty of [**] on that portion of such Net Sales of such Licensed Product that
exceeds [**] in such Calendar Year. The royalty payable hereunder shall be
payable only once with respect to the same unit of Licensed Product.

                                       21
<PAGE>

7.9      PAYMENT OF ROYALTY; REPORTING; EXCHANGE RATES. Within [**] after the
end of each [**], Genentech will pay (and/or cause its Affiliates and/or Product
Licensees to pay) the royalty owed under this Agreement, if any, on applicable
Net Sales invoiced during such just-ended [**]. Such payment will be accompanied
by the report showing: (i) the Gross Sales and Net Sales of Products sold during
the reporting period and the calculation of Net Sales from such Gross Sales;
(ii) the royalties payable in Dollars which shall have accrued hereunder in
respect of such Net Sales; (iii) withholding taxes, if any, required by law to
be deducted in respect of such royalties; (iv) the dates of the first commercial
sales of Licensed Products in any country during the reporting period, if
applicable; and (v) the exchange rates used in determining the amount of Dollars
payable hereunder. Royalties payable on sales in countries other than the United
States shall be calculated in accordance with the standard exchange rate
conversion practices used by Genentech, its Affiliates or the Product Licensee,
as applicable, for financial accounting purposes. If no royalty or payment is
due for any royalty period hereunder, Genentech shall so report. Genentech shall
keep, and shall require its Affiliates and Product Licensees to keep (all in
accordance with GAAP), complete and accurate records in sufficient detail to
properly reflect all gross sales and Net Sales and to enable the royalties
payable hereunder to be determined.

7.10     U.S. CURRENCY; WIRE TRANSFERS. All payments, including any interest
pursuant to Section 7.12, payable by Genentech, its Affiliates and Product
Licensees to Lexicon under this Agreement will be paid in Dollars and will be
made by wire transfer, in immediately available funds, to an account designated
in writing by Lexicon.

7.11     TAXES. Any and all taxes levied on any payments from Genentech to
Lexicon under this Agreement will be the liability of, and paid by, Lexicon.
However, if Applicable Laws require the withholding of such taxes, Genentech
will deduct such taxes from its payment to Lexicon and remit such withheld
amount to the proper tax authority. Genentech will provide proof of payment to
Lexicon within [**] of such payment. This Agreement shall not be considered a
partnership for tax reporting purposes.

7.12     INTEREST ON OVERDUE PAYMENTS. In the event a royalty or other payment
under this Agreement is not made within [**] of when due, such outstanding
payment will accrue interest (from the date such payment is due through and
including the date upon which full payment is made) at the annual rate equal to
the [**]. Payment of accrued interest will accompany payment of the outstanding
payment.

7.13     ROYALTY RECORDS; AUDIT RIGHTS. Genentech will keep, and maintain for a
period of [**] following the end of a Calendar Year, accurate records in
sufficient detail to enable royalties under this Agreement for such Calendar
Year to be determined. Lexicon has the right, upon prior written notice to
Genentech, not more than [**], through an independent certified public
accountant selected by Lexicon and acceptable to Genentech (which acceptance
shall not be unreasonably refused) to have access during normal business hours
to those records of Genentech as may be reasonably necessary to verify the
accuracy of the royalty reports furnished by Genentech under this Agreement for
the previous Calendar Year. Prior to implementing an audit, Lexicon agrees to
submit an

                                       22
<PAGE>

audit plan, including audit scope, to Genentech for Genentech's approval (which
shall not be unreasonably withheld). Lexicon's independent certified public
accountant will keep confidential all information obtained during such audit and
will report to Lexicon only the amount of Genentech's Gross Sales and Net Sales
made during, and royalties due for, the Calendar Year in question. Genentech
shall have the right, at its own expense, to have its own independent certified
public accountant review and confirm the results of the audit performed by
Lexicon's accountants. In the event that the Parties' accountants do not agree
as to the results of the audit, the Parties agree that such accountants shall
attempt in good faith to resolve any discrepancies between their results
according to GAAP and the terms of this Agreement.

Lexicon is solely responsible for all the expenses of an audit, unless the
independent certified public accountant's report correctly shows any
underpayment of royalties by Genentech exceeding [**] of the total royalties it
owed for the Calendar Year then being reviewed. If the independent certified
public accountant's report correctly shows that Genentech underpaid its
royalties by more than [**], Genentech is responsible for the reasonable
expenses incurred by Lexicon for the independent certified public accountant's
services.

If the independent certified public accountant's report correctly shows any
underpayment of royalties by Genentech, Genentech shall remit to Lexicon within
[**] after the Genentech receipt of such report:

         (i)      the amount of such royalty underpayment;

         (ii)     interest on the amount being paid in (i), which interest shall
                  be calculated pursuant to Section 7.12; and

         (iii)    if such royalty underpayment exceeds [**] of Genentech's total
                  royalties owed for the Calendar Year then being reviewed, the
                  reasonable expenses incurred by Lexicon for the independent
                  certified public accountant's services.

If the independent certified public accountant's report correctly shows any
overpayment of royalties by Genentech, such overpayment shall be fully
creditable against future royalties payable by Genentech in subsequent royalty
periods.

The calculation of royalties payable with respect to a Calendar Year will be
binding and conclusive on the Parties upon the expiration of [**] following the
end of such Calendar Year, unless (i) an audit of such Calendar Year, initiated
before the expiration of such [**], is on-going or (ii) Lexicon has, in good
faith and through written notice to Genentech, disputed such calculation before
the expiration of such [**] or, if applicable, within [**] after receipt of the
audit report.

7.14     CONVERTIBLE NOTE. Simultaneously with the execution and delivery of
this Agreement, the parties hereto shall enter into a Note Agreement (the "Note
Agreement"),

                                       23
<PAGE>
dated as of the date hereof, substantially in the form attached as
Exhibit C hereto. Under the Note Agreement, Genentech shall loan Lexicon Four
Million Dollars (U.S.$4,000,000), on or before December 31, 2002, pursuant to
the terms and conditions set forth in such Note Agreement.

                                   ARTICLE 8

                     INTELLECTUAL PROPERTY RESPONSIBILITIES

8.1      OWNERSHIP.

         (a)      Lexicon shall own all Lexicon Knock-Out Technology, Lexicon
Pre-Existing Patents and Know-How and Restricted Rights Project Patents and
Know-How. Genentech shall own all Genentech Gene Patents and Know-How and
Project Patents and Know-How.

         (b)      Lexicon shall assign all right, title and interest in
inventions encompassed within Project Patents and Know-How to Genentech by
taking, and causing its employees and agents to take, all necessary actions and
executing, and causing its employees and agents to execute, all necessary
documents to assign such rights, title and interest to Genentech. Moreover,
Lexicon covenants and agrees to cooperate, and cause its employees and agents to
cooperate, with Genentech to enable Genentech to enjoy to the fullest extent the
right, title and interest herein conveyed in the United States and foreign
countries. Such cooperation shall include prompt production of pertinent facts
and documents, giving of testimony, execution of petitions, oaths,
specifications, declarations or other papers, and other assistance all to the
extent deemed necessary or desirable by Genentech (a) for perfecting the right,
title and interest herein conveyed; (b) for prosecuting any of said
applications; (c) for filing and prosecuting applications for reissuance of any
of said patents; (d) for interference or other priority proceedings involving
said invention; and (e) for legal proceedings involving said invention and any
applications therefor and any patents granted thereon, including without
limitation opposition proceedings, cancellation proceedings, priority contests,
public use proceedings, infringement actions and court actions; provided,
however, that the expense incurred by Lexicon, its employees and agents in
providing such cooperation shall be paid for by Genentech.

8.2      PATENT PROSECUTION OF LEXICON KNOCK-OUT TECHNOLOGY, LEXICON
PRE-EXISTING PATENTS AND RESTRICTED RIGHTS PROJECT PATENTS.

         (a)      Patentable Inventions. Lexicon shall be responsible, at its
sole discretion and expense, for filing, prosecuting, and maintaining Lexicon
Knock-Out Technology, Lexicon Pre-Existing Patents and Restricted Rights Project
Patents; provided that Genentech shall be responsible, at its sole discretion,
for filing, prosecuting, and maintaining Lexicon Pre-Existing Patents and
Restricted Rights Project Patents (to the

                                       24
<PAGE>

extent exclusively licensed to Genentech) claiming Protein Candidates and uses
thereof following their designation as Protein Candidates.

         (b)      Review and Comment. Lexicon shall provide Genentech with a
copy of any patent application (including any provisional applications) within
Lexicon Knock-Out Technology specifically related to a Protein Candidate prior
to filing in any jurisdiction, for review and comment by Genentech. Lexicon
shall reasonably consider comments and suggestions provided in a timely manner
by Genentech. Genentech shall maintain any such applications in confidence.

         (c)      Notice of Decision. If Lexicon decides not to file an
application within Lexicon Knock-Out Technology specifically related to a
Protein Candidate in any country, it shall give Genentech prompt notice to this
effect. After such notice, Genentech may file, prosecute (including any
interference), and maintain, at its own expense, such application in such
country, and Lexicon shall execute such documents and perform such acts as may
be reasonably necessary for Genentech to continue such filing, prosecution, or
maintenance.

         (d)      Prosecution and Maintenance. Lexicon agrees to use reasonable
diligence to prosecute and maintain the Lexicon Knock-Out Technology
specifically related to a Protein Candidate it filed and to prosecute any
interference proceedings with respect thereto, unless it provides Genentech
notice under Subsection (c) or (e). Upon Genentech's request, Lexicon shall
provide Genentech with (i) a copy of communications with any patent office with
respect to any Lexicon Knock-Out Technology specifically related to a Protein
Candidate and (ii) the opportunity to review and comment on any or all such
communications. Genentech shall provide its comments on any such communication
within [**] after receipt of such communication, and should no comments be
received by Lexicon on or before the [**], then it shall be deemed that
Genentech has no comment to make on such communication. Lexicon shall reasonably
consider comments and suggestions provided in a timely manner by Genentech.
Genentech shall maintain any such communications in confidence. All such
communications provided to Genentech pursuant to this Section shall be sent to a
person to be designated by Genentech by written notice to Lexicon.

         (e)      Cessation of Prosecution or Maintenance. Lexicon shall give
prior written notice to Genentech of any decision by Lexicon to cease the
prosecution (including any interference) and maintenance of Lexicon Knock-Out
Technology specifically related to a Protein Candidate and, in such case,
Genentech shall have the right at its sole discretion and expense to continue
such prosecution (including any interference) or maintenance. If Genentech
continues such prosecution or maintenance, Lexicon shall execute such documents
and perform such acts as may be reasonably necessary for Genentech to continue
such prosecution or maintenance.

8.3      PATENT PROSECUTION OF GENENTECH GENE PATENTS, PROJECT PATENTS AND
LEXICON PRE-EXISTING PATENTS AND RESTRICTED RIGHTS PROJECT PATENTS CLAIMING
PROTEIN CANDIDATES.

                                       25
<PAGE>

         (a)      Patentable Inventions. Genentech shall be responsible, at its
sole discretion and expense, for filing, prosecuting, and maintaining Genentech
Gene Patents, Project Patents and, following designation of a Protein Candidate,
any Lexicon Pre-Existing Patents and Restricted Rights Project Patents (to the
extent exclusively licensed to Genentech) related to such Protein Candidate.

         (b)      Review and Comment. Genentech shall provide Lexicon with a
copy of any patent application (including any provisional applications) within
(i) Project Patents and (ii) Lexicon Pre-Existing Patents or Restricted Rights
Project Patents relating to Protein Candidates prior to filing in any
jurisdiction for review and comment by Lexicon. Genentech shall reasonably
consider comments and suggestions provided in a timely manner by Lexicon.
Lexicon shall maintain any such applications in confidence.

         (c)      Notice of Decision. If Genentech decides not to file an
application within (i) Project Patents related to a specific Project or (ii)
Lexicon Pre-Existing Patents or Restricted Rights Project Patents related to a
Protein Candidate in any country, it shall give Lexicon prompt notice to this
effect. After such notice, Lexicon may file, prosecute (including any
interference), and maintain, at its own expense, such application in such
country, and Genentech shall execute such documents and perform such acts as may
be reasonably necessary for Lexicon to continue such filing, prosecution, or
maintenance.

         (d)      Prosecution and Maintenance. Genentech agrees to use
reasonable diligence to prosecute and maintain (i) Project Patents and (ii)
Lexicon Pre-Existing Patents and Restricted Rights Project Patents related to
Protein Candidates it filed and to prosecute any interference proceedings with
respect thereto, unless it provides Lexicon notice under Subsection (c) or (e).
Upon Lexicon's request, Genentech shall provide Lexicon with (i) a copy of
communications with any patent office with respect to any (A) Project Patents
and (B) Lexicon Pre-Existing Patents and Restricted Rights Project Patents
related to Protein Candidates and (ii) the opportunity to review and comment on
any or all such communications. Lexicon shall provide its comments on any such
communication within [**] after receipt of such communication, and should no
comments be received by Genentech on or before the [**], then it shall be deemed
that Lexicon has no comment to make on such communication. Genentech shall
reasonably consider comments and suggestions provided in a timely manner by
Lexicon. Lexicon shall maintain any such communications in confidence. All such
communications provided to Lexicon pursuant to this Section shall be sent to a
person to be designated by Lexicon by written notice to Genentech.

         (e)      Cessation of Prosecution or Maintenance. Genentech shall give
prior written notice to Lexicon of any decision by Genentech to cease the
prosecution (including any interference) and maintenance of (i) Project Patents
related to a specific Project or (ii) Lexicon Pre-Existing Patents or Restricted
Rights Project Patents related to a Protein Candidate and, in such case, Lexicon
shall have the right at its sole discretion and expense to continue such
prosecution (including any interference) or maintenance. If Lexicon continues
such prosecution or maintenance, Genentech shall execute

                                       26
<PAGE>

such documents and perform such acts as may be reasonably necessary for Lexicon
to continue such prosecution or maintenance.

8.4      INFRINGEMENT AND MISAPPROPRIATION.

         (a)      Notice. Each Party shall promptly notify the other Party in
writing of any alleged infringement or misappropriation, of which it becomes
aware, by any person of any intellectual property licensed or sublicensed to a
Party under this Agreement.

         (b)      Infringement of Lexicon Knock-Out Technology, Project Patents
and Lexicon Pre-Existing Patents involving Small Molecule Drugs, and Restricted
Rights Project Patents. Lexicon shall have the sole right, but not the
obligation, to take appropriate steps to remove the infringement or alleged
infringement of (i) Lexicon Knock-Out Technology, (ii) Project Patents and
Lexicon Pre-Existing Patents involving infringement or alleged infringement of a
Small Molecule Drug, and (iii) Restricted Rights Project Patents (except to the
extent exclusively licensed to Genentech), including, without limitation, by
initiation, prosecution and control, at its own expense, of any suit, proceeding
or other legal action by counsel of its own choice. Any damages or other
monetary awards recovered by Lexicon shall be owned by Lexicon.

         (c)      Notwithstanding the above, if the infringement or alleged
infringement relates to Lexicon Knock-Out Technology specifically related to a
Protein Candidate or to Project Patents and Lexicon Pre-Existing Patents
involving infringement or alleged infringement of a Small Molecule Drug, Lexicon
shall have the first right, but not the obligation, to take appropriate steps to
remove the infringement or alleged infringement, including, without limitation,
by initiation, prosecution and control, at its own expense, of any suit,
proceeding or other legal action by counsel of its own choice, provided that
Lexicon keeps Genentech reasonably informed of the progress of such suit,
proceeding or legal action and provides Genentech with copies of any substantive
documents related to such suit, proceeding or legal action and reasonable notice
thereof. Lexicon shall notify Genentech of its decision to exercise its right to
enforce Lexicon Knock-Out Technology specifically related to a Protein Candidate
or to Project Patents and Lexicon Pre-Existing Patents involving infringement or
alleged infringement of a Small Molecule Drug not later than [**] following its
discovery or notice of alleged infringement of Lexicon Knock-Out Technology
specifically related to a Protein Candidate or to Project Patents and Lexicon
Pre-Existing Patents involving infringement or alleged infringement of a Small
Molecule Drug. Genentech shall have the right, at its own expense, to be
represented in any such action by counsel of its own choice. If Lexicon decides
not to institute an infringement suit, proceeding or other legal action that
Genentech feels is reasonably required to protect such Lexicon Knock-Out
Technology specifically related to a Protein Candidate or to Project Patents and
Lexicon Pre-Existing Patents involving infringement or alleged infringement of a
Small Molecule Drug, Genentech shall have the right, at its sole discretion, to
institute such suit, proceeding or other legal action and Lexicon shall have the
right to be represented in such suit, proceeding or legal action, at its own
expense, by counsel of its own choice. For this purpose, the Party not bringing

                                       27
<PAGE>

the suit shall execute such legal papers necessary for such suit as may be
reasonably requested by the Party bringing suit.

In the case of infringement or alleged infringement of a Project Patent,
Genentech in its sole discretion, may elect to assign such a Project Patent to
Lexicon so that Lexicon may maintain such suit, proceding or legal action in its
own name. In such event, the licenses to Genentech under such a Project Patent
shall remain unaffected.

If Lexicon brings an action under this Subsection, any damages or other monetary
awards recovered by Lexicon shall be applied proportionately first to defray the
unreimbursed costs and expenses (including actual and reasonable attorneys'
fees) incurred by the Parties in the action. If any balance remains, such
balance shall be the property of Lexicon. If Lexicon fails to bring an action
under this Subsection, but Genentech brings an action, any damages or other
monetary awards recovered by Genentech shall be applied first to defray the
costs and expenses (including actual and reasonable attorneys' fees) incurred in
the action by the Parties. The balance that remains shall be the property of
Genentech

         (d)      Infringement of Genentech Gene Patents and Know-How, Project
Patents and Know-How, and Lexicon Pre-Existing Patents and Know-How and
Restricted Rights Project Patents related to Protein Candidates. Genentech shall
have the sole right, but not the obligation, to take appropriate steps to remove
the infringement or alleged infringement of (i) Genentech Gene Patents and
Know-How, and (ii) (A) Project Patents and Know-How and (B) Lexicon Pre-Existing
Patents and Know-How (except to the extent such infringement or alleged
infringement relates to the development of Small Molecule Drugs, which shall be
controlled by subsection (c) above) and Restricted Rights Project Patents and
Know-How (to the extent exclusively licensed to Genentech) related to Protein
Candidates, including, without limitation, by initiation, prosecution and
control, at its own expense, of any suit, proceeding or other legal action by
counsel of its own choice. Any damages or other monetary awards recovered by
Genentech shall be owned by Genentech.

         (e)      If Genentech brings action under Subsection (d) above with
respect to (i) Project Patents and Know-How or (ii) Lexicon Pre-Existing Patents
and Know-How or Restricted Rights Project Patents and Know-How (to the extent
exclusively licensed to Genentech) related to Protein Candidates, any damages or
other monetary awards recovered by Genentech shall be applied proportionately
first to defray the unreimbursed costs and expenses (including actual and
reasonable attorneys' fees) incurred by the Parties in the action. If any
balance remains, Lexicon shall retain as its own property an amount of
compensatory damages equal to the royalty that Lexicon would otherwise be
entitled to under this Agreement if such remaining balance was treated as
Genentech Net Sales. If any balance remains after Lexicon's retained amount,
such balance shall be the property of Genentech.

8.5      NOTICE OF INFRINGEMENT BY A PARTY. If the making, using, importing,
offer for sale, or selling a Licensed Product results in a claim against a Party
of patent

                                       28
<PAGE>

infringement by any Third Person, the Party first having notice of that claim
shall promptly notify the other Party in writing. The notice shall set forth the
facts of the claim in reasonable detail.

If any notice of infringement is received by, or a suit is initiated against,
either Party with respect to any Licensed Product, the Parties shall consult in
good faith regarding the best response.

Notwithstanding the foregoing, if the claim involves an allegation of a
violation of the trade secret rights of a Third Person, the Party accused of
such violation shall have the obligation to defend against such claim and shall
indemnify the other Party against all costs associated with such claim.

8.6      LITIGATION EXPENSES. Each Party shall assume and pay all of its own
out-of-pocket expenses incurred in connection with all litigation described in
this Article 8, including without limitation, the fees and expenses of that
Party's counsel.

8.7      SETTLEMENT APPROVAL. No settlement, consent judgment or other voluntary
final disposition of a suit being prosecuted by a Party under this Article may
be entered into without the consent of the other Party if such settlement,
consent judgment or other voluntary final disposition would alter, derogate, or
diminish such other Party's rights under the Agreement, which consent will not
be unreasonably withheld or delayed.

8.8      PATENT TERM EXTENSIONS. When appropriate, the Parties shall cooperate
with each other in gaining patent term extension. All filings for such extension
shall be made by the Party that is the owner of the patent.

8.9      AUDIT RIGHTS REGARDING INVOICES. In the event there is a good faith
dispute over an amount owed by a Party under this Article, the disputed payment
may be delayed, and such payment will not be considered delinquent pending a
resolution of the Parties' dispute. Section 7.13 (i.e., "Royalty and Reasonable
Expenses Records; Audit Rights") is applicable with regard to all invoices
submitted by a Party to the other Party under this Article.

                                   ARTICLE 9

                                 CONFIDENTIALITY

9.1      OBLIGATIONS. Except upon obtaining the other Party's prior written
consent to the contrary, each Party agrees that it will, for a period of [**]
after the expiration or early termination of the entire Agreement:

         (i)      maintain in confidence, and not disclose to any person (except
                  as provided in Section 9.2), the other Party's Confidential
                  Information or any Project Confidential Information; and

                                       29
<PAGE>

         (ii)     not use such Confidential Information for any purpose except
                  as contemplated in this Agreement.

9.2      AUTHORIZED DISCLOSURES OF CONFIDENTIAL INFORMATION.

         (a)      Permitted Persons. Each Party may disclose Confidential
Information of the other Party or Project Confidential Information, without such
other Party's prior written consent, to its and its Affiliates' (or the other
Party's and its Affiliates') directors, employees, agents, consultants,
permitted (sub)licensees, suppliers, and other Third Persons who:

         (i)      need to know such Confidential Information to assist the Party
                  in fulfilling its obligations or exploiting its rights
                  hereunder (or to determine their interest in providing such
                  assistance); and

         (ii)     are bound by written confidentiality and non-use obligations
                  no less stringent than those contained herein.

         (b)      Legally Required or Necessary. Each Party may also disclose
the Confidential Information of the other Party or Project Confidential
Information, without such other Party's prior written consent, to any person or
to a government or regulatory authority to the extent that such disclosure is:

         (i)      required by Applicable Law; or

         (ii)     otherwise necessary for filing a patent application,
                  prosecuting, maintaining, or enforcing a patent, obtaining or
                  maintaining authorizations to conduct pre-clinical or clinical
                  studies regarding a product, or obtaining or maintaining a
                  registration regarding a product (provided such Party is
                  entitled at the time to engage in such activities under this
                  Agreement).

Prior to disclosing the other Party's Confidential Information or Project
Confidential Information under this Subsection (b), the disclosing Party, to the
extent practicable, will give the other Party a copy of the Confidential
Information to be disclosed and provide such Party a reasonable opportunity to
comment on the necessity and the text of the proposed disclosure. The disclosing
Party agrees to consider such comments in good faith and to reasonably avail
itself of available means under the applicable law to minimize the disclosure of
such Confidential Information.

         (c)      Court Orders. Each Party may also disclose the Confidential
Information of the other Party or Project Confidential Information, without such
other Party's prior written consent, pursuant to an order of a regulatory
authority or court of competent jurisdiction, provided that it promptly notifies
the other Party of the required disclosure in order to provide such Party an
opportunity to take legal action to prevent or limit such disclosure and, if
asked, reasonably assists the other Party in pursuing such action.

                                       30
<PAGE>

         (d)      Legal Actions. Each Party may also disclose the Confidential
Information of the other Party or Project Confidential Information, without such
other Party's prior written consent, as is necessary to pursue or defend against
a legal or regulatory action related to this Agreement.

9.3      DISCLOSURE OF THE TERMS OF THE AGREEMENT. Each Party agrees that it
will maintain in confidence, and not to disclose, the terms of this Agreement
without the prior written consent of the other Party, except as authorized under
Subsections (a), (b), (c), or (d) of Section 9.2. In addition, if a Party
receives a request from an authorized representative of a U.S. or foreign tax
authority for a copy of the Agreement, that Party may provide a copy of the
Agreement to such tax authority representative without advance notice to or the
consent or cooperation of the other Party, but the disclosing Party must notify
the other Party of the disclosure as soon as practical.

9.4      PUBLICITY ABOUT THE AGREEMENT. If a Party desires to issue a press
release or other public statement or announcement concerning this Agreement, the
subject matter hereof, or the research, development or commercial results of the
products hereunder, it must first obtain the other Party's written approval of
the proposed release or announcement; provided that such approval shall not be
unreasonably withheld if required pursuant to the disclosure requirements of the
Securities and Exchange Commission ("SEC") or the national securities exchange
or other stock market on which such Party's securities are traded ("Exchange").
All press releases and other publicity will conform to the publicity strategy
and policy developed by the Steering Committee in accordance with Section
2.2(v). Without limiting the generality of the foregoing, each Party agrees that
the other Party will have no less than [**] to review and provide comment
regarding any such proposed press release or publicity, unless a shorter review
time is agreed to by both Parties. Neither Party may use any trademarks, logos,
or symbols associated with the other Party without the prior written permission
of such other Party. In the event that one Party reasonably concludes that a
given disclosure is required by law and the other Party disagrees with the
substance or extent of the disclosure, then the Party seeking such disclosure
shall either (i) limit said disclosure to address the concerns of the other
Party, or (ii) provide a written opinion from counsel stating that such
disclosure is indeed required by law. With respect to complying with the
disclosure requirements of the SEC, in connection with any required SEC filing
of this Agreement, the filing Party shall seek confidential treatment of
portions of this Agreement from the SEC and the other Party shall have the right
to review and comment on such an application for confidential treatment prior to
its being filed with the SEC. The non-filing Party shall provide its comments,
if any, on such application as soon as practicable and in no event later than
[**] after such application is provided to the non-filing Party. Notwithstanding
the foregoing, Genentech shall not be prohibited from making a statement
regarding the development or commercialization of a Protein Candidate, Licensed
Product or Small Molecule Drug and Lexicon shall not be prohibited from making a
statement regarding the development or commercialization of a Small Molecule
Drug.

                                       31
<PAGE>

9.5      PUBLICATIONS. Genentech and Lexicon (as applicable, the "Publishing
Party") may each publish or present data and/or results generated by or on
behalf of such Publishing Party utilizing Knock-Out Mice or Progeny, subject to
the prior review of the proposed disclosure by the other Party (the "Reviewing
Party") solely to determine (i) whether the proposed disclosure contains
Confidential Information of the Reviewing Party or Project Confidential
Information or (ii) whether information contained in the proposed disclosure
should be the subject of a patent application to be filed by Lexicon or
Genentech prior to such disclosure. The Publishing Party shall provide the
Reviewing Party with the opportunity to review any proposed abstract, manuscript
or presentation which discloses the results of research conducted utilizing the
Knock-Out Mice or Progeny by delivering a copy thereof to the Reviewing Party no
less than [**] before its intended submission for publication or presentation.
The Reviewing Party shall have [**] from its receipt of any such abstract,
manuscript or presentation in which to notify the Publishing Party in writing of
any specific objections to the disclosure, based on either the need to seek
patent protection or concern regarding the specific disclosure of the
Confidential Information of the Reviewing Party or Project Confidential
Information. In the event the Reviewing Party objects to the disclosure, the
Publishing Party agrees not to submit the publication or abstract or make the
presentation containing the objected-to information until the Reviewing Party is
given a reasonable additional period of time (not to exceed an additional [**])
to seek patent protection for any material in the disclosure which the Reviewing
Party believes is patentable (subject, in all events, to Article 8) or, in the
case of Confidential Information of the Reviewing Party, to allow the Publishing
Party to delete any Confidential Information of Reviewing Party from the
proposed disclosure. Each Party agrees to delete from the proposed disclosure
any Confidential Information of the Reviewing Party upon request.
Notwithstanding the foregoing, publication of Patent applications shall not be
subject to this Section 9.5

                                   ARTICLE 10

                        TERM AND TERMINATION OF AGREEMENT

10.1     TERM. This Agreement commences on the Effective Date and will remain in
full force and effect, unless earlier terminated as provided in this Article 10,
until the later of: (i) [**] after the last Project Gene becomes a Rejected
Project hereunder; or (ii) the expiration of all royalty obligations under this
Agreement between the Parties.

10.2     [**]

10.3     TERMINATION FOR INSOLVENCY OR BANKRUPTCY. Either Party may, by written
notice, terminate this Agreement with immediate effect if the other Party:

         (i)      makes a general assignment for the benefit of creditors;

         (ii)     files an insolvency petition in bankruptcy;

                                       32
<PAGE>

         (iii)    petitions for or acquiesces in the appointment of any
                  receiver, trustee or similar officer to liquidate or conserve
                  its business or any substantial part of its assets;

         (iv)     commences under the laws of any jurisdiction any proceeding
                  involving its insolvency, bankruptcy, reorganization,
                  adjustment of debt, dissolution, liquidation or any other
                  similar proceeding for the release of financially distressed
                  debtors; or

         (v)      becomes a party to any proceeding or action of the type
                  described above in (iii) or (iv), and such proceeding or
                  action remains undismissed or unstayed for a period of more
                  than sixty (60) days.

All rights and licenses granted under or pursuant to this Agreement by each
Party as a licensor or sublicensor are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of Title XI, U.S. Code (the "Bankruptcy Code"),
licenses (or, if applicable, sublicenses) of rights to "intellectual property"
as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that
each licensee (or, if applicable, sublicensee) of such rights under this
Agreement shall retain and may fully exercise all rights and elections it would
have in the case of a licensor (or sublicensor) bankruptcy under the Bankruptcy
Code. Each Party agrees during the term of this Agreement to create or maintain
current copies, or if not amenable to copying, detailed descriptions or other
appropriate embodiments, of all such intellectual property licensed or
sublicensed to the other Party.

10.4     SURVIVING OBLIGATIONS. The rights and obligations of the Parties under
Article 1 (Definitions), Article 9 (Confidentiality), Article 11 (Disclaimers,
Representations and Warranties), Article 12 (Indemnification), and Article 13
(General Provisions) survive the termination or expiration of this Agreement.
Also, termination or expiration of the Agreement shall not affect the rights and
obligations of the Parties that by their nature survive, including, but not
limited to, those in Article 8 (Intellectual Property Responsibilities) and, to
the extent applicable, the effects of termination contained in Sections 10.2
through 10.4. [**] The provisions of Sections 7.7 through 7.13 shall survive
termination of this Agreement [**]. Finally, except as specifically provided to
the contrary in this Agreement, termination or expiration of the Agreement shall
be without prejudice to any rights that shall have accrued to the benefit of
either Party prior to such termination or expiration and shall not relieve the
Parties of any obligations accrued hereunder prior to such termination or
expiration. This Section survives the termination or expiration of this
Agreement for any reason.

                                       33
<PAGE>

                                   ARTICLE 11

                  DISCLAIMERS, REPRESENTATIONS, AND WARRANTIES

11.1     CORPORATE EXISTENCE AND AUTHORITY. Each Party represents and warrants
to the other Party that:

         (i)      it is a corporation or entity duly organized and validly
                  existing under the law of the state or country of its
                  incorporation; and

         (ii)     it has the full authority to enter into and perform all of the
                  duties and obligations contemplated under this Agreement.

11.2     AUTHORIZED EXECUTION; BINDING OBLIGATION. Each Party represents and
warrants to the other Party that its execution, delivery, and performance of
this Agreement have been duly authorized and approved by all necessary corporate
action and that this Agreement is binding, upon and enforceable against it in
accordance with the Agreement's terms (subject to bankruptcy and similar laws
affecting the rights of creditors generally).

11.3     NO CONFLICTS. Each Party represents and warrants that its execution,
delivery, and performance of this Agreement:

         (i)      does not, except as otherwise described in this Agreement,
                  require the approval or consent of any Third Person, which has
                  not already been obtained;

         (ii)     does not, to the best of its knowledge, contravene any
                  Applicable Law; and

         (iii)    does not contravene the provisions of, nor constitutes a
                  default under, its Certificate of Incorporation or bylaws or
                  any indenture, mortgage, contract or other agreement or
                  instrument to which it is a signatory.

11.4     NO DEBARMENT. Each Party represents and warrants to the other that it
is not debarred under the Generic Drug Enforcement Act of 1992 (the "Act") and
is in compliance with the provisions of such Act. Each Party also covenants
that, while this Agreement is in effect, it will comply with such Act, will not
become debarred under the Act, and will not use in connection with this
Agreement the services of any person debarred under such Act. Finally, upon
request by the other Party, a Party will certify its compliance with the Act and
this Section in writing to such other Party. If, at any time, a Party breaches a
covenant under this Section, the breaching Party shall immediately notify the
other Party of such fact.

11.5     REPRESENTATIONS AND WARRANTIES REGARDING LICENSES. With regard to each
license granted under this Agreement, the Party granting such license (the
"Granting

                                       34
<PAGE>

Party") will be deemed to represent and warrant to the other Party, at the time
any such license is granted, that, to the Granting Party's Actual Knowledge:

         (a)      the Granting Party's grant of such license does not require
the approval or consent of any person or entity, which has not already been
obtained;

         (b)      the Granting Party's grant of such license does not contravene
any Applicable Law;

         (c)      the Granting Party's grant of such license does not contravene
the provisions of, nor constitutes a default under, the Granting Party's
Certificate of Incorporation or bylaws or any indenture, mortgage, contract or
other agreement or instrument to which the Granting Party is a signatory;

         (d)      the Granting Party has the ability and right to grant the
other Party such license;

         (e)      except as previously identified in a written notice, the
Granting Party has not received, nor been made aware of, any communications
alleging that its practice of the licensed intellectual property rights has
infringed or misappropriated (or that it, or the other Party, will infringe or
misappropriate in carrying out such license) the intellectual property rights of
any person or entity;

         (f)      except as previously identified in a written notice, there
have been no claims made against the Granting Party asserting the invalidity,
abuse, misuse, or unenforceability of the licensed intellectual property rights;
and

         (g)      there are no outstanding encumbrances on, licenses under, or
covenants-not-to-sue with respect to the licensed intellectual property rights,
which, in the case of licenses or covenants not-to-sue, would conflict with the
rights granted herein.

11.6     DISCLAIMER OF IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE, OR OTHERWISE, AND EACH
PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES
INCLUDING WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE.

11.7     LIMITATION OF LIABILITY. NEITHER PARTY WILL BE LIABLE TO THE OTHER
PARTY FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES INCLUDING, BUT
NOT LIMITED TO, LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. HOWEVER,
NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF ANY PARTY.

                                       35
<PAGE>

                                   ARTICLE 12

                                 INDEMNIFICATION

12.1     INDEMNIFICATION OBLIGATIONS.

         (a)      Genentech's Obligation. Genentech will defend, indemnify, and
hold harmless Lexicon, its Affiliates and their respective directors, officers,
shareholders, employees, and agents ("Lexicon Indemnitees"), from and against
any and all liabilities, damages, losses, penalties, fines, costs, interest, and
expenses, including, without limitation, reasonable attorneys' fees ("Damages"),
arising from or occurring as a result of a Third Person's claim, action, suit,
judgment, or settlement against a Lexicon Indemnitee that is due to or based
upon:

         (i)      any breach of a representation, warranty, covenant,
                  obligation, or agreement of Genentech under this Agreement;

         (ii)     any grossly negligent or more culpable act of Genentech or a
                  Genentech Affiliate or sublicensee, or their respective
                  directors, officers, shareholders, employees, and agents
                  related to this Agreement; or

         (iii)    the development, manufacture, marketing, sale or other
                  disposition, offer to sell, use, importation, or exportation
                  of a Licensed Product, Protein Candidate or other product in
                  the Field by Genentech or Genentech's Affiliates,
                  sublicensees, subcontractors, or customers, or the customers
                  of Genentech's Affiliates and sublicensees (any of clauses of
                  (i) through (iii), a "Lexicon Third Person Claim").

[**] Genentech's obligations under this Subsection shall survive the expiration
or termination of this Agreement for any reason.

         (b)      Lexicon's Obligation. Lexicon will defend, indemnify, and hold
                  harmless Genentech, its Affiliates and their respective
                  directors, officers, shareholders, employees and agents
                  ("Genentech Indemnitees"), from and against any and all
                  Damages arising from or occurring as a result of a Third
                  Person's claim, action, suit, judgment, or settlement against
                  a Genentech Indemnitee that is due to or based upon:

         (i)      any breach of a representation, warranty, covenant,
                  obligation, or agreement of Lexicon under this Agreement;

         (ii)     any grossly negligent or more culpable act of Lexicon or a
                  Lexicon Affiliate or sublicensee, or their respective
                  directors, officers, shareholders, employees, and agents
                  related to this Agreement (any of clauses (i) through (ii), a
                  "Genentech Third Person Claim"); or

                                       36
<PAGE>

         (iii)    the development, manufacture, marketing, sale or other
                  disposition, offer to sell, use, importation, or exportation
                  of a Small Molecule Drug by Lexicon or Lexicon's Affiliates,
                  sublicensees, subcontractors, or customers, or the customers
                  of Lexicon's Affiliates and sublicensees.

[**] Lexicon's obligations under this Subsection shall survive expiration or
termination of this Agreement for any reason.

12.2     INDEMNIFICATION PROCEDURES.

         (a)      Notice. Promptly after a Genentech Indemnitee or a Lexicon
Indemnitee (each, an "Indemnitee") receives notice of a pending or threatened
Lexicon Third Person Claim or Genentech Third Person Claim, as the case may be
(an "Action"), such Indemnitee shall give written notice of the Action to the
Party to whom the Indemnitee is entitled to look for indemnification pursuant to
this Article 12 (the "Indemnifying Party"). However, an Indemnitee's delay in
providing or failure to provide such notice shall not relieve the Indemnifying
Party of its indemnification obligations, except to the extent it can
demonstrate prejudice due to the delay or lack of notice.

         (b)      Defense. Upon receipt of notice under Subsection (a) from the
Indemnitee, the Indemnifying Party will have the duty to either to compromise or
defend, at its own expense and by counsel (reasonably satisfactory to
Indemnitee), such Action. The Indemnifying Party will promptly (and in any event
not more than [**] after receipt of the Indemnitee's original notice) notify the
Indemnitee in writing of its intention to either compromise or defend such
Action. Once the Indemnifying Party notifies the Indemnitee of its election to
assume the defense of an Action, the Indemnifying Party is not liable to the
Indemnitee for the fees of other counsel or any other expenses subsequently
incurred by the Indemnitee in connection with such defense, other than the
Indemnitee's reasonable costs of investigation and cooperation. However, the
Indemnitee shall have the right to employ separate counsel and to participate in
the defense of an Action (and the Indemnifying Party shall bear the reasonable
fees, costs, and expenses of such counsel) if:

         (i)      the use of the counsel chosen by the Indemnifying Party would
                  present such counsel with a conflict of interest;

         (ii)     the actual or potential defendants in, or targets of, such
                  Action include both the Indemnifying Party and the Indemnitee,
                  and the Indemnitee reasonably concludes that there may be
                  legal defenses available to it that are different from or
                  additional to those available to the Indemnifying Party (in
                  which case the Indemnifying Party shall not have the right to
                  assume the defense of such Action on the Indemnitee's behalf);

         (iii)    the Indemnifying Party does not employ counsel satisfactory to
                  the Indemnitee to represent the Indemnitee within a reasonable
                  time after the Indemnitee's notice of such Action;

                                       37
<PAGE>

         (iv)     the Indemnifying Party denies or fails to timely admit its
                  obligation to defend and indemnify the Action; or

         (v)      in the reasonable opinion of counsel to the Indemnitee, the
                  claim could result in the Indemnitee becoming subject to
                  injunctive relief or relief other than the payment of Damages
                  that could have a materially adverse effect on the ongoing
                  business of the Indemnitee.

         (c)      Cooperation. The Indemnitee shall cooperate fully with the
Indemnifying Party and its legal representatives in the investigation and
defense of an Action. The Indemnifying Party will keep the Indemnitee informed
on a reasonable and timely basis as to the status of such Action (to the extent
the Indemnitee is not participating jointly in the defense of such Action) and
conduct the defense of such Action in a prudent manner.

         (d)      Settlement. If an Indemnifying Party assumes the defense of an
Action, no compromise or settlement of such Action may be effected by the
Indemnifying Party without the Indemnitee's written consent (which consent shall
not be unreasonably withheld or delayed), unless (i) there is no finding or
admission of any violation of law or any violation of the rights of any person
and no effect on any other claims that may be made against the Indemnitee, (ii)
the sole relief provided is monetary damages that are paid in full by the
Indemnifying Party, and (iii) the Indemnitee's rights under this Agreement are
not adversely affected. In any event, the Indemnitee shall have no right to
settle any such Action without the prior written consent of the Indemnifying
Party, unless (i) there is no finding or admission of any violation of law or
any violation of the rights of any person and no effect on any other claims that
may be made against the Indemnifying Party, (ii) the sole relief provided is
monetary damages that are paid in full by the Indemnitee, and (iii) the
Indemnifying Party's rights under this Agreement are not adversely affected; any
settlement under this Subsection (d) without the prior written consent of the
Indemnifying Party shall relieve the Indemnifying Party of its obligations under
this Article 12.

12.3     INSURANCE.

         (a)      During the term of this Agreement, each Party shall maintain
an ongoing basis, Commercial General Liability ("CGL") insurance, including
contractual liability, in the minimum amount of [**] per occurrence and [**]
annual aggregate combined single limit for bodily injury and property damage
liability; provided that Lexicon may satisfy such requirement by maintaining a
combination of CGL insurance and umbrella insurance in such combined per
occurrence and aggregate amounts. Within [**] of the Effective Date, the Parties
shall provide one another with their respective certificates of such insurance.
The aggregate deductible under CGL shall be reasonably satisfactory to the other
Party. The insurance policy shall be an occurrence or claims-made form, but if
only on a claims made form, the insurance coverage shall be maintained for at
least [**] following completion of the work performed under this Agreement.

                                       38
<PAGE>

         (b)      Commencing not later than [**] prior to the first use in
humans of the first potential Licensed Product and thereafter for the period of
time required below, Genentech shall obtain and maintain on an ongoing basis
Products Liability insurance (including contractual liability), with a reputable
carrier, in the amount of at least [**] per occurrence and annual aggregate
combined single limit for bodily injury and property damage liability. No later
than [**] prior to the first use in humans of the first potential Licensed
Product with respect to the Product Liability insurance coverage, Genentech
shall provide to Lexicon a certificate evidencing all such coverage required
hereunder. Thereafter Genentech shall maintain such Products Liability insurance
coverage without interruption during the term of this Agreement and for a period
of at least [**] after the expiration or termination of the term, except as
provided under the next paragraph below.

         (c)      In addition, the Parties agree with respect to (a) and (b)
above that:

         (i)      The Parties shall use Commercially Reasonable Efforts to name
                  each other as additional insureds under their respective CGL
                  and Products Liability insurance;

         (ii)     Each of the above insurance policies shall be primary
                  insurance as respects each Party's participation under this
                  Agreement; and

         (iii)    Each of the above insurance coverage shall be maintained with
                  an insurance company or companies having an A.M. Best rating
                  of "A" or better.

                                   ARTICLE 13

                               DISPUTE RESOLUTION

13.1     INTERNAL RESOLUTION. The Parties shall attempt to settle any dispute,
controversy or claim arising out of or relating to the validity, enforceability
or performance of this Agreement, including disputes relating to alleged breach
or termination of this Agreement but excluding any determination as to the
validity of the Parties' patents (hereinafter, the "Dispute"), in accordance
with the provisions of this Section 13.1. The Parties have entered into the
Agreement in good faith and in the belief that it is mutually advantageous to
them. It is with that same spirit of cooperation that they pledge to attempt to
resolve any Dispute amicably. Accordingly, the Parties agree that if any Dispute
should arise, it shall be referred to a member of senior management from each of
the Parties and from any sublicensee (if any).

13.2     ARBITRATION. Should the senior management be unable to resolve the
dispute, any controversy, dispute or claim which may arise out of or in
connection with this Agreement, or the breach, termination or validity thereof,
shall be settled by final and binding arbitration pursuant to the Arbitration
Rules of the American Arbitration Association as hereinafter provided:

                                       39
<PAGE>

         (a)      The arbitration tribunal shall consist of three arbitrators.
Each party shall nominate in the request for arbitration and the answer thereto
one arbitrator and the two arbitrators so named will then jointly appoint the
third arbitrator as chairman of the arbitration tribunal. If one party fails to
nominate its arbitrator or, if the parties' arbitrators cannot agree on the
person to be named as chairman within [**], the President of the American
Arbitration Association shall make the necessary appointments for arbitrator or
chairman.

         (b)      The place of arbitration shall be in a neutral location (i.e.,
not California or Texas) to be decided by the Party not initiating such
arbitration, and the arbitration proceedings shall be held in English. The
procedural law of the State of Delaware shall apply where the said Arbitration
Rules are silent.

         (c)      The decision of the arbitration tribunal must be in writing
and must specify the basis on which the decision was made, and the award of the
arbitration tribunal shall be final and judgement upon such an award may be
entered in any competent court or application may be made to any competent court
for juridical acceptance of such an award and order of enforcement.

                                   ARTICLE 14

                               GENERAL PROVISIONS

14.1     COMMON INFORMATION TECHNOLOGY. In order to facilitate efficient
communication between Genentech and Lexicon regarding the Projects, the Parties
agree to establish and maintain a secure communication link between Genentech
and Lexicon and work together to identify and support hardware, software, and
services, in accordance with Genentech's platforms and technology architecture,
appropriate for the sharing of Project information. Each Party shall bear its
own costs identifying, acquiring, operating, and maintaining such hardware,
software, and services.

14.2     LEGAL COMPLIANCE. Each Party will comply with all Applicable Laws in
the performance of its obligations or the exercise of its rights hereunder.

14.3     ASSIGNMENT. (a) Neither Party may assign this Agreement (nor any part
thereof) without the prior written consent of the other Party. Notwithstanding
the foregoing, if either Party is a party to a merger and it will not be the
surviving entity of such transaction, such Party may assign, without the other
Party's prior written consent (but with [**] prior written notice to the other
Party) all of its rights and obligations hereunder to the surviving or new
entity resulting from such merger so long as the surviving or new entity
expressly agrees in writing to assume all obligations of such Party under this
Agreement.

                                       40
<PAGE>

         (b)      Any attempted assignment of this Agreement, other than as
allowed in this Section, will be of no force or effect. Subject to the
provisions set forth in this Section, this Agreement will be binding upon and
will inure to the benefit of the successors and permitted assigns of the
Parties.

14.4     INDEPENDENT CONTRACTORS. It is understood and agreed that the Parties
are independent contractors and are engaged in the operation of their own
respective businesses, and neither Party is to be considered the agent of the
other Party or to have a fiduciary responsibility to such other Party for any
purpose whatsoever. The rights and obligations of each Party under this
Agreement do not constitute the formation of a partnership for federal, state,
or any other tax purpose. Each Party shall file all income tax returns
consistent with that position. Neither Party will have any authority to enter
into any contracts or assume any obligations for the other Party nor make any
warranties or representations on behalf of that other Party.

14.5     GOVERNING LAW. This Agreement and all amendments, modifications,
alterations, or supplements hereto, and the rights of the Parties hereunder,
will be construed under and governed by the laws of the State of Delaware
exclusive of its conflicts of laws principles.

14.6     ENTIRE AGREEMENT. This Agreement, including all Exhibits, Schedules and
attachments hereto, constitutes the entire agreement between Lexicon and
Genentech with respect to the subject matter hereof, and all previous or other
negotiations, representations and understandings with respect to the subject
matter hereof between Lexicon and Genentech, including without limitation, the
Origianl Agreement, are superceded as of the Effective Date. This Agreement has
been prepared jointly and will not be strictly construed against either Party.

14.7     SEVERABILITY. All rights and restrictions contained herein may be
exercised and will be applicable and binding only to the extent that they do not
violate any applicable laws and are intended to be limited to the extent
necessary so that they will not render this Agreement illegal, invalid or
unenforceable. If any provision or portion of any provision of this Agreement,
not essential to the commercial purpose of this Agreement, will be held to be
illegal, invalid or unenforceable by a court of competent jurisdiction, it is
the intention of the Parties that the remaining provisions or portions thereof
shall constitute their agreement with respect to the subject matter hereof, and
all such remaining provisions, or portions thereof, will remain in full force
and effect. To the extent legally permissible, any illegal, invalid or
unenforceable provision of this Agreement will be replaced by a valid provision
which will implement the commercial purpose of the illegal, invalid, or
unenforceable provision. In the event that any provision essential to the
commercial purpose of this Agreement is held to be illegal, invalid or
unenforceable and cannot be replaced by a valid provision which will implement
the commercial purpose of this Agreement, the Parties will promptly negotiate a
suitable resolution (potentially even termination of the Agreement) in good
faith.

                                       41
<PAGE>

14.8     FORCE MAJEURE. Any delays in, or failure of, performance of any
obligations of a Party will not constitute a default hereunder or give rise to
any claim for damages, if, and to the extent, caused by Force Majeure. The Party
asserting this Section will promptly notify the other Party of the event
constituting Force Majeure, of all relevant details of the occurrence, and an
estimate of how long such Force Majeure event shall continue. The affected Party
will also take reasonable and diligent actions to cure such cause, and the
Parties will consult with each other in order to find a fair solution and shall
use all reasonable endeavors to minimize the consequences of such Force Majeure.

14.9     COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.

14.10    NOTICES. All notices, statements, and reports required to be given
under this Agreement will be in writing, delivered in person, via registered or
certified mail postage prepaid, or through a professional courier service (e.g.,
FedEx or DHL), and addressed as follows:

                  To Lexicon:        Lexicon Genetics Incorporated
                                     8800 Technology Forest Place
                                     Woodlands, TX 77381-1160
                                     Fax:  (281) 863-8088
                                     Phone:  (281) 863-3000
                                     Attn:  President, CEO

                  With a copy to:    General Counsel

                  To Genentech:      Genentech, Inc.
                                     1 DNA Way
                                     South San Francisco, California  94080
                                     Fax:  (650) 952-9881
                                     Phone:  (650) 225-1000
                                     Attn:  Corporate Secretary

                  With a copy to:    Vice President, Research

Notice will be deemed to have been given when delivered if personally delivered
on a business day, on the [**] after dispatch if sent by a professional courier,
and on the [**] following the date of mailing if sent by registered or certified
mail. A Party may change the address to which notices to such Party are to be
sent by giving written notice to the other Party at the address and in the
manner provided above. Any notice may be given, in addition to the manner set
forth above, by facsimile or e-mail, provided that the Party giving such notice
obtains acknowledgment by facsimile or e-mail that such notice has been received
by the Party to be notified. Notices made in this manner will be deemed to have
been given when such acknowledgment has been transmitted.

                                       42
<PAGE>

14.11    WAIVER. The failure of either Party to enforce any provision of this
Agreement at any time will not be construed as a present or future waiver of
such provision or any other provision of this Agreement. The written waiver by
either Party, pursuant to this Section 14.11, of any provision or requirement
hereunder will neither be deemed nor operate as a future waiver of such or any
other provision or requirement.

14.12    MODIFICATIONS. No amendment, waiver or modification of this Agreement
will be valid or binding on either Party unless made in writing and signed by
duly authorized representatives of both Parties.

14.13    HEADINGS. All headings and captions used in this Agreement are for
convenience only, and are not intended to have any substantive effect.

14.14    NO IMPLIED LICENSES. Except as specifically provided for in this
Agreement, neither Party grants, expressed or implied, any license to the other
Party under this Agreement.

14.15    NO THIRD PARTY BENEFICIARIES: Except as expressly provided herein, this
Agreement shall not confer any rights or remedies upon any Third Person other
than the Parties and their respective successors and permitted assigns.

14.16    R&D TAX CREDITS. To the extent permitted by Applicable Law, Genentech
will be entitled to any tax credits due on account of research and development
expenses it pays to Lexicon under this Agreement.

14.17    RESPONSIBLE FOR SUBLICENSEES. If a Party sublicenses to another person
any of the rights it received under this Agreement from the other Party, such
Party agrees to remain responsible to other Party for the performance and
compliance of such sublicensee with all obligations under this Agreement that
apply to such sublicensee.

                        [The rest of this page is blank]

                                       43
<PAGE>

14.18    FURTHER ACTIONS. Each Party agrees to execute, acknowledge, and deliver
such further instruments, and to do all other acts, as may be necessary or
appropriate to carry out the purposes and intent of this Agreement.

                  IN WITNESS WHEREOF, each Party has executed this Agreement by
its respective, duly authorized officer as of the day and year herein written.

GENENTECH, INC.                            LEXICON GENETICS INCORPORATED

         /s/ Arthur D. Levinson                     /s/ Arthur T. Sands
-------------------------------------      ----------------------------
By:  Arthur D. Levinson                    By: Arthur T. Sands
Title:  CEO                                Title:  President and CEO

                                       44

<PAGE>
                                    EXHIBIT A

        Comprehensive Therapeutic Protein Discovery & Validation Program

                 First Pass Phenotypic Analysis of Project Genes

                                      [**]

<PAGE>
                                    EXHIBIT C

                                 NOTE AGREEMENT

          THIS NOTE AGREEMENT is entered into as of December 17, 2002 (this
"Note Agreement"), between LEXICON GENETICS INCORPORATED, A Delaware corporation
(herein called "Borrower"), and GENENTECH, INC., a Delaware corporation (herein
called "Lender").

         1.       COMMITMENT. Subject to all the terms and conditions of this
Note Agreement and prior to the termination of its commitment as hereinafter
provided, Lender hereby agrees to make a loan (the "Loan"), up to an aggregate
principal amount not to exceed $4,000,000, pursuant to Article 7.14 of the
Collaboration and License Agreement dated as of the date hereof, between
Borrower and Lender (the "Collaboration Agreement"). The Loan shall become
available to Borrower on or before December 31, 2002. The Loan shall be
evidenced by a convertible promissory note, in the form of the Convertible
Promissory Note attached as Exhibit A hereto and incorporated herein by this
reference (the "Note"), which Note shall reflect the date of payment of the Loan
(the "Effective Date"). The Loan will be advanced to Borrower in immediately
available funds by wire transfer to a deposit account of Borrower in accordance
with the wire transfer instructions set forth beneath Borrower's signature to
this Agreement (as the same may be amended by written notice from Borrower to
Lender).

         2.       LOAN.

                  A. MATURITY DATE. Borrower promises to pay to Lender the
entire outstanding principal balance (and all accrued interest thereon) of the
Loan on or before the date (the "Maturity Date") that is the earlier of (i)
December 31, 2005, (ii) six (6) months after the termination of the
Collaboration Agreement or (iii) the date of an Event of Default as set forth in
Section 8 below.

                           (1) PAYMENT IN NOTE SHARES. At Borrower's option,
subject to the limitations set forth in Section 2.A.(3), on the Maturity Date,
Borrower may elect to pay the outstanding principal balance (and all accrued
interest thereon) of the Loan in (a) shares of Borrower's common stock, par
value $0.001 per share (the "Common Stock"), pursuant to the Note (the "Note
Shares"), (b) immediately available funds, or (c) a combination of Note Shares
and immediately available funds.

                           (2) OPTIONAL PREPAYMENT. At Borrower's option,
subject to the limitations set forth in Section 2.A.(3), Borrower may at any
time, upon fifteen (15) days written notice to Lender, prepay all or any portion
of the outstanding principal balance (and all accrued interest on the principal
amount so prepaid) of the Loan in (a) Note Shares pursuant to the Note, (b)
immediately available funds, or (c) a combination of Note Shares and immediately
available funds.

<PAGE>

                           (3) LIMITATIONS ON PAYMENT IN NOTE SHARES.

                                    (a) Borrower shall have no right to pay in
Note Shares any amounts in respect of principal outstanding under the Loan and
accrued interest in respect thereof to the extent that the number of such Note
Shares, calculated pursuant to Section 3 of the Note, would, when added to all
other shares of Common Stock of Borrower then owned by Lender or issuable to
Lender pursuant to the terms of any convertible securities of Borrower then
owned by Lender, cause Lender to own, in the aggregate, shares of Common Stock
equal to more than 15% of Borrower's issued and outstanding Common Stock plus
the Note Shares so contemplated to be issued, calculated at the time such
payment in Note Shares is contemplated. In such event, then Borrower shall pay
in Note Shares only up to such amount as, in Lender's good faith opinion, based
on the advice of legal counsel, would not exceed 15% of Borrower's issued and
outstanding Common Stock plus the Note Shares so issued unless Lender elects, in
its sole discretion, to receive payment of the entire amount due under the Loan
in Note Shares, notwithstanding the foregoing limitation on repayment in Note
Shares. Any remaining balance payable to Lender in respect of the Loan shall be
paid in immediately available funds.

                                    (b) Borrower may make payments in Note
Shares only to the extent that Borrower then has in reserve and available
sufficient of its authorized but unissued shares of Common Stock to effect such
payment in Note Shares.

                  B. INTEREST ON LOAN. Interest shall accrue on the sum of the
daily unpaid principal balance of the Loan outstanding on each day in lawful
money of the United States of America from the Effective Date until all such
principal amounts shall have been paid in full, which interest shall accrue at a
rate equal to eight percent (8%) per annum. Interest shall be compounded
quarterly and computed at the above rate on the basis of the actual number of
days elapsed year of 365 days; provided, however, that in no event shall
Borrower be bound to pay for the use or forbearance of the money loaned pursuant
hereto, interest of more than the maximum rate permitted by law to be charged by
Lender; the right to demand any such excess being hereby expressly waived by
Lender. All accrued and unpaid interest attributable to the principal amount of
the Loan then being paid shall be payable concurrently with such payment of
principal, whether in connection with any prepayment, on the Maturity Date or
otherwise.

                  C. USE OF PROCEEDS. The Loan may only be used for the
generation and phenotypic analysis of knock-out mice and Over-Expression Mice
for Project Genes (as such terms are defined in the Collaboration Agreement).

         3.       DELIVERY AND APPLICATION OF PAYMENTS. Payment to Lender of all
amounts due hereunder shall be made in immediately available funds on the date
when due by wire transfer to a deposit account of Lender in accordance with the
wire transfer instructions set forth beneath Lender's signature to this
Agreement (as the same may be amended by written notice from Lender to
Borrower). Payment to Lender of all amounts due hereunder payable in Note Shares
shall be made by delivery of an appropriate stock certificate within two
business days after the Maturity Date (in the case of a payment pursuant to
Section 2.A.(l)) or two business days after the effective date of an election by
Borrower to prepay (in the case of a prepayment pursuant to Section 2.A.(2)), to
the office of Lender at I DNA Way, South San Francisco, California 94080,
<PAGE>

Attention: Treasurer, or at such other place as may be designated in writing by
Lender from time to time. If any payment date falls on a day that is not a
business day, the payment due date shall be extended to the next business day.
Any payment or prepayment received or deemed received in respect of the Loan
shall be applied first, to accrued and unpaid interest, and then, to the
outstanding principal balance of the Note.

         4.       BORROWER REPRESENTATIONS AND COVENANTS. Borrower hereby
represents, warrants and covenants to Lender as follows:

                  A. AUTHORITY. Borrower has full right, power, authority and
capacity to enter into this Note Agreement and the Note (collectively, the "Loan
Documents") and to consummate the transactions contemplated hereby and thereby.
Upon due execution and delivery by Borrower, the Loan Documents will constitute
a legal, valid and binding obligation of Borrower enforceable in accordance with
its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific
performance, injunctive relief or other equitable remedies.

                  B. GOOD STANDING. Borrower is qualified to do business and is
in good standing in the State of Delaware and each jurisdiction in which the
failure to so qualify would have a material adverse effect on the business,
operations, financial condition or results of operations of Borrower and its
subsidiaries, taken as a whole.

                  C. CONSENTS. The execution and delivery of the Loan Documents,
and performance by Borrower of its obligations hereunder and thereunder, have
been duly authorized by all necessary corporate action on the part of Borrower.
No consent, approval, order or authorization of any federal, state or local
governmental authority on the part of Borrower is required in connection with
the consummation of the transactions contemplated by this Note Agreement.

                  D. COMPLIANCE WITH SECURITIES LAWS. Assuming the accuracy of
the representations made by Lender in Section 5 hereof, the Note Shares issuable
upon conversion of any portion of the Note will be issued to Lender in
compliance with (i) the registration and prospectus delivery requirements of the
Securities Act of 1933, as amended (the "Securities Act"), and the registration
and qualification requirements of all applicable securities laws of the states
of the United States or (ii) applicable exemptions therefrom.

                  E. NO CONFLICTS. The execution and delivery by Borrower of the
Loan Documents and consummation of the transactions contemplated thereby do not
and will not (i) violate the Certificate of Incorporation or Bylaws of Borrower
or any material judgment, order, writ, decree, statute, rule or regulation
applicable to Borrower; (ii) violate any provision of, or result in the breach
of, any material mortgage, indenture, agreement, instrument, contract, judgment
or decrees to which Borrower is a party or by which it is bound; or (iii) result
in the creation or imposition of any lien upon any property, asset or revenue of
Borrower or the suspension, revocation or nonrenewal of any material permit,
license, authorization or approval applicable to Borrower, its business or
operations, or any of its assets or properties.

                                       3
<PAGE>

                  F. DISCLOSURE. No representation or warranty of Borrower
contained in the Loan Documents, the Collaboration Agreement or any other
documents, certificate or statement furnished to Lender by or on behalf of
Borrower in connection with the transactions contemplated hereby or thereby
contains any untrue statement of a material fact or omits to state a material
fact necessary to make the statement contained herein or therein nor misleading.
To the best of Borrower's knowledge, there is no fact known to Borrower that
materially adversely affects the business, operations, property, assets,
condition or prospects of Borrower that has not been disclosed in any filing
with the Securities and Exchange Commission.

         5.       LENDER REPRESENTATIONS AND COVENANTS. Lender hereby
represents, warrants and covenants to Borrower as follows:

                  A. AUTHORITY. Lender has full right, power, authority and
capacity to enter into this Note Agreement and to consummate the transactions
contemplated hereby. Upon due execution and delivery by Lender, this Note
Agreement will constitute a legal, valid and binding obligation of Lender
enforceable in accordance with its terms, subject to laws of general application
relating to bankruptcy, insolvency and the relief of debtors and rules of law
governing specific performance, injunctive relief or other equitable remedies.

                  B. INVESTMENT EXPERIENCE; INVESTMENT INTENT; ETC. (i) Lender
is knowledgeable, sophisticated and experienced in making, and is qualified to
make, decisions with respect to investments in shares presenting an investment
decision like that involved in the purchase of the Note and the Note Shares that
may be issued in payment thereof (collectively, the "Securities"); (ii) Lender
has received all the information it considers necessary or appropriate for
deciding whether to purchase the Securities; (iii) Lender is acquiring the
Securities in the ordinary course of its business and for its own account solely
for investment and with no present intention of distributing any of such
Securities, except in accordance with an effective Registration Statement or
otherwise pursuant to an available exemption from registration under the
Securities Act, and no arrangement or understanding exists with any other person
regarding the distribution of such Securities; (iv) Lender will not, directly or
indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit
any offers to buy, purchase or otherwise acquire or take a pledge of) the
Securities except in compliance with the Securities Act, and the rules and
regulations promulgated thereunder; and (v) Lender is an "accredited investor"
within the meaning of Rule 501 of Regulation D promulgated under the Securities
Act.

                  C. LENDER UNDERSTANDING AND AGREEMENTS. Lender acknowledges
and agrees that it will acquire the Securities being purchased by it in
transactions not involving a public offering and that such Securities are
subject to certain restrictions as to resale under the federal and state
Securities laws. Lender agrees and understands that each certificate
representing Note Shares issued in payment of the Note delivered on transfer of
or in substitution for any such certificate, shall bear a legend in
substantially the following form:

                  THE SECURiTIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
                  RESTRICTIONS IMPOSED BY THE SECURiTIES ACT OF 1933, AS
                  AMENDED, AND

                                       4
<PAGE>

                  APPLICABLE STATE SECURITIES LAW. THE SHARES MAY NOT BE SOLD OR
                  TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN EXEMPTION
                  THEREFROM UNDER THE SECURITIES ACT OF 1933 AND ANY APPLICABLE
                  STATE SECURITIES LAWS.

         Lender agrees that it will not sell, pledge, assign, transfer or
otherwise dispose (collectively, "Transfer") of any Securities unless the
Transfer will be made pursuant to an exemption from the registration
requirements of the Securities Act or pursuant to an effective registration
statement under the Securities Act and pursuant to an exemption from any
applicable state securities laws or an effective registration or other
qualification under any applicable state securities laws.

                  D. CONSENTS. The execution and delivery of this Note
Agreement, and performance by Lender of its obligations hereunder, have been
duly authorized by all necessary corporate action on the part of Lender.

         6.       CONDITIONS TO MAKING OF LOAN. Lender's obligation to make the
Loan to Borrower under the Loan Documents is subject to satisfaction of each of
the following conditions as of the date the Loan is to be made, any of which may
be waived in whole or in part by Lender:

                  A.       REPRESENTATIONS AND WARRANTIES. The representations
and warranties made by Borrower in Section 4 hereof shall be true and correct as
of the date the Loan is to be made, except that to the extent any representation
or warranty is made as of a specified date, it shall have been true and correct
as of such date.

                  B.       NO DEFAULTS. No Event of Default or event which, with
notice or lapse of time or both would become an Event of Default, shall have
occurred and be continuing under the Loan Documents, and no breach shall have
occurred and be continuing under the Collaboration Agreement.

         7.       SUBORDINATION. The indebtedness evidenced by the Note is
hereby subordinated, only in right of payment to the prior payment of (a) the
indebtedness of Borrower outstanding as of the date of this Note Agreement to
banks or commercial finance or other lending institutions regularly engaged in
the business of lending money, whether or not secured ("Senior Indebtedness")
and (b) any indebtedness or debentures, notes or other evidences of indebtedness
issued in exchange for Senior Indebtedness.

         8.       DEFAULT AND REMEDIES. The occurrence of any one or more of the
following shall constitute an "Event of Default": (a) default in the payment of
any obligation by Borrower under the Note within five (5) business days after
the date the same became due and payable; (b) any representation or warranty
made by Borrower in Section 4 of this Note Agreement shall prove to have been
untrue in any material respect when made or deemed made; (c) except for any
failure to pay as described in clause (a) above, breach of any covenant
contained in the Loan Documents

                                       5
<PAGE>

if such breach shall not have been cured to the reasonable satisfaction of
Lender within sixty (60) days after Borrower shall have received written notice
thereof from Lender; (d) Borrower files any petition or action for relief under
any bankruptcy, reorganization, insolvency or moratorium law or any other law
for the relief of, or relating to, debtors, now or hereafter in effect, or makes
any assignment for the benefit of creditors or takes any corporate action in
furtherance of any of the foregoing; (e) an involuntary petition is filed
against Borrower (unless such petition is dismissed or discharged within sixty
(60) days) under any bankruptcy statute now or hereafter in effect, or a
custodian, receiver, trustee, assignee for the benefit of creditors (or other
similar official) is appointed to take possession, custody or control of any
property, of Borrower (provided that no Loan will be made prior to the dismissal
of such proceeding); (f) Lender terminates the Collaboration Agreement pursuant
to Article 10.2 of the Collaboration Agreement; or (g) failure to pay when due
any amount in respect of Senior Indebtedness, or occurrence of any other default
in respect of Senior Indebtedness that pursuant to which the holder thereof
accelerates the due date thereof. Upon the occurrence and during the continuance
of an Event of Default, Lender may, at its option, upon notice to Borrower, do
any one or more of the following: (i) terminate its obligation to make the Loan
to Borrower as provided in Section 2 hereof if such Loan has not yet been made;
provided that in the case of an Event of Default pursuant to clause (d) or (e)
above, Lender's obligation to make the Loan to Borrower as provided in Section 3
hereof shall automatically terminate, without notice to Borrower, if such Loan
has not yet been made; (ii) declare all sums evidenced hereby immediately due
and payable; provided that in the case of an Event of Default pursuant to clause
(d) or (e) above, all sums evidenced hereby shall be automatically and
immediately due and payable, without notice to or demand on Borrower; or (iii)
exercise any remedies of an unsecured creditor under applicable law.

         9.       GOVERNING LAW. This Agreement shall be deemed to have been
made in the State of California and the validity, construction, interpretation,
and enforcement hereof, and the rights of the parties hereto, shall be
determined under, governed by, and construed in accordance with the internal
laws of the State of California, without regard to principles of conflicts of
law.

         10.      MISCELLANEOUS PROVISIONS.

                  A.       Nothing herein shall in any way limit the effect of
the conditions set forth in any other security or other agreement executed by
Borrower, but each and every condition hereof shall be in addition thereto.

                  B.       No failure or delay on the part of Lender, in the
exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise thereof.

                  C.       All rights and remedies existing under this Note
Agreement or any other Loan Document are cumulative to, and not exclusive of,
any rights or remedies otherwise available.

                  D.       All headings and captions in this Note Agreement and
any related documents are for convenience only and shall not have any
substantive effect.

                                       6
<PAGE>

                  E.       This Note Agreement may be executed in any number of
counterparts, each of which when so delivered shall be deemed an original, but
all such counterparts shall constitute but one and the same instrument. Each
such agreement shall become effective upon the execution of a counterpart hereof
or thereof by each of the parties hereto and telephonic notification that such
executed counterparts has been received by Borrower and Lender.

                  F.       Neither party shall assign any of its rights or
obligations hereunder except: (a) as incident to the merger, consolidation,
reorganization or acquisition of stock or assets affecting substantially all of
the assets or voting control of the assigning party; (b) to any wholly-owned
Affiliate of such party; provided, however, that such assignment shall not
relieve the assigning party of its responsibilities for performance of its
obligations under this Note Agreement; or (c) with the prior written consent of
the other party (in its sole discretion). This Note Agreement shall be binding
upon the successors and permitted assigns of the parties, and the name of a
party appearing herein shall be deemed to include the names of such party's
successor's and permitted assigns to the extent necessary to carry out the
intent of this Agreement. Any assignment not in accordance with this section
shall be null and void.

                            (Signature page follows)

                                       7
<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Note Agreement
to be executed as of the date first written above.

LENDER:                                    BORROWER:

GENENTECH, INC.,                           LEXICON GENETICS INCORPORATED,
a Delaware corporation                     a Delaware corporation

By:                                        By:
   ------------------------------             ------------------------------
                                           Name:
                                                ----------------------------
Name:    Thomas T. Thomas                  Title:
                                                  --------------------------
Title:   Treasurer

Wire Transfer Instructions:                Wire Transfer Instructions:
--------------------------                 --------------------------

Account Name:    Genentech, Inc.
Account Number:  040-1699
Bank Name:       Mellon Bank, Pittsburgh, PA
ABA Number:      043-000-261

                                       8

<PAGE>

                                    EXHIBIT A

                       FORM OF CONVERTIBLE PROMISSORY NOTE

<PAGE>

THIS CONVERTIBLE PROMISSORY NOTE IS SUBJECT TO RESTRICTIONS IMPOSED BY THE
SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAW. THIS
NOTE MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN
EXEMPTION THEREFROM UNDER THE SECURITIES ACT OF 1933 AND ANY APPLICABLE STATE
SECURITIES LAWS.

                           CONVERTIBLE PROMISSORY NOTE
$4,000,000.00                                                             [DATE]

         FOR VALUE RECEIVED, LEXICON GENETICS INCORPORATED, a Delaware
corporation ("Borrower"), hereby promises to pay to the order of GENENTECH,
INC., a Delaware corporation ("Lender"), in lawful money of the United States of
America and in immediately available funds, the principal sum of $4,000,000.00
or such lesser amount as shall have been advanced by Lender and shall remain
outstanding (the "Loan"), together with accrued and unpaid interest thereon, due
and payable on the date and in the manner set forth below.

         This Convertible Promissory Note ("Note") is the note referred to in
and is executed and delivered in connection with the Note Agreement dated as of
December 17, 2002, between Borrower and Lender (the "Note Agreement").
Additional rights and obligations of Lender and Borrower are set forth in the
Note Agreement. All capitalized terms used herein and not otherwise defined
shall have the respective meanings given to them in the Note Agreement.

         1.       MATURITY DATE. Subject to Section 3 below, all amounts payable
hereunder shall be due and payable on the Maturity Date. This Note may be,
prepaid in whole or in part at any time without penalty, in accordance with the
terms of the Note Agreement.

         2.       INTEREST RATE AND PAYMENT. Borrower further promises to pay
interest on the outstanding Loan amount, which interest shall accrue from the
date hereof and shall be added to the principal balance of the Loan. Interest
shall accrue on the sum of the daily unpaid principal balance of the Loan
outstanding on each day in lawful money of the United States of America, from
the Effective Date until all such principal amounts shall have been paid in
full, which interest shall accrue at a rate equal to eight percent (8%) per
annum. Interest shall be compounded quarterly and computed at the above rate on
the basis of the actual number of days elapsed year of 365 days; provided,
however, that in no event shall Borrower be bound to pay for the use or
forbearance of the money loaned pursuant hereto, interest of more than the
maximum rate permitted by law to be charged by Lender; the right to demand any
such excess being hereby expressly waived by Lender. All accrued and unpaid
interest attributable to the principal amount of the Loan then being paid shall
be payable concurrently with such payment of principal, whether in connection
with any prepayment, on the Maturity Date or otherwise.

         3.       PAYMENT. At Borrower's sole option and subject to the
limitations contained in Section 2.A.(3) of the Note Agreement, (a) on the
Maturity Date, the outstanding principal balance of, and accrued interest on,
this Note shall be payable in (i) shares of Borrower's Common Stock, (ii)
immediately available funds, or (iii) a combination of Common Stock and

<PAGE>

immediately available funds; and (b) on any date upon which Borrower desires to
prepay all or any portion of the outstanding principal balance of, and accrued
interest on the amount so prepaid, such prepayment shall be payable in (i)
Common Stock, (ii) immediately available funds, or (iii) a combination of Common
Stock and immediately available funds. The number of shares of Common Stock
which shall be issuable to make any payment under this Note, including, without
limitation, any optional prepayment amount, which may be made by Borrower shall
be determined by dividing the amount of such payment by the Fair Market Value.
"Fair Market Value" shall mean the average of the closing prices for Borrower's
Common Stock as reported in The Wall Street Journal (Western Edition) for the
twenty (20) trading days immediately preceding the Maturity Date or the date
upon which an optional prepayment amount is paid, as the case may be.

                  A.       MECHANICS AND EFFECT OF PAYMENT IN COMMON STOCK. No
fractional shares of Common Stock shall be issued in payment of this Note. In
lieu of Borrower issuing any fractional shares to Lender upon payment of this
Note (or any amount thereof) in Common Stock, Borrower shall pay to Lender in
cash the amount of any such payment that is not so paid in Common Stock, such
payment to be in the form provided below. Upon payment of this Note in full
pursuant to this Section 3, Lender shall surrender this Note, duly endorsed, at
the principal office of Borrower. The payment in Common Stock shall be deemed to
have been made immediately prior to the close of business on the date of such
surrender of this Note or the date any optional prepayment amount is paid, as
the case may be, and the person or persons entitled to receive the shares of
Common Stock issuable upon such payment shall be treated for all purposes as the
record holder or holders of such shares of Common Stock as of such date.
Borrower shall, in accordance with Section 2 of the Note Agreement, issue and
deliver to Lender at such principal office a certificate or certificates for the
number of shares of Common Stock to which Lender shall be entitled upon such
payment bearing such legends as are required by applicable state and federal
securities laws and pursuant to Section S.C. of the Note Agreement, together
with any other securities and property to which Lender is entitled upon such
payment under the terms of this Note, including a check payable to Lender for
any cash amounts payable as described above.

         4.       SUBORDINATION. The indebtedness evidenced by this Note is
hereby subordinated, only to the extent set forth in Section 7 of the Note
Agreement, in right of payment to the prior payment of the Senior Indebtedness.

         5.       PLACE OF PAYMENT. All amounts payable hereunder shall be
payable in accordance with terms of the Note Agreement, unless otherwise
specified in writing by Lender.

         6.       APPLICATION OF PAYMENTS. Payment on this Note shall be applied
first to accrued interest, and thereafter to the outstanding principal balance
hereof.

         7.       DEFAULT. The occurrence of an "Event of Default" under and as
defined in the Note Agreement shall constitute an "Event of Default" hereunder.
Upon the occurrence of an Event of Default, Lender shall have such rights and
remedies as are provided under the Note Agreement or by law.

                                       2
<PAGE>

         8.       GOVERNING LAW. This Note shall be governed by, and construed
and enforced in accordance with, the laws of the State of California, excluding
conflict of laws principles that would cause the application of laws of any
other jurisdiction.

         9.       SUCCESSORS AND ASSIGNS. Subject to the limitations of Section
10.F. of the Note Agreement, the provisions of this Note shall inure to the
benefit of and be binding on any successor to Borrower and shall extend to any
holder hereof.

                               BORROWER:

                               LEXICON GENETICS INCORPORATED

                               By:
                                    ------------------------------------

                               Printed Name:
                                              --------------------------

                               Title:
                                      ----------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]